An mRNA Vaccine against SARS-CoV-2 â€" Preliminary

New England Journal of Medicine
383, 1920-1931
DOI: 10.1056/nejmoa2022483

Citation Report

#	Article	IF	Citations
1	Calling for a united action to defeat COVID-19. Precision Clinical Medicine, 2020, 3, 235-239.	1.3	3
2	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. Pharmaceutics, 2020, 12, 945.	2.0	14
3	Genetics of COVID-19. Jornal De Pediatria, 2021, 97, 378-386.	0.9	17
5	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. British Journal of Biomedical Science, 2020, 77, 168-184.	1.2	12
6	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12, .	5.8	204
7	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. MBio, 2020, 11, .	1.8	186
8	Nucleic acid-based therapy for coronavirus disease 2019. Heliyon, 2020, 6, e05007.	1.4	31
9	COVID-19 Vaccine: A comprehensive status report. Virus Research, 2020, 288, 198114.	1.1	628
10	Signal hotspot mutations in SARS-CoV-2 genomes evolve as the virus spreads and actively replicates in different parts of the world. Virus Research, 2020, 289, 198170.	1.1	37
11	What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. Vaccine: X, 2020, 6, 100076.	0.9	62
12	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open, 2020, 5, e000947.	2.0	63
13	COVID-19 in the Pediatric Populationâ€"Review and Current Evidence. Current Infectious Disease Reports, 2020, 22, 29.	1.3	32
14	Leveraging the advances in HIV for COVID-19. Lancet, The, 2020, 396, 943-944.	6.3	8
15	Challenges in the Development of a Vaccine Against COVID-19. Engineering, 2020, 6, 1067-1069.	3.2	0
16	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine, 2020, 383, 2427-2438.	13.9	1,242
17	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. Frontiers in Microbiology, 2020, 11, 583252.	1.5	18
18	Coronavirus disease-19 vaccine development utilizing promising technology. Current Opinion in HIV and AIDS, 2020, 15, 351-358.	1.5	4
19	Strategies and Advances in Combating COVID-19 in China. Engineering, 2020, 6, 1076-1084.	3.2	16

#	Article	IF	Citations
20	Upcoming SARS-CoV-2 vaccine: expectations and reality. Postgraduate Medical Journal, 2022, 98, e75-e76.	0.9	0
21	Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection. Vaccines, 2020, 8, 584.	2.1	48
22	Fact vs Fallacy: The Anti-Vaccine Discussion Reloaded. Advances in Therapy, 2020, 37, 4481-4490.	1.3	46
23	The transmission modes and sources of COVID-19: A systematic review. International Journal of Surgery Open, 2020, 26, 125-136.	0.2	84
24	COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano, 2020, 14, 12522-12537.	7.3	259
25	A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 2020, 5, 237.	7.1	427
26	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. Expert Review of Anti-Infective Therapy, 2022, 20, 1275-1298.	2.0	21
27	Is a COVID-19 vaccine developed by nature already at work?. Medical Hypotheses, 2020, 145, 110335.	0.8	6
28	Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine. Vaccine, 2020, 38, 7409-7413.	1.7	23
29	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, The, 2020, 396, 1595-1606.	6.3	511
30	Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines. Npj Vaccines, 2020, 5, 88.	2.9	21
31	SARS-CoV-2 vaccines in development. Nature, 2020, 586, 516-527.	13.7	1,659
33	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Advances in Biomarker Sciences and Technology, 2020, 2, 1-23.	0.8	79
34	Inhaled RNA Therapy: From Promise to Reality. Trends in Pharmacological Sciences, 2020, 41, 715-729.	4.0	58
35	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	13.9	2,107
36	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell, 2020, 183, 996-1012.e19.	13.5	1,494
37	Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present Î±-gal epitopes. Vaccine, 2020, 38, 6487-6499.	1.7	31
38	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research, 2020, 288, 198141.	1.1	116

#	Article	IF	Citations
39	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. Clinical Infectious Diseases, 2021, 73, 336-340.	2.9	70
40	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology, 2020, 17, 543-558.	6.1	999
41	The Covid-19 Vaccine-Development Multiverse. New England Journal of Medicine, 2020, 383, 1986-1988.	13.9	109
42	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. Infectious Diseases and Therapy, 2020, 9, 525-536.	1.8	16
43	Profile of SARS-CoV-2. Wiener Klinische Wochenschrift, 2020, 132, 635-644.	1.0	4
44	The known unknowns of T cell immunity to COVID-19. Science Immunology, 2020, 5, .	5.6	122
45	The immunology of SARS-CoV-2 infections and vaccines. Seminars in Immunology, 2020, 50, 101422.	2.7	85
46	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Advances in Chronic Kidney Disease, 2020, 27, 434-441.	0.6	5
47	Cardiovascular Manifestations of COVID-19 Infection. Cells, 2020, 9, 2508.	1.8	142
48	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62, 103132.	2.7	77
49	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 2020, 53, 1281-1295.e5.	6.6	285
50	Nanomaterials for Therapeutic RNA Delivery. Matter, 2020, 3, 1948-1975.	5.0	67
51	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in Cellular and Infection Microbiology, 2020, 10, 587269.	1.8	552
52	RNA Vaccines for COVID-19. JACC Basic To Translational Science, 2020, 5, 1240-1243.	1.9	7
54	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	7.1	149
55	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host and Microbe, 2020, 28, 880-891.e8.	5.1	153
56	Current COVID-19 vaccine candidates: Implications in the Saudi population. Saudi Pharmaceutical Journal, 2020, 28, 1743-1748.	1.2	17
57	New viral vectors for infectious diseases and cancer. Seminars in Immunology, 2020, 50, 101430.	2.7	55

#	Article	IF	Citations
58	Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time?. Med, 2020, 1, 28-32.	2.2	10
59	Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines, 2020, 8, 739.	2.1	98
60	A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. Frontiers in Immunology, 2020, 11, 573526.	2.2	31
61	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 723-730.	0.6	22
62	Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Frontiers in Immunology, 2020, 11, 583019.	2.2	98
63	COVIDâ€19 vaccines: the importance of transparency and factâ€based education. British Journal of Clinical Pharmacology, 2020, 86, 2107-2110.	1.1	13
64	Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein and Cell, 2020, 11, 776-782.	4.8	77
65	COVID-19 spread in the UK: the end of the beginning?. Lancet, The, 2020, 396, 587-590.	6.3	66
66	Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host and Microbe, 2020, 28, 364-370.	5.1	98
67	Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities. Nature Reviews Cardiology, 2020, 17, 533-535.	6.1	34
68	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Expert Review of Clinical Pharmacology, 2020, 13, 957-975.	1.3	6
69	Emerging Therapeutic Modalities against COVID-19. Pharmaceuticals, 2020, 13, 188.	1.7	24
70	Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs, 2020, 34, 879-896.	2.7	80
71	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. Pharmaceuticals, 2020, 13, 155.	1.7	88
73	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	13.9	936
74	SARS-CoV-2 Vaccine Development: Current Status. Mayo Clinic Proceedings, 2020, 95, 2172-2188.	1.4	96
75	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Trends in Pharmacological Sciences, 2020, 41, 815-829.	4.0	108
76	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity, 2020, 53, 724-732.e7.	6.6	267

#	Article	IF	Citations
77	Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clinical Infectious Diseases, 2021, 73, e531-e539.	2.9	177
78	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA - Journal of the American Medical Association, 2020, 324, 951.	3.8	671
79	Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?. Viruses, 2020, 12, 861.	1.5	43
80	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. MBio, 2020, 11, .	1.8	99
81	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in Immunology, 2020, 11, 579250.	2.2	72
82	Vaccines against COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 703-705.	0.6	31
83	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	5.9	1,115
85	Issues affecting nanomedicines on the way from the bench to the market. Journal of Materials Chemistry B, 2020, 8, 10681-10685.	2.9	14
86	The Current Status of COVID-19 Vaccines. Frontiers in Genome Editing, 2020, 2, 579297.	2.7	25
87	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
88	COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines.. Expert Review of Vaccines, 2020, 19, 937-947.	2.0	12
89	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. Frontiers in Cell and Developmental Biology, 2020, 8, 580202.	1.8	20
90	An update on the global vaccine development for coronavirus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 2053-2055.	1.8	20
91	An Effective COVID-19 Vaccine Needs to Engage T Cells. Frontiers in Immunology, 2020, 11, 581807.	2.2	75
92	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	13.5	420
93	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology, 2020, 11, 585354.	2.2	384
94	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. International Journal of Antimicrobial Agents, 2020, 56, 106208.	1.1	22
95	Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity, 2020, 53, 1095-1107.e3.	6.6	273

#	Article	IF	Citations
96	Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. Journal of Experimental Medicine, 2020, 217, .	4.2	55
97	What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist. Frontiers in Immunology, 2020, 11, 2173.	2.2	8
98	Remdesivir: First Approval. Drugs, 2020, 80, 1355-1363.	4.9	176
99	Vaccine Against Covid-19 Disease â€“ Present Status of Development. Indian Journal of Pediatrics, 2020, 87, 810-816.	0.3	38
100	Snapshot of COVID-19 Related Clinical Trials in India. Indian Journal of Clinical Biochemistry, 2020, 35, 418-422.	0.9	21
101	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet, The, 2020, 396, 887-897.	6.3	822
102	COVID-19 vaccines: early success and remaining challenges. Lancet, The, 2020, 396, 868-869.	6.3	29
103	Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 2020, 20, 615-632.	10.6	806
104	Rapid Real-time Tracking of Nonpharmaceutical Interventions and Their Association With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity: The Coronavirus Disease 2019 (COVID-19) Pandemic Pulse Study. Clinical Infectious Diseases, 2021, 73, e1822-e1829.	2.9	28
105	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	6.0	504
106	Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines, 2020, 8, 534.	2.1	44
107	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 200.	3.5	25
108	Medical, Genomic, and Evolutionary Aspects of the Peptide Sharing between Pathogens, Primates, and Humans. Global Medical Genetics, 2020, 07, 064-067.	0.4	11
109	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. ACS Pharmacology and Translational Science, 2020, 3, 790-800.	2.5	20
110	SARS-CoV-2 Vaccine Development: An Overview and Perspectives. ACS Pharmacology and Translational Science, 2020, 3, 844-858.	2.5	34
111	Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Review of Vaccines, 2020, 19, 919-936.	2.0	72
112	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. International Journal of Molecular Sciences, 2020, 21, 6790.	1.8	52
113	Vaccines targeting SARS-CoV-2 tested in humans. Nature Medicine, 2020, 26, 1336-1338.	15.2	7

#	Article	IF	Citations
114	Developing Safe and Effective Covid Vaccines â€" Operation Warp Speedâ€™s Strategy and Approach. New England Journal of Medicine, 2020, 383, 1701-1703.	13.9	143
116	Pathogenesis, clinical manifestationsÂand complications of coronavirus disease 2019 (COVID-19). Future Microbiology, 2020, 15, 1287-1305.	1.0	86
117	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	2.1	103
118	Obesity: A critical risk factor in the <scp>COVID</scp>â€19 pandemic. Clinical Obesity, 2020, 10, e12403.	1.1	191
119	Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia, 2020, 34, 3047-3049.	3.3	81
121	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2020, 16, 2921-2931.	1.4	85
122	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Frontiers in Medical Technology, 2020, 2, 571030.	1.3	29
123	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	1.1	185
124	Efforts towards a <scp>COVID</scp>â€19 vaccine. Environmental Microbiology, 2020, 22, 4071-4084.	1.8	16
125	Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. Journal of Biomolecular Structure and Dynamics, 2022, 40, 585-611.	2.0	113
126	COVID-19: Second Wave or Multiple Peaks, Natural Herd Immunity or Vaccine â€" We Should be Prepared. Disaster Medicine and Public Health Preparedness, 2022, 16, 718-725.	0.7	17
127	A SARS-CoV-2 mRNA Vaccine â€" Preliminary Report. New England Journal of Medicine, 2020, 383, 1190-1192.	13.9	26
128	Fast-and-fit vaccines. Nature Biomedical Engineering, 2020, 4, 757-758.	11.6	1
129	Next Generation Influenza Vaccines: Looking into the Crystal Ball. Vaccines, 2020, 8, 464.	2.1	5
130	Development of vaccines and antivirals for combating viral pandemics. Nature Biomedical Engineering, 2020, 4, 1128-1133.	11.6	66
131	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. Clinical Infectious Diseases, 2020, 73, 1540-1544.	2.9	15
132	Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 2020, 27, 104.	2.6	287
133	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Frontiers in Immunology, 2020, 11, 569760.	2.2	30

#	Article	IF	Citations
134	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Frontiers in Immunology, 2020, 11, 571481.	2.2	48
135	COVID-19: Coronavirus Vaccine Development Updates. Frontiers in Immunology, 2020, 11, 602256.	2.2	143
136	RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. Frontiers in Immunology, 2020, 11, 608460.	2.2	54
137	Flu RNA Vaccine: A Game Changer?. Vaccines, 2020, 8, 760.	2.1	2
138	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. Vaccines, 2020, 8, 746.	2.1	6
139	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	5.6	244
140	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. Frontiers in Chemistry, 2020, 8, 590263.	1.8	24
141	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	2.1	61
142	Knowledge and Attitudes on Vaccination in Southern Romanians: A Cross-Sectional Questionnaire. Vaccines, 2020, 8, 774.	2.1	27
143	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 2020, 5, .	5.6	404
144	Nanotechnology shows promise for next-generation vaccines in the fight against COVID-19. MRS Bulletin, 2020, 45, 981-982.	1.7	9
145	A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following COVID-19 Pneumonia â€“ Case Reports . Therapeutics and Clinical Risk Management, 2020, Volume 16, 1039-1046.	0.9	18
146	Current Prevention of COVID-19: Natural Products and Herbal Medicine. Frontiers in Pharmacology, 2020, 11, 588508.	1.6	99
147	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. Vaccines, 2020, 8, 649.	2.1	42
148	The role of the allergist/immunologist in the COVID-19 pandemic: A Janus-faced presentation. Allergy and Asthma Proceedings, 2020, 41, 397-412.	1.0	16
149	IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. Pharmaceutical Medicine, 2020, 34, 223-231.	1.0	111
150	Azithromycin for COVID-19: More Than Just an Antimicrobial?. Clinical Drug Investigation, 2020, 40, 683-686.	1.1	83
151	Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Research Reviews, 2021, 65, 101205.	5.0	601

#	Article	IF	Citations
152	Structure-altering mutations of the SARS-CoV-2 frameshifting RNA element. Biophysical Journal, 2021, 120, 1040-1053.	0.2	43
153	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. Journal of Biological Chemistry, 2021, 296, 100025.	1.6	43
154	Who should be prioritised for COVID-19 vaccination?. Human Vaccines and Immunotherapeutics, 2021, 17, 1317-1321.	1.4	53
155	Animal coronaviruses and SARSâ€CoVâ€2. Transboundary and Emerging Diseases, 2021, 68, 1097-1110.	1.3	33
156	Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials, 2021, 266, 120431.	5.7	131
157	Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 2021, 19, 141-154.	13.6	3,334
158	Adjustment for international surgical outreach missions due to COVID-19. Burns, 2021, 47, 964-965.	1.1	3
159	COVID-19: Discovery, diagnostics and drug development. Journal of Hepatology, 2021, 74, 168-184.	1.8	302
160	Are open-source approaches the most efficient way forward for COVID-19 drug discovery?. Expert Opinion on Drug Discovery, 2021, 16, 115-117.	2.5	1
161	COVIDâ€19 vaccine research and development: ethical issues. Tropical Medicine and International Health, 2021, 26, 14-19.	1.0	71
162	Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomedical Journal, 2021, 44, 18-30.	1.4	42
163	Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. Molecular and Cellular Proteomics, 2021, 20, 100058.	2.5	105
164	Severe acute respiratory syndromeâ€coronavirusâ€2 spike (S) protein based vaccine candidates: State of the art and future prospects. Reviews in Medical Virology, 2021, 31, e2183.	3.9	43
165	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Advanced Therapeutics, 2021, 4, 2000203.	1.6	16
166	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infectious Diseases, The, 2021, 21, 39-51.	4.6	923
167	COVID-19 pandemic lockdown-induced altered sleep/wake circadian rhythm, health complaints and stress among traffic police personnel in India. Chronobiology International, 2021, 38, 140-148.	0.9	20
168	A promising inactivated whole-virion SARS-CoV-2 vaccine. Lancet Infectious Diseases, The, 2021, 21, 2-3.	4.6	15
169	Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219.	13.6	126

#	Article	IF	Citations
170	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	1.0	88
171	SARSâ€CoVâ€2 infection in patients with a normal or abnormal liver. Journal of Viral Hepatitis, 2021, 28, 4-11.	1.0	29
172	COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology, 2021, 892, 173751.	1.7	201
173	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine, 2021, 39, 197-201.	1.7	67
174	Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 2021, 592, 116-121.	13.7	1,380
175	Review of registered clinical trials for the treatment of COVIDâ€19. Drug Development Research, 2021, 82, 474-493.	1.4	26
176	The Urgency of Justice in Research: Beyond COVID-19. Trends in Molecular Medicine, 2021, 27, 97-100.	3.5	29
177	Nucleic Acid-Based Technologies Targeting Coronaviruses. Trends in Biochemical Sciences, 2021, 46, 351-365.	3.7	35
178	Racing to immunity: Journey to a COVIDâ€19 vaccine and lessons for the future. British Journal of Clinical Pharmacology, 2021, 87, 3408-3424.	1.1	16
179	Interpretative immune targets and contemporary position for vaccine development against SARSâ€CoVâ€2: A systematic review. Journal of Medical Virology, 2021, 93, 1967-1982.	2.5	15
180	Intradermal delivery of receptorâ€binding domain of <scp>SARSâ€CoVâ€2</scp> spike protein with dissolvable microneedles to induce humoral and cellular responses in mice. Bioengineering and Translational Medicine, 2021, 6, e10202.	3.9	35
181	Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets. Cell Systems, 2021, 12, 102-107.e4.	2.9	35
182	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	5.1	308
183	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, 2021, 384, 80-82.	13.9	665
184	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. Human Vaccines and Immunotherapeutics, 2021, 17, 1635-1649.	1.4	14
185	SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29.	3.2	44
186	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomedicine and Pharmacotherapy, 2021, 133, 111008.	2.5	40
187	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	1.0	86

#	Article	IF	Citations
188	A comprehensive review on potential therapeutics interventions for COVID-19. European Journal of Pharmacology, 2021, 890, 173741.	1.7	30
190	Subsequent Curves of COVID-19 in Society. Archives of Medical Research, 2021, 52, 121-122.	1.5	1
191	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18â€“59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases, The, 2021, 21, 181-192.	4.6	1,104
192	SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. Journal of Immunology, 2021, 206, 109-117.	0.4	96
193	COVID-19: A review of therapeutic strategies and vaccine candidates. Clinical Immunology, 2021, 222, 108634.	1.4	180
194	Nano-based approaches in the development of antiviral agents and vaccines. Life Sciences, 2021, 265, 118761.	2.0	20
195	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Advanced Drug Delivery Reviews, 2021, 169, 168-189.	6.6	62
196	Coronavirus disease 2019 vaccines in pregnancy. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100295.	1.3	51
197	COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. International Immunopharmacology, 2021, 90, 107247.	1.7	87
198	Cellular reprogramming: Mathematics meets medicine. WIREs Mechanisms of Disease, 2021, 13, e1515.	1.5	5
199	Individual and community-level risk for COVID-19 mortality in the United States. Nature Medicine, 2021, 27, 264-269.	15.2	70
200	Spheroids and organoids as humanized 3D scaffoldâ€free engineered tissues for SARSâ€CoVâ€2 viral infection and drug screening. Artificial Organs, 2021, 45, 548-558.	1.0	21
201	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. SLAS Discovery, 2021, 26, 311-329.	1.4	4
202	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. Frontiers in Molecular Biosciences, 2021, 7, 585899.	1.6	12
203	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
204	Viral targets for vaccines against COVID-19. Nature Reviews Immunology, 2021, 21, 73-82.	10.6	832
205	DNA vaccines against COVID-19: Perspectives and challenges. Life Sciences, 2021, 267, 118919.	2.0	172
206	SARSâ€CoVâ€2 candidate vaccines â€•composition, mechanisms of action and stages of clinical development. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1922-1924.	2.7	23

#	Article	IF	Citations
207	Next-generation vaccines and the impacts of state-of-the-art in-silico technologies. Biologicals, 2021, 69, 83-85.	0.5	16
209	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine, 2021, 31, 100689.	3.2	206
210	COVID-19 and Solid Organ Transplantation: A Review Article. Transplantation, 2021, 105, 37-55.	0.5	241
211	Considerations for Size, Surface Charge, Polymer Degradation, Coâ€Ðelivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. Advanced NanoBiomed Research, 2021, 1, 2000041.	1.7	37
212	COVID-19 and the second wave during autumn: preventive strategies in cardiac and thoracic surgery divisions. European Surgery - Acta Chirurgica Austriaca, 2021, 53, 37-39.	0.3	1
213	Non-viral COVID-19 vaccine delivery systems. Advanced Drug Delivery Reviews, 2021, 169, 137-151.	6.6	152
214	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
215	COVID-19. Critical Care Nursing Quarterly, 2021, 44, 128-137.	0.4	17
216	Self-amplifying RNA vaccines for infectious diseases. Gene Therapy, 2021, 28, 117-129.	2.3	212
217	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	1.9	232
218	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 2021, 17, 1248-1261.	1.4	81
219	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. International Reviews of Immunology, 2021, 40, 54-71.	1.5	10
220	Exploring lectinâ€“glycan interactions to combat COVID-19: Lessons acquired from other enveloped viruses. Glycobiology, 2021, 31, 358-371.	1.3	25
221	Is there a role for childhood vaccination against COVIDâ€19?. Pediatric Allergy and Immunology, 2021, 32, 9-16.	1.1	38
222	Repurposed Drugs, Molecular Vaccines, Immuneâ€Modulators, and Nanotherapeutics to Treat and Prevent COVIDâ€19 Associated with SARSâ€CoVâ€2, a Deadly Nanovector. Advanced Therapeutics, 2021, 4, 2000172.	1.6	24
223	Deciphering Vaccines for COVID-19: where do we stand today?. Immunopharmacology and Immunotoxicology, 2021, 43, 8-21.	1.1	13
224	A Cytometrist's Guide to Coordinating and Performing Effective COVID â€19 Research. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 11-18.	1.1	2
225	SARSâ€CoVâ€2: Mechanism of infection and emerging technologies for future prospects. Reviews in Medical Virology, 2021, 31, e2168.	3.9	28

#	Article	IF	Citations
226	An update on coronavirus disease-19 vaccines. Journal of Medical Evidence, 2021, 2, 24.	0.2	2
227	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Frontiers in Immunology, 2020, 11, 607583.	2.2	12
228	Structural Insights into the Interaction of Clinically Relevant Phosphorothioate mRNA Cap Analogs with Translation Initiation Factor 4E Reveal Stabilization via Electrostatic Thio-Effect. ACS Chemical Biology, 2021, 16, 334-343.	1.6	16
230	Promising COVID-19 Vaccines. SpringerBriefs in Applied Sciences and Technology, 2021, , 115-126.	0.2	0
232	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerging Microbes and Infections, 2021, 10, 1589-1597.	3.0	41
233	Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines. Clinical Infectious Diseases, 2021, 73, 1320-1321.	2.9	10
234	Pathogenic Human Coronaviruses. , 2021, , .		5
235	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. Current Topics in Microbiology and Immunology, 2021, , 1.	0.7	9
236	Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials. Global Health Action, 2021, 14, 1892309.	0.7	14
237	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 2021, 9, 73.	2.1	24
238	Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases. Przeglad Gastroenterologiczny, 2021, 16, 2-4.	0.3	7
239	Active vitamin D supplementation and COVID-19 infections: review. Irish Journal of Medical Science, 2021, 190, 1271-1274.	0.8	11
240	COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 2021, 184, 476-488.e11.	13.5	586
241	Safety in Endoscopy for Patients and Healthcare Workers During the COVID-19 Pandemic. Techniques and Innovations in Gastrointestinal Endoscopy, 2021, 23, 170-178.	0.4	9
242	The role and uses of antibodies in COVID-19 infections: a living review. Oxford Open Immunology, 2021, 2, iqab003.	1.2	17
243	AutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus. Computational and Structural Biotechnology Journal, 2021, 19, 5029-5038.	1.9	4
244	An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 2021, 9, 97.	2.1	117
245	Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerging Microbes and Infections, 2021, 10, 629-637.	3.0	118

#	Article	IF	Citations
246	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerging Microbes and Infections, 2021, 10, 1598-1608.	3.0	76
247	COVID-19 vaccines: where we stand and challenges ahead. Cell Death and Differentiation, 2021, 28, 626-639.	5.0	626
248	Vaccinations in CLL: implications for COVID-19. Blood, 2021, 137, 144-146.	0.6	20
249	Therapeutic Potential of Nucleic Acids when Combined with Extracellular Vesicles. , 2021, 12, 1476.		12
252	Genome sequencing and its use in public health responses to COVID-19. Microbiology Australia, 2021, 42, 44.	0.1	1
253	El movimiento antivacunas: un aliado de la COVID-19. Revista Internacional De Pensamiento PolÃtico, 0, 15, 127-138.	0.0	5
254	Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Communications, 2021, 3, fcab169.	1.5	48
255	Vaccination Strategies for Minimizing Loss of Life in COVID-19 in a Europe Lacking Vaccines. SSRN Electronic Journal, 0, , .	0.4	3
256	The Next Generation of Influenza Vaccines: Towards a Universal Solution. Vaccines, 2021, 9, 26.	2.1	19
259	Structure of SARS-CoV-2 Proteins. , 2021, , 91-120.		0
260	Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries. The American Journal of Chinese Medicine, 2021, 49, 543-575.	1.5	21
261	Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design. Viruses, 2021, 13, 109.	1.5	223
262	COVID-19: An overview and a clinical update. World Journal of Clinical Cases, 2021, 9, 8-23.	0.3	38
263	The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. Immunotherapy Advances, 2021, 1, ltab019.	1.2	4
264	Drivers of Acceptance of COVID-19 Proximity Tracing Apps in Switzerland: Panel Survey Analysis. JMIR Public Health and Surveillance, 2021, 7, e25701.	1.2	83
265	Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 147-153.	2.5	29
267	Nextâ€Generation Vaccines: Nanoparticleâ€Mediated DNA and mRNA Delivery. Advanced Healthcare Materials, 2021, 10, e2001812.	3.9	130
268	Development of mRNA Vaccines: Scientific and Regulatory Issues. Vaccines, 2021, 9, 81.	2.1	56

#	Article	IF	Citations
269	A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines, 2021, 9, 39.	2.1	78
270	A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy. Arab Journal of Basic and Applied Sciences, 2021, 28, 225-233.	1.0	13
271	SARS-CoV-2 vaccine development and how Brazil is contributing. Genetics and Molecular Biology, 2021, 44, e20200320.	0.6	7
272	Acute treatment with monoclonal antibodies: their design and their use. Microbiology Australia, 2021, 42, 39.	0.1	0
273	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	0.7	29
275	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Frontiers in Physiology, 2021, 12, 593223.	1.3	113
276	Evaluation of the safety and efficacy of using human menstrual bloodâ€derived mesenchymal stromal cells in treating severe and critically ill COVIDâ€19 patients: An exploratory clinical trial. Clinical and Translational Medicine, 2021, 11, e297.	1.7	90
277	SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nature Communications, 2021, 12, 541.	5.8	66
278	Antibodies to neutralising epitopes synergistically block the interaction of the receptorâ€binding domain of SARSâ€CoVâ€2 to ACE 2. Clinical and Translational Immunology, 2021, 10, e1260.	1.7	13
279	ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC REVIEW. Frontiers of Agricultural Science and Engineering, 2021, 8, 603.	0.9	14
281	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. Annual Review of Microbiology, 2021, 75, 19-47.	2.9	52
282	Antibodies, epicenter of SARS-CoV-2 immunology. Cell Death and Differentiation, 2021, 28, 821-824.	5.0	9
283	Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines. Brazilian Journal of Medical and Biological Research, 2021, 54, e10725.	0.7	9
284	The Worldwide Effort to Develop Vaccines for COVID-19. Advances in Experimental Medicine and Biology, 2021, 1327, 215-223.	0.8	3
285	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.1	5
286	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
287	The evolutionary dynamics of endemic human coronaviruses. Virus Evolution, 2021, 7, veab020.	2.2	40
288	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). 3 Biotech, 2021, 11, 89.	1.1	29

#	Article	IF	Citations
290	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses, 2021, 13, 134.	1.5	56
291	The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 2021, 11, 1690-1702.	4.6	71
292	Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces. International Journal of Biological Sciences, 2021, 17, 1461-1468.	2.6	37
293	Future perspectives on swine viral vaccines: where are we headed?. Porcine Health Management, 2021, 7, 1.	0.9	26
295	Safe and effective aerosolization of in vitro transcribed mRNA to the respiratory tract epithelium of horses without a transfection agent. Scientific Reports, 2021, 11, 371.	1.6	10
299	Vaccinology in the postâ^'COVID-19 era. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	62
300	The role of pseudotype neutralization assays in understanding SARS CoV-2. Oxford Open Immunology, 2021, 2, iqab005.	1.2	20
301	New Enkephalin Nanomedicines for Pain Alleviation, Overcoming the Side Effects of Morphine. , 2021, , 191-212.		0
303	Minimizing Loss of Life in COVID-19 in a 100 Day Period in the U.S.A. by Personalized-Dose Vaccination. SSRN Electronic Journal, 0, , .	0.4	1
304	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
306	Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma. SSRN Electronic Journal, 0, , .	0.4	2
307	Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. Neurotherapeutics, 2021, 18, 244-251.	2.1	10
308	A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice. Biomaterials Science, 2021, 9, 7287-7296.	2.6	10
309	A Vaccination Simulator for COVID-19: Effective and Sterilizing Immunization Cases. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 4317-4327.	3.9	8
310	mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences, 2021, 17, 1446-1460.	2.6	185
311	IBD in the Time of COVID-19. Clinical Gastroenterology, 2021, , 345-352.	0.0	0
312	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines, 2021, 9, 36.	2.1	41
313	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS Journal, 2021, 23, 14.	2.2	291

#	Article	IF	Citations
314	SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1.	1.9	104
315	Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines, 2021, 9, 61.	2.1	105
316	Immune response to COVID-19 infection: a double-edged sword. Immunological Medicine, 2021, 44, 187-196.	1.4	14
317	Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease. Infection and Drug Resistance, 2021, Volume 14, 151-161.	1.1	49
318	Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery. Biochemistry, 2021, 60, 966-990.	1.2	18
319	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS Nano, 2021, 15, 9627-9637.	7.3	66
320	The Vaccine Supply Chain: A Call for Resilience Analytics to Support COVID-19 Vaccine Production and Distribution. Risk, Systems and Decisions, 2021, , 389-437.	0.5	21
322	Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. Communications Biology, 2021, 4, 267.	2.0	25
325	Tick-Tattoo: DNA Vaccination Against B. burgdorferi or Ixodes scapularis Tick Proteins. Frontiers in Immunology, 2021, 12, 615011.	2.2	12
326	COVID-19 basics and vaccine development with a Canadian perspective. Canadian Journal of Microbiology, 2021, 67, 112-118.	0.8	3
327	Ten commonly asked questions about Covid-19 and lessons learned from Thailand. Journal of Health Research, 2021, 35, 329-344.	0.4	7
328	Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines. Pharmaceutics, 2021, 13, 240.	2.0	24
329	Instrumental analysis of RNA modifications. Critical Reviews in Biochemistry and Molecular Biology, 2021, 56, 178-204.	2.3	26
330	Promoting versatile vaccine development for emerging pandemics. Npj Vaccines, 2021, 6, 26.	2.9	26
331	Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine, 2021, 39, 1310-1318.	1.7	113
333	A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach. Frontiers in Immunology, 2021, 12, 598778.	2.2	14
334	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communications, 2021, 12, 776.	5.8	65
337	Aptamer Conjugated Gold Nanostar-Based Distance-Dependent Nanoparticle Surface Energy Transfer Spectroscopy for Ultrasensitive Detection and Inactivation of Corona Virus. Journal of Physical Chemistry Letters, 2021, 12, 2166-2171.	2.1	53

#	Article	IF	Citations
339	The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. Drugs in Context, 2021, 10, 1-10.	1.0	77
340	Immune thrombocytopenia in a <scp>22</scp>â€yearâ€old post <scp>C</scp>ovidâ€<scp>19</scp> vaccine. American Journal of Hematology, 2021, 96, E133-E134.	2.0	99
341	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open, 2021, 7, e001594.	1.8	59
342	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416.	13.9	7,910
343	The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine, 2021, 39, 1157-1164.	1.7	105
344	Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. Journal of Biomolecular Structure and Dynamics, 2022, 40, 6545-6555.	2.0	40
345	Next-generation COVID-19 vaccines: here come the proteins. Lancet, The, 2021, 397, 643-645.	6.3	9
352	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. IScience, 2021, 24, 102021.	1.9	66
353	Biosecurity risks associated with vaccine platform technologies. Vaccine, 2022, 40, 2514-2523.	1.7	9
355	COVID-19 Vaccination: From Interesting Agent to the Patient. Vaccines, 2021, 9, 120.	2.1	7
357	A Review on SERS-Based Detection of Human Virus Infections: Influenza and Coronavirus. Biosensors, 2021, 11, 66.	2.3	60
358	How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?. Diabetes, 2021, 70, 1021-1028.	0.3	2
359	Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19. Heliyon, 2021, 7, e06350.	1.4	86
360	The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. Journal of Controlled Release, 2021, 330, 305-316.	4.8	24
361	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biology, 2021, 19, e3001091.	2.6	163
362	COVIDâ€19: Current knowledge in clinical features, immunological responses, and vaccine development. FASEB Journal, 2021, 35, e21409.	0.2	71
363	Omics-Driven Biotechnology for Industrial Applications. Frontiers in Bioengineering and Biotechnology, 2021, 9, 613307.	2.0	49
364	Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nature Human Behaviour, 2021, 5, 337-348.	6.2	1,002

#	Article	IF	Citations
365	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. Annual Review of Pharmacology and Toxicology, 2022, 62, 25-53.	4.2	20
366	Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus. Npj Vaccines, 2021, 6, 22.	2.9	7
368	COVID-19 and immunity: quo vadis?. International Immunology, 2021, 33, 507-513.	1.8	5
369	Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Frontiers in Immunology, 2021, 12, 640093.	2.2	93
371	Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. Journal of Virology, 2021, 95, .	1.5	48
372	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	5.8	316
373	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 397, 682-694.	6.3	235
374	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. Mayo Clinic Proceedings, 2021, 96, 446-463.	1.4	62
376	COVID-19 vaccine candidates: A review. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 58-63.	0.1	1
377	Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. Molecules, 2021, 26, 1134.	1.7	11
379	A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. Protein Journal, 2021, 40, 260-295.	0.7	24
380	Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. Cell, 2021, 184, 881-898.	13.5	56
381	Vaccines - safety in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 76, 23-40.	1.4	39
382	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. Journal of the Royal Society Interface, 2021, 18, 20200950.	1.5	22
383	The impact of immuno-aging on SARS-CoV-2 vaccine development. GeroScience, 2021, 43, 31-51.	2.1	31
384	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Frontiers in Immunology, 2021, 12, 631139.	2.2	117
387	COVID-19 mRNA vaccines. Journal of Genetics and Genomics, 2021, 48, 107-114.	1.7	59
388	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines, 2021, 9, 147.	2.1	175

#	Article	IF	Citations
389	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	13.7	1,232
390	Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. Saudi Pharmaceutical Journal, 2021, 29, 173-187.	1.2	23
391	Maintaining Safety with SARS-CoV-2 Vaccines. New England Journal of Medicine, 2021, 384, 643-649.	13.9	330
392	Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of mRNA COVID-19 Vaccines?. Pain Medicine, 2021, 22, 994-1000.	0.9	7
393	Harnessing biomaterials for therapeutic strategies against COVID-19. Emergent Materials, 2021, 4, 9-18.	3.2	9
394	The impact of COVIDâ€19 on kidney transplantation and the kidney transplant recipient â€“ One year into the pandemic. Transplant International, 2021, 34, 612-621.	0.8	40
395	Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19. Chinese Medicine, 2021, 16, 24.	1.6	21
396	COVID-19 Pandemic: the story is not over yet. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100802.	0.6	2
398	Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. RMD Open, 2021, 7, e001553.	1.8	23
399	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications, 2021, 12, 1018.	5.8	82
402	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9, 171.	2.1	43
404	Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. Journal of Ovarian Research, 2021, 14, 39.	1.3	5
407	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduction and Targeted Therapy, 2021, 6, 48.	7.1	79
409	â€œCOVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatmentâ€• Archives of Dermatological Research, 2022, 314, 1-15.	1.1	99
410	Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. Viruses, 2021, 13, 270.	1.5	53
411	Development and deployment of COVID-19 vaccines for those most vulnerable. Science Translational Medicine, 2021, 13, .	5.8	60
412	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Npj Vaccines, 2021, 6, 28.	2.9	507
413	DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. Scientific Reports, 2021, 11, 3125.	1.6	17

#	Article	IF	Citations
414	Three salvianolic acids inhibit 2019â€nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2. Journal of Medical Virology, 2021, 93, 3143-3151.	2.5	33
415	mRNA Vaccines against Flaviviruses. Vaccines, 2021, 9, 148.	2.1	25
416	Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. MBio, 2021, 12, .	1.8	64
417	Optical Detection of CoV-SARS-2 Viral Proteins to Sub-Picomolar Concentrations. ACS Omega, 2021, 6, 6404-6413.	1.6	38
418	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	13.5	1,364
419	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. Frontiers in Medicine, 2021, 8, 606755.	1.2	4
420	SARS-CoV-2 virus: Vaccines in development. Fundamental Research, 2021, 1, 131-138.	1.6	12
421	An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo. Vaccines, 2021, 9, 244.	2.1	15
422	Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study. International Journal of Molecular Sciences, 2021, 22, 2977.	1.8	4
426	In Vivo Production of RNA Aptamers and Nanoparticles: Problems and Prospects. Molecules, 2021, 26, 1422.	1.7	3
427	Do sleep quality and sleep duration before or after COVID-19 vaccination affect antibody response?. Chronobiology International, 2021, 38, 941-943.	0.9	10
428	A short discussion about the SARS-CoV-2 mRNA-1273 vaccine. International Journal of Infectious Diseases, 2021, 104, 532-533.	1.5	3
430	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight, 2021, 6, .	2.3	39
432	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. International Journal of Infectious Diseases, 2021, 104, 441-451.	1.5	14
433	Does COVID-19 Vaccination Warrant the Classical Principle â€œofelein i mi vlaptinâ€?. Medicina (Lithuania), 2021, 57, 253.	0.8	10
434	Adverse Events Reported From ÂCOVID-19 Vaccine Trials: A Systematic Review. Indian Journal of Clinical Biochemistry, 2021, 36, 427-439.	0.9	175
435	Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic. Journal of Infectious Diseases, 2022, 226, 1357-1361.	1.9	30
436	The conundrum of current anti-SARS-CoV-2 vaccines. Cytokine and Growth Factor Reviews, 2021, 60, 46-51.	3.2	6

#	Article	IF	Citations
437	Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. Frontiers in Immunology, 2021, 12, 637982.	2.2	9
439	Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. Drug Delivery and Translational Research, 2021, 11, 1420-1437.	3.0	18
440	The potential neurological effect of the COVIDâ€19 vaccines: A review. Acta Neurologica Scandinavica, 2021, 144, 3-12.	1.0	85
441	An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. Pharmaceutics, 2021, 13, 455.	2.0	55
442	Can a COVID-19 vaccine live up to Americansâ€™ expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions. Social Science and Medicine, 2021, 272, 113642.	1.8	109
443	Review of COVID-19 Vaccines and Their Evidence in Older Adults. Annals of Geriatric Medicine and Research, 2021, 25, 4-9.	0.7	43
444	SARS-CoV-2 vaccines in patients with SLE. Lupus Science and Medicine, 2021, 8, e000479.	1.1	30
445	Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These?. ACS Omega, 2021, 6, 6528-6536.	1.6	63
447	Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews, 2021, 170, 83-112.	6.6	248
449	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innovations, 2021, 7, 327-336.	1.0	27
450	Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data. Frontiers in Artificial Intelligence, 2021, 4, 630955.	2.0	13
451	Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 2021, 33, 521-527.	1.8	19
452	Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioengineering and Translational Medicine, 2021, 6, e10213.	3.9	142
453	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Science Advances, 2021, 7, .	4.7	80
454	Potential neutralizing antibodies discovered for novel corona virus using machine learning. Scientific Reports, 2021, 11, 5261.	1.6	62
455	Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Clinical Drug Investigation, 2021, 41, 499-509.	1.1	14
456	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Frontiers in Immunology, 2021, 12, 657711.	2.2	50
457	The Limitless Future of RNA Therapeutics. Frontiers in Bioengineering and Biotechnology, 2021, 9, 628137.	2.0	296

#	Article	IF	Citations
460	COVID-19 vaccines: rapid development, implications, challenges and future prospects. Human Cell, 2021, 34, 711-733.	1.2	227
461	SARSâ€CoVâ€2 and pediatric solid organ transplantation: Current knowns and unknowns. Pediatric Transplantation, 2021, 25, e13986.	0.5	6
462	Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opinion on Investigational Drugs, 2021, 30, 529-541.	1.9	26
464	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS ONE, 2021, 16, e0248007.	1.1	32
465	Cationic lipids for gene delivery: many players, one goal. Chemistry and Physics of Lipids, 2021, 235, 105032.	1.5	55
466	RNA-based therapies: A cog in the wheel of lung cancer defense. Molecular Cancer, 2021, 20, 54.	7.9	53
468	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. Future Cardiology, 2021, 17, 1277-1291.	0.5	9
469	Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165.	2.2	33
470	One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	60
472	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines, 2021, 9, 227.	2.1	47
473	Nanotechnology approaches for global infectious diseases. Nature Nanotechnology, 2021, 16, 369-384.	15.6	232
474	COVIDâ€19 reâ€infection. European Journal of Clinical Investigation, 2021, 51, e13537.	1.7	51
475	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses, 2021, 13, 418.	1.5	51
476	mRNA in cancer immunotherapy: beyond a source of antigen. Molecular Cancer, 2021, 20, 48.	7.9	46
477	Impact of the COVID-19 pandemic on cardiac arrest systems of care. Current Opinion in Critical Care, 2021, 27, 239-245.	1.6	26
478	COVID-19 in early 2021: current status and looking forward. Signal Transduction and Targeted Therapy, 2021, 6, 114.	7.1	191
480	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	6.0	468
481	Maxillofacial Trauma and COVID-19: A Review of the First 6 Months of the Pandemic. Craniomaxillofacial Trauma & Reconstruction, 2022, 15, 194338752110020.	0.6	0

#	Article	IF	Citations
482	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines, 2021, 9, 248.	2.1	0
483	Adaptations of an Integrated Behavioral Health Program During COVID-19. Cognitive and Behavioral Practice, 2021, 28, 481-491.	0.9	3
485	Severe Acute Respiratory Syndrome Coronavirus 2: Vaccine Hesitancy Among Underrepresented Racial and Ethnic Groups With HIV in Miami, Florida. Open Forum Infectious Diseases, 2021, 8, ofab154.	0.4	18
486	Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2021, 73, 1927-1939.	2.9	19
487	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncology, The, 2021, 22, 298-301.	5.1	11
489	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics, 2021, 11, 579.	1.3	114
490	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. Viruses, 2021, 13, 532.	1.5	18
492	Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses. Journal of Infectious Diseases, 2021, 224, 49-59.	1.9	26
493	CURRENT UPDATES ON COVID-19 VACCINES. Asian Journal of Pharmaceutical and Clinical Research, 0, , 17-23.	0.3	5
494	Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic. Journal of Controlled Release, 2021, 331, 121-141.	4.8	89
495	Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China. Vaccines, 2021, 9, 223.	2.1	20
496	Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Research, 2021, 1, 139-150.	1.6	19
497	Recombinant protein vaccines, a proven approach against coronavirus pandemics. Advanced Drug Delivery Reviews, 2021, 170, 71-82.	6.6	157
498	Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines, 2021, 9, 238.	2.1	49
499	Potential interactions between COVID-19 vaccines and antiepileptic drugs. Seizure: the Journal of the British Epilepsy Association, 2021, 86, 80-81.	0.9	17
500	Considering Mandatory Vaccination of Children for COVID-19. Pediatrics, 2021, 147, .	1.0	38
501	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	13.5	541
502	Lessons learned in the collection of convalescent plasma during the COVIDâ€19 pandemic. Vox Sanguinis, 2021, 116, 872-879.	0.7	8

#	Article	IF	Citations
503	Multilobed Magnetic Liposomes Enable Remotely Controlled Collection, Transport, and Delivery of Membrane-Soluble Cargos to Vesicles and Cells. ACS Applied Bio Materials, 2021, 4, 4833-4840.	2.3	3
504	Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity. European Heart Journal, 2021, 42, 2724-2726.	1.0	38
505	The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?. Clinical Therapeutics, 2021, 43, 549-556.	1.1	13
506	Messenger RNA vaccines against SARS-CoV-2. Cell, 2021, 184, 1401.	13.5	44
507	Engineered drug delivery devices to address Global Health challenges. Journal of Controlled Release, 2021, 331, 503-514.	4.8	35
508	First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization. Discoveries, 2021, 9, e122.	1.5	37
509	Plant in vitro Culture Technologies; A Promise Into Factories of Secondary Metabolites Against COVID-19. Frontiers in Plant Science, 2021, 12, 610194.	1.7	25
510	Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. Current Clinical Microbiology Reports, 2021, 8, 178-185.	1.8	46
511	Therapeutic Delivery of Pip4k2câ€Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart. Advanced Science, 2021, 8, 2004661.	5.6	14
512	Frontrunners in the race to develop a SARS-CoV-2 vaccine. Canadian Journal of Microbiology, 2021, 67, 189-212.	0.8	11
513	Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine. Cureus, 2021, 13, e14099.	0.2	54
514	Super-rapid race for saving lives by developing COVID-19 vaccines. Journal of Integrative Bioinformatics, 2021, 18, 27-43.	1.0	14
515	Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands. Clinical Chemistry, 2021, 67, 707-709.	1.5	4
518	Updates in neonatal coronavirus disease 2019: WhatÂcan we learn from detailed case reports? (Review). Molecular Medicine Reports, 2021, 23, .	1.1	7
519	Longitudinal antibody repertoire in â€œmildâ€•versus â€œsevereâ€•COVID-19 patients reveals immune markers associated with disease severity and resolution. Science Advances, 2021, 7, .	4.7	63
521	Therapeutic RNA Delivery for COVID and Other Diseases. Advanced Healthcare Materials, 2021, 10, e2002022.	3.9	31
522	International Collaboration to Ensure Equitable Access to Vaccines for COVIDâ€19: The ACTâ€Accelerator and the COVAX Facility. Milbank Quarterly, 2021, 99, 426-449.	2.1	98
523	COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 2021, 170, 1-25.	6.6	262

#	Article	IF	Citations
525	Novel approaches for vaccine development. Cell, 2021, 184, 1589-1603.	13.5	145
526	A Review of the Animal and Human Trials of the Ad5-nCoV Vaccine Candidate. Journal of Student Research, 2021, 10, .	0.0	2
527	Medical publishing during the COVID-19 pandemic: then and now. Journal of Thrombosis and Thrombolysis, 2021, 51, 1101-1106.	1.0	2
528	Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. Journal of College of Medical Sciences-Nepal, 2021, 11, 959-982.	0.2	17
531	Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. Vaccines, 2021, 9, 296.	2.1	6
532	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communications, 2021, 12, 1403.	5.8	65
534	Nanotechnology for modern medicine: next step towards clinical translation. Journal of Internal Medicine, 2021, 290, 486-498.	2.7	88
535	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2021, 170, 113-141.	6.6	71
536	COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice. Journal of Virology, 2021, 95, .	1.5	78
537	Perspectives on RNA Vaccine Candidates for COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 635245.	1.6	44
539	Precision therapeutic targets for COVID-19. Virology Journal, 2021, 18, 66.	1.4	40
540	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. Bioscience Reports, 2021, 41, .	1.1	16
541	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Reports, 2021, 34, 108837.	2.9	23
542	Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro. Frontiers in Immunology, 2021, 12, 613045.	2.2	14
543	COVID-19: Insights into Potential Vaccines. Microorganisms, 2021, 9, 605.	1.6	31
545	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	5.3	217
546	A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. Journal of Clinical Microbiology, 2021, 59, .	1.8	110
547	Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates. Scientific Reports, 2021, 11, 5804.	1.6	15

#	Article	IF	Citations
548	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science Advances, 2021, 7, .	4.7	100
550	Transgene Delivery to Human Induced Pluripotent Stem Cells Using Nanoparticles. Pharmaceuticals, 2021, 14, 334.	1.7	3
551	Quantum Biotech and Internet of Virus Things: Towards a Theoretical Framework. Applied System Innovation, 2021, 4, 27.	2.7	2
552	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Frontiers in Immunology, 2021, 12, 589095.	2.2	102
554	Gender differences in vaccine therapy: where are we in COVID-19 pandemic?. Monaldi Archives for Chest Disease, 2021, , .	0.3	17
555	COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey. Vaccines, 2021, 9, 399.	2.1	34
556	Cationic Nanoparticle-Based Cancer Vaccines. Pharmaceutics, 2021, 13, 596.	2.0	21
558	Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics, 2021, 13, 501.	2.0	15
559	Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design. Frontiers in Immunology, 2021, 12, 660198.	2.2	28
560	Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use. Vaccine, 2021, 39, 2295-2302.	1.7	72
562	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals, 2021, 14, 406.	1.7	101
563	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	3.8	260
565	Current Advances in Novel SARS-CoV-2 Disease (COVID-19) Treatment and Intervention Strategies. Coronaviruses, 2021, 2, 353-358.	0.2	2
566	Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational Study. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 123-129.	0.1	1
567	A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. Virus Research, 2021, 295, 198305.	1.1	14
569	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines, 2021, 9, 433.	2.1	85
570	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nature Reviews Immunology, 2021, 21, 395-404.	10.6	223
572	T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine, 2021, 13, .	5.8	128

#	Article	IF	Citations
573	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239.	6.6	66
574	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chinese Medical Journal, 2021, 134, 1289-1298.	0.9	49
575	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	2.9	46
577	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood, 2021, 137, 3165-3173.	0.6	539
578	Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. New England Journal of Medicine, 2021, 384, 1468-1470.	13.9	417
579	COVID-19 Pandemic Is Associated with an Adverse Impact on Burnout and Mood Disorder in Healthcare Professionals. International Journal of Environmental Research and Public Health, 2021, 18, 3654.	1.2	16
580	Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review. Dermatitis, 2021, 32, 133-139.	0.8	12
582	Women perception of SARS-CoV-2 vaccination during pregnancy and subsequent maternal anxiety: a prospective observational study. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 6302-6305.	0.7	50
583	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine, 2021, 180, 106355.	1.3	25
584	Strategies for Immunomonitoring after Vaccination and during Infection. Vaccines, 2021, 9, 365.	2.1	12
585	Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. Npj Vaccines, 2021, 6, 53.	2.9	23
586	Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. Journal of Pharmacy Practice, 2022, 35, 947-951.	0.5	82
588	Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain. Scientific Reports, 2021, 11, 9166.	1.6	13
589	Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. AAPS PharmSciTech, 2021, 22, 126.	1.5	41
590	Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach. Viruses, 2021, 13, 787.	1.5	13
591	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature Medicine, 2021, 27, 1062-1070.	15.2	114
592	mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine, 2021, 39, 2190-2200.	1.7	214
593	Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clinical Infectious Diseases, 2021, 73, 2065-2072.	2.9	409

#	Article	IF	Citations
595	A multiplex antigen microarray for simultaneous IgG and IgM detection against SARSâ€CoVâ€2 reveals higher seroprevalence than reported. Microbial Biotechnology, 2021, 14, 1228-1236.	2.0	11
596	Prolonged Anaphylaxis to Pfizer Coronavirus Disease 2019 Vaccine: A Case Report and Mechanism of Action. , 2021, 3, e0397.		7
597	COVID-19 Vaccine in Veterans with Multiple Sclerosis: Protect the Vulnerable. , 2021, 38, S28-S32.		1
599	T lymphocytes as critical mediators in tissue regeneration, fibrosis, and the foreign body response. Acta Biomaterialia, 2021, 133, 17-33.	4.1	42
600	Nanostrategies to Develop Current Antiviral Vaccines. ACS Applied Bio Materials, 2021, 4, 3880-3890.	2.3	3
601	Development of COVIDVax Model to Estimate the Risk of SARS-CoV-2â€"Related Death Among 7.6 Million US Veterans for Use in Vaccination Prioritization. JAMA Network Open, 2021, 4, e214347.	2.8	33
602	mRNA-Based Vaccines. Vaccines, 2021, 9, 390.	2.1	67
603	Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. IScience, 2021, 24, 102298.	1.9	70
604	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight, 2021, 6, .	2.3	52
605	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Frontiers in Immunology, 2021, 12, 669339.	2.2	81
606	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. Cell Reports Medicine, 2021, 2, 100252.	3.3	33
607	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	1.0	16
608	Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1453-1462.	1.4	59
609	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. Journal of Clinical Investigation, 2021, 131, .	3.9	154
610	Innate and adaptive immune responses toward nanomedicines. Acta Pharmaceutica Sinica B, 2021, 11, 852-870.	5.7	26
611	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host and Microbe, 2021, 29, 529-539.e3.	5.1	324
613	Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. Npj Vaccines, 2021, 6, 61.	2.9	66
614	SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight, 2021, 6, .	2.3	72

#	Article	IF	Citations
615	Potential 3â€chymotrypsinâ€like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVIDâ€19 vaccine and drug development. FASEB Journal, 2021, 35, e21573.	0.2	18
616	Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. Npj Vaccines, 2021, 6, 65.	2.9	36
618	Impact of Ribosome Activity on SARS-CoV-2 LNP â€“ Based mRNA Vaccines. Frontiers in Molecular Biosciences, 2021, 8, 654866.	1.6	10
619	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. ACS Nano, 2021, 15, 5793-5818.	7.3	32
620	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. Journal of Biomaterials Science, Polymer Edition, 2021, 32, 1219-1249.	1.9	19
621	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. Infectious Diseases & Immunity, 2021, 1, 43-51.	0.2	4
622	Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults. Immunological Investigations, 2021, 50, 810-820.	1.0	10
623	Status Report on COVID-19 Vaccines Development. Current Infectious Disease Reports, 2021, 23, 9.	1.3	56
625	Practical handling of allergic reactions to COVID-19 vaccines. Allergo Journal International, 2021, 30, 79-95.	0.9	25
626	SARSâ€‘CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Human Vaccines and Immunotherapeutics, 2021, 17, 2356-2366.	1.4	64
629	A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment. Annals of Palliative Medicine, 2021, 10, 4777-4798.	0.5	9
631	The importance of genomic analysis in cracking the coronavirus pandemic. Expert Review of Molecular Diagnostics, 2021, 21, 547-562.	1.5	14
632	Reconcile the debate over protective effects of BCG vaccine against COVID-19. Scientific Reports, 2021, 11, 8356.	1.6	22
633	Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. Journal of Molecular and Cellular Cardiology, 2021, 153, 72-85.	0.9	12
635	Microarray patches enable the development of skin-targeted vaccines against COVID-19. Advanced Drug Delivery Reviews, 2021, 171, 164-186.	6.6	45
637	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. Journal of Physical Chemistry Letters, 2021, 12, 4059-4066.	2.1	22
638	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host and Microbe, 2021, 29, 516-521.e3.	5.1	199
639	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Frontiers in Immunology, 2021, 12, 656362.	2.2	29

#	Article	IF	Citations
640	Bursting the bubble: A molecular understanding of surfactant-water interfaces. Journal of Chemical Physics, 2021, 154, 170901.	1.2	7
642	Isolating Nanoparticles from Complex Biological Media by Immunoprecipitation. Nano Letters, 2021, 21, 4530-4538.	4.5	9
644	Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): Epidemiology and Vaccinology in Nigeria. International Journal of Travel Medicine and Global Health, 2021, 9, 60-69.	0.1	2
645	Influenza Virus and SARS-CoV-2 Vaccines. Journal of Immunology, 2021, 206, 2509-2520.	0.4	11
646	Impact of COVID-19 in patients with lymphoid malignancies. World Journal of Virology, 2021, 10, 97-110.	1.3	11
647	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18â€“59Âyears: A phase I randomized, double-blinded, controlled trial. Vaccine, 2021, 39, 2746-2754.	1.7	43
648	Recent Advances in Cellular and Molecular Bioengineering for Building and Translation of Biological Systems. Cellular and Molecular Bioengineering, 2021, 14, 293-308.	1.0	2
649	Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination. Journal of Immunology, 2021, 206, 2503-2507.	0.4	11
650	Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Microbial Cell Factories, 2021, 20, 95.	1.9	23
652	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Emerging Microbes and Infections, 2021, 10, 1002-1015.	3.0	22
653	Acute Coronary Tree Thrombosis After Vaccination for COVID-19. JACC: Cardiovascular Interventions, 2021, 14, e103-e104.	1.1	46
654	Smart Nucleic Acids as Future Therapeutics. Trends in Biotechnology, 2021, 39, 1289-1307.	4.9	15
656	Chemoâ€Enzymatic Modification of the 5â€² Cap Maintains Translation and Increases Immunogenic Properties of mRNA. Angewandte Chemie - International Edition, 2021, 60, 13280-13286.	7.2	34
657	Impact of COVID-19 pandemic on non-COVID-19 publications. Resuscitation, 2021, 162, 102-103.	1.3	4
659	Seropositivity in blood donors and pregnant women during the first year of SARSâ€CoVâ€2 transmission in Stockholm, Sweden. Journal of Internal Medicine, 2021, 290, 666-676.	2.7	34
660	Evaluation of COVID-19 vaccine acceptance of healthcare providers in a tertiary Pediatric hospital. Human Vaccines and Immunotherapeutics, 2021, 17, 2946-2950.	1.4	21
661	Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases. Molecules, 2021, 26, 3304.	1.7	21
662	SARS-COV-2 vaccination after stem cell transplantation for scleroderma. Annals of the Rheumatic Diseases, 2021, 80, 1354-1355.	0.5	8

#	Article	IF	Citations
663	Coronavirus disease 2019 (COVIDâ€19) vaccines: A concise review. Oral Diseases, 2022, 28, 2326-2336.	1.5	36
664	Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. Vaccine, 2021, 39, 2995-3006.	1.7	71
666	Targets and strategies for vaccine development against SARS-CoV-2. Biomedicine and Pharmacotherapy, 2021, 137, 111254.	2.5	58
667	Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA - Journal of the American Medical Association, 2021, 325, 1896.	3.8	125
668	Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA - Journal of the American Medical Association, 2021, 325, 1784.	3.8	452
669	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicineâ€"Specific Cancer Targeting with Undetectable Toxicity. Chemical Reviews, 2021, 121, 7398-7467.	23.0	45
670	Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. Transplantation, 2021, 105, e104-e106.	0.5	49
673	Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. NeurologÃa (English Edition), 2021, 36, 451-461.	0.2	10
675	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. Cell Reports, 2021, 35, 109179.	2.9	63
676	The evolution and future of influenza pandemic preparedness. Experimental and Molecular Medicine, 2021, 53, 737-749.	3.2	88
677	COVID-19 vaccines: progress and understanding on quality control and evaluation. Signal Transduction and Targeted Therapy, 2021, 6, 199.	7.1	21
678	The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. American Journal of Obstetrics and Gynecology, 2021, 224, 484-495.	0.7	68
679	Airâ"Liquid Interface Cultures of the Healthy and Diseased Human Respiratory Tract: Promises, Challenges, and Future Directions. Advanced NanoBiomed Research, 2021, 1, 2000111.	1.7	47
680	Demonstrating the ascendancy of COVID-19 research using acronyms. Scientometrics, 2021, 126, 6127-6130.	1.6	11
681	SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development. International Journal of Biological Macromolecules, 2021, 179, 45-60.	3.6	14
682	An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines. MBio, 2021, 12, .	1.8	20
683	Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles. Journal of Immunology Research, 2021, 2021, 1-8.	0.9	9
684	Novel formulations and drug delivery systems to administer biological solids. Advanced Drug Delivery Reviews, 2021, 172, 183-210.	6.6	25

#	Article	IF	Citations
685	Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions. Advanced Healthcare Materials, 2021, 10, e2100299.	3.9	20
686	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	6.6	75
687	Polymeric Delivery of Therapeutic Nucleic Acids. Chemical Reviews, 2021, 121, 11527-11652.	23.0	138
688	A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. Journal of Virology, 2021, 95, .	1.5	37
689	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 569-578.	0.3	6
690	Eine chemoâ€enzymatische Modifizierung der 5â€²â€Kappe erhÃlt die Translation und erhÃ¶ht die ImmunogenitÃt der mRNA. Angewandte Chemie, 2021, 133, 13390-13397.	1.6	2
691	Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates. Science Advances, 2021, 7, .	4.7	28
692	Advances of nanomaterialsâ€based strategies for fighting against COVIDâ€19. View, 2021, 2, 20200180.	2.7	16
693	Cations Regulate Membrane Attachment and Functionality of DNA Nanostructures. Journal of the American Chemical Society, 2021, 143, 7358-7367.	6.6	44
694	Computational Ab Initio Interaction Analyses between Neutralizing Antibody and SARS-CoV-2 Variant Spike Proteins Using the Fragment Molecular Orbital Method. Bulletin of the Chemical Society of Japan, 2021, 94, 1794-1798.	2.0	4
695	Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 1146-1153.	2.0	45
696	Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses. Frontiers in Immunology, 2021, 12, 656433.	2.2	11
697	Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation. Npj Vaccines, 2021, 6, 73.	2.9	78
698	Lack of immune response after mRNA vaccination to SARSâ€CoVâ€2 in a solid organ transplant patient. Journal of Medical Virology, 2021, 93, 5623-5625.	2.5	10
699	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerging Infectious Diseases, 2021, 27, 1343-1352.	2.0	74
700	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 637-646.	4.6	326
702	In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2. Journal of Biomolecular Structure and Dynamics, 2021, , 1-16.	2.0	2
703	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. World Journal of Clinical Cases, 2021, 9, 2951-2968.	0.3	8

#	Article	IF	Citations
704	Herpesviruses in Reptiles. Frontiers in Veterinary Science, 2021, 8, 642894.	0.9	11
706	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1397-e1401.	2.9	44
707	The hydrodynamics of an active squirming particle inside of a porous container. Journal of Fluid Mechanics, 2021, 919, .	1.4	4
708	Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2. Frontiers in Molecular Biosciences, 2021, 8, 628585.	1.6	31
709	A rigorous evaluation of optimal peptide targets for MS-based clinical diagnostics of Coronavirus Disease 2019 (COVID-19). Clinical Proteomics, 2021, 18, 15.	1.1	7
711	Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and inÂvitro validation of protease activity inhibition using an enzymatic inhibition assay. Journal of Molecular Graphics and Modelling, 2021, 104, 107851.	1.3	29
713	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. Biomedicines, 2021, 9, 611.	1.4	10
714	Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality. Frontiers in Immunology, 2021, 12, 659339.	2.2	33
715	The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19. Annual Review of Biophysics, 2021, 50, 493-523.	4.5	12
716	OMIP 075: A 22â€color panel for the measurement of antigenâ€specific Tâ€cell responses in human and nonhuman primates. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 884-887.	1.1	8
718	Optimism and caution for an inactivated COVID-19 vaccine. Lancet Infectious Diseases, The, 2021, 21, 581-582.	4.6	8
719	Immune response scenario and vaccine development for SARS-CoV-2 infection. International Immunopharmacology, 2021, 94, 107439.	1.7	10
720	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39, 2791-2799.	1.7	185
721	The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 2021, 333, 511-520.	4.8	276
722	Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nature Communications, 2021, 12, 2656.	5.8	51
723	Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. Journal of Theoretical Biology, 2021, 517, 110621.	0.8	110
725	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	2.9	198
726	Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ, The, 2021, 373, n1087.	3.0	59

#	Article	IF	Citations
729	Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA - Journal of the American Medical Association, 2021, 325, 2204.	3.8	835
730	Fillers for aesthetics on the face â€“ Newer perspectives. , 0, 1, 6.		1
731	Evolving pharmacovigilance requirements with novel vaccines and vaccine components. BMJ Global Health, 2021, 6, e003403.	2.0	6
732	Drug combination therapy for emerging viral diseases. Drug Discovery Today, 2021, 26, 2367-2376.	3.2	65
733	Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. Frontiers in Immunology, 2021, 12, 674048.	2.2	26
734	Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2. Viruses, 2021, 13, 980.	1.5	15
736	The need for ethical and pragmatic strategies for sample and data collection during public health emergenciesâ€”minimizing missed opportunities. European Heart Journal, 2021, 42, 3114-3116.	1.0	0
737	The safety of Covid-19 mRNA vaccines: a review. Patient Safety in Surgery, 2021, 15, 20.	1.1	150
738	On the road to ending the COVID-19 pandemic: Are we there yet?. Virology, 2021, 557, 70-85.	1.1	38
739	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine, 2021, 35, 100861.	3.2	153
740	COVID-19 vaccine decisions: considering the choices and opportunities. Microbes and Infection, 2021, 23, 104811.	1.0	17
741	Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clinical Infectious Diseases, 2022, 74, 715-718.	2.9	141
742	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. Human Genomics, 2021, 15, 27.	1.4	39
743	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines, 2021, 9, 467.	2.1	228
744	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 2021, 80, 1339-1344.	0.5	202
745	Interim Results of a Phase 1â€“2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 2021, 384, 1824-1835.	13.9	962
747	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 1205-1211.	15.2	3,133
748	A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. Frontiers in Genetics, 2021, 12, 684152.	1.1	10

#	Article	IF	Citations
749	Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Diagnostics, 2021, 11, 1190.	1.3	10
750	N-Glycosylation Network Construction and Analysis to Modify Glycans on the Spike (S) Glycoprotein of SARS-CoV-2. Frontiers in Bioinformatics, 2021, 1, .	1.0	5
751	SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine, 2021, 68, 103410.	2.7	56
752	Future considerations for the mRNA-lipid nanoparticle vaccine platform. Current Opinion in Virology, 2021, 48, 65-72.	2.6	63
753	Review: Vaccine Myth-Buster â€“ Cleaning Up With Prejudices and Dangerous Misinformation. Frontiers in Immunology, 2021, 12, 663280.	2.2	22
755	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. Canadian Journal of Physiology and Pharmacology, 2021, 99, 577-588.	0.7	2
758	A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics. Plants, 2021, 10, 1213.	1.6	15
759	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines, 2021, 9, 588.	2.1	12
760	A reasoned approach towards administering COVIDâ€19 vaccines to pregnant women. Prenatal Diagnosis, 2021, 41, 1018-1035.	1.1	9
761	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Human Gene Therapy, 2021, 32, 541-562.	1.4	9
762	Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2021, 32, 2147-2152.	3.0	155
763	Immunological imprinting of the antibody response in COVID-19 patients. Nature Communications, 2021, 12, 3781.	5.8	149
764	Allergenic components of the mRNAâ€1273 vaccine for COVIDâ€19: Possible involvement of polyethylene glycol and IgGâ€mediated complement activation. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3307-3313.	2.7	92
765	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. Advances in Molecular Pathology, 2021, , .	0.2	1
766	COVID-19 and the Response of Transplant Centers: the Global Response with an Emphasis on the Kidney Recipient. Current Transplantation Reports, 2021, 8, 1-20.	0.9	4
768	COVID-19 vaccines: Frequently asked questions and updated answers. Infectious Diseases Now, 2021, 51, 319-333.	0.7	10
769	Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioactive Materials, 2022, 9, 590-601.	8.6	33
770	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Science Translational Medicine, 2021, 13, .	5.8	198

#	Article	IF	Citations
772	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). BioMed Research International, 2021, 2021, 1-20.	0.9	13
773	SARS-CoV-2 vaccines, where do we stand?. Comptes Rendus - Biologies, 2021, 344, 43-55.	0.1	3
774	Homologous and heterologous serological response to the Nâ€terminal domain of SARSâ€CoVâ€2 in humans and mice. European Journal of Immunology, 2021, 51, 2296-2305.	1.6	7
775	Is rapid scientific publication also high quality? Bibliometric analysis of highly disseminated <scp>COVID</scp>â€19 research papers. Learned Publishing, 2021, 34, 568-577.	0.8	27
776	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 701752.	2.2	17
777	Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants. Viruses, 2021, 13, 1171.	1.5	27
778	Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality. JAMA Network Open, 2021, 4, e2110782.	2.8	90
779	Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. Journal of Allergy and Clinical Immunology, 2021, 147, 2075-2082.e2.	1.5	117
780	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. Pathogens, 2021, 10, 710.	1.2	8
781	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine, 2021, 384, 2259-2261.	13.9	603
782	Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127990.	1.0	2
786	The Status and Prospects of Epsteinâ€“Barr Virus Prophylactic Vaccine Development. Frontiers in Immunology, 2021, 12, 677027.	2.2	23
787	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennye Tehnologii V Medicine, 2021, 13, 81.	0.4	4
788	Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies. Scientific Reports, 2021, 11, 13120.	1.6	11
789	Deep sequence modelling for predicting COVID-19 mRNA vaccine degradation. PeerJ Computer Science, 2021, 7, e597.	2.7	4
790	COVID-19 vaccine: Potential candidates, achievements, and challenges. GSC Biological and Pharmaceutical Sciences, 2021, 15, 102-109.	0.1	0
791	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Frontiers in Immunology, 2021, 12, 710263.	2.2	32
792	Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 1754-1755.	0.4	10

#	Article	IF	Citations
793	Postvaccine Antiâ€“SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 1699-1700.	0.4	37
794	Coronavirus disease 2019 vaccination in transplant recipients. Current Opinion in Infectious Diseases, 2021, 34, 275-287.	1.3	15
795	Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. Cell Reports, 2021, 35, 109305.	2.9	38
796	Updates on the coronavirus disease 2019 vaccine and consideration in children. Clinical and Experimental Pediatrics, 2021, 64, 328-338.	0.9	8
797	Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19. Nature Cell Biology, 2021, 23, 620-630.	4.6	67
798	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. ACS Nano, 2021, 15, 11180-11191.	7.3	60
799	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. International Journal of Pharmaceutics, 2021, 603, 120686.	2.6	83
800	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature, 2021, 596, 109-113.	13.7	586
802	Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. Molecules and Cells, 2021, 44, 408-421.	1.0	18
804	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology, 2021, 6, .	5.6	34
805	Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. Journal of Clinical Microbiology, 2021, 59, e0038821.	1.8	99
806	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. Virology, 2021, 558, 1-12.	1.1	17
808	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. Microorganisms, 2021, 9, 1303.	1.6	2
809	Vaccine allergy: evidence to consider for COVID-19 vaccines. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 401-409.	1.1	32
811	Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. Open Forum Infectious Diseases, 2021, 8, ofab353.	0.4	99
813	What gastroenterologists should know about SARSâ€“CoV 2 vaccine: World Endoscopy Organization perspective. United European Gastroenterology Journal, 2021, 9, 787-796.	1.6	4
815	Vaccines and allergic reactions: The past, the current COVIDâ€19 pandemic, and future perspectives. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1640-1660.	2.7	72
816	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3575-3583.	2.0	41

#	Article	IF	Citations
818	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. Open Forum Infectious Diseases, 2021, 8, ofab329.	0.4	7
819	COVID-19 vaccine development from the perspective of cancer patients. Human Vaccines and Immunotherapeutics, 2021, 17, 3281-3287.	1.4	4
820	Minor Intron Splicing from Basic Science to Disease. International Journal of Molecular Sciences, 2021, 22, 6062.	1.8	13
821	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. Drug Metabolism Reviews, 2021, 53, 508-541.	1.5	0
822	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells, 2021, 10, 1412.	1.8	6
823	COVID-19 in Women's health: Epidemiology. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 73, 81-90.	1.4	8
824	Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate. Journal of Virology, 2021, 95, e0223220.	1.5	25
825	Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2. BMC Infectious Diseases, 2021, 21, 580.	1.3	20
826	The Effect of COVID-19 Vaccinations in 47 European Countries. European Journal of Medical and Health Sciences, 2021, 3, 134-140.	0.1	1
827	An intra-host SARS-CoV-2 dynamics model to assess testing and quarantine strategies for incoming travelers, contact management, and de-isolation. Patterns, 2021, 2, 100262.	3.1	15
829	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. IScience, 2021, 24, 102646.	1.9	79
830	A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Molecular Therapy, 2021, 29, 1970-1983.	3.7	111
831	SARS-CoV-2 vaccines: Lights and shadows. European Journal of Internal Medicine, 2021, 88, 1-8.	1.0	90
832	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	64
833	Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS ONE, 2021, 16, e0249499.	1.1	148
834	Tackling COVID-19 with neutralizing monoclonal antibodies. Cell, 2021, 184, 3086-3108.	13.5	309
835	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases, The, 2021, 21, 803-812.	4.6	415
836	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host and Microbe, 2021, 29, 917-929.e4.	5.1	132

#	Article	IF	Citations
837	In Silico Screening of the Phenolic Compound Oleuropein and Its Hydrolysis Product 3-Hydroxytyrosol Against Certain Structural and Non-Structural Proteins of SARS-CoV- 2. Turkish Journal of Agricultural and Natural Sciences, 0, , .	0.1	0
839	Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19. BMJ Case Reports, 2021, 14, e242344.	0.2	20
840	Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertension Research, 2021, 44, 1047-1053.	1.5	7
841	A rational strategy to support approved COVID-19 vaccines prioritization. Human Vaccines and Immunotherapeutics, 2021, 17, 3474-3477.	1.4	4
842	Shoulder Injury Related to Vaccine Administration. Journal of the American Academy of Orthopaedic Surgeons, The, 2021, 29, 732-739.	1.1	25
843	Weak antiâ€“SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney International, 2021, 99, 1487-1489.	2.6	126
844	Nano-Microparticle Platforms in Developing Next-Generation Vaccines. Vaccines, 2021, 9, 606.	2.1	29
846	Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population. Vaccines, 2021, 9, 624.	2.1	26
848	Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects. Advanced Drug Delivery Reviews, 2021, 173, 427-438.	6.6	38
849	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry, 2021, 60, 2153-2169.	1.2	54
850	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. Journal of Virology, 2021, 95, e0020321.	1.5	35
851	A COVID-19 Epidemic Model Predicting the Effectiveness of Vaccination in the US. Infectious Disease Reports, 2021, 13, 654-667.	1.5	16
852	Prioritizing the First Doses of SARS-CoV-2 Vaccine to Save the Elderly: The Case Study of Italy. Frontiers in Public Health, 2021, 9, 684760.	1.3	1
853	Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 233-250.	2.6	13
854	Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles. Journal of Controlled Release, 2021, 335, 465-480.	4.8	55
855	Consideration for the scaleâ€up manufacture of nanotherapeuticsâ€”A critical step for technology transfer. View, 2021, 2, 20200190.	2.7	34
856	An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opinion on Drug Discovery, 2021, 16, 1307-1317.	2.5	37
858	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Frontiers in Immunology, 2021, 12, 701501.	2.2	157

#	Article	IF	Citations
859	Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?. Nephrology Dialysis Transplantation, 2021, 36, 1565-1569.	0.4	39
860	Microfluidic formulation of nanoparticles for biomedical applications. Biomaterials, 2021, 274, 120826.	5.7	143
862	Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. Nature Communications, 2021, 12, 4396.	5.8	24
863	The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. Clinics in Dermatology, 2021, 39, 966-984.	0.8	42
864	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 2021, 19, 173.	2.3	156
865	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infectious Diseases, The, 2021, 21, 1654-1664.	4.6	200
867	SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review. Biosafety and Health, 2021, 3, 249-263.	1.2	16
868	Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses, 2021, 13, 1351.	1.5	1
869	Preparation and evaluation of reduction-responsive micelles based on disulfide-linked chondroitin sulfate A-tocopherol succinate for controlled antitumour drug release. Journal of Pharmacy and Pharmacology, 2021, 73, 1405-1417.	1.2	6
870	Profiling SARS-CoV-2 HLA-I peptidome reveals TÂcell epitopes from out-of-frame ORFs. Cell, 2021, 184, 3962-3980.e17.	13.5	98
871	COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Review of Vaccines, 2021, 20, 1013-1025.	2.0	56
872	Does the light at the end of the tunnel shine for everyone? The need for early paediatric participation in vaccine trials during infectious pandemics. Clinical Ethics, 0, , 147775092110366.	0.5	0
873	Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. Journal of Controlled Release, 2021, 335, 237-246.	4.8	146
874	Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Top-Down Mass Spectrometry. Journal of the American Chemical Society, 2021, 143, 12014-12024.	6.6	48
875	Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Reports, 2021, 14, e243173.	0.2	46
876	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathogens, 2021, 17, e1009761.	2.1	66
877	Development and Delivery Systems of mRNA Vaccines. Frontiers in Bioengineering and Biotechnology, 2021, 9, 718753.	2.0	60
878	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. Inflammopharmacology, 2021, 29, 1331-1346.	1.9	7

#	Article	IF	Citations
879	Early antibody responses associated with survival in COVID19 patients. PLoS Pathogens, 2021, 17, e1009766.	2.1	13
880	Encapsulation state of messenger RNA inside lipid nanoparticles. Biophysical Journal, 2021, 120, 2766-2770.	0.2	86
881	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. Cells, 2021, 10, 1756.	1.8	19
882	Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review. Journal of Infection and Public Health, 2021, 14, 910-921.	1.9	14
883	Commentary on â€œMaking the world a better place: achieving impact through innovation and an entrepreneurial ethosâ€• Tizard Learning Disability Review, 2021, 26, 157-159.	0.3	0
884	Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?. Vaccines, 2021, 9, 761.	2.1	17
885	The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology, 2021, 559, 1-9.	1.1	29
886	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. Cell Host and Microbe, 2021, 29, 1137-1150.e6.	5.1	173
887	Targeting Viral Surface Proteins through Structure-Based Design. Viruses, 2021, 13, 1320.	1.5	10
888	Recent developments and opportunities in fighting COVID-19. Coronaviruses, 2021, 2, .	0.2	0
890	Quarter-dose of Moderna COVID vaccine still rouses a big immune response. Nature, 2021, , .	13.7	3
891	SARSâ€CoVâ€2 vaccination in patients with inflammatory bowel disease. GastroHep, 2021, 3, 212-228.	0.3	7
892	A Brief Overview of COVID-19 Vaccines. Iranian Journal of Public Health, 2021, 50, i-vi.	0.3	6
893	Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies. Frontiers in Immunology, 2021, 12, 705360.	2.2	48
894	Two Cases of Post-Moderna COVID-19 Vaccine Encephalopathy Associated With Nonconvulsive Status Epilepticus. Cureus, 2021, 13, e16172.	0.2	32
895	COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers. Journal of Racial and Ethnic Health Disparities, 2022, 9, 1543-1549.	1.8	14
896	COVID-19 Vaccines and Thrombosisâ€”Roadblock or Dead-End Street?. Biomolecules, 2021, 11, 1020.	1.8	28
897	Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer. Future Virology, 2021, 16, 443-446.	0.9	3

#	Article	IF	Citations
898	Predictive Analytics of COVID-19 with Neural Networks. , 2021, , .		7
900	Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. Journal of Neuroimmunology, 2021, 356, 577599.	1.1	62
901	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 950-961.	4.6	271
902	Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia, 2021, 35, 3534-3541.	3.3	71
903	SARS-CoV-2 Antibodies Detected in Motherâ€™s Milk Post-Vaccination. Journal of Human Lactation, 2021, 37, 492-498.	0.8	59
904	Colloidal gold immunochromatographic assay (GICA) is an effective screening method for identifying detectable anti-SARS-CoV-2 neutralizing antibodies. International Journal of Infectious Diseases, 2021, 108, 483-486.	1.5	14
905	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses, 2021, 13, 1397.	1.5	6
906	Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report. Journal of Infection and Public Health, 2021, 14, 1392-1394.	1.9	35
907	Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines, 2021, 9, 734.	2.1	89
908	Over 1â€year duration and age difference of SARSâ€CoVâ€2 antibodiesÂin convalescent COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 6506-6511.	2.5	26
909	Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines. Vaccines, 2021, 9, 820.	2.1	18
911	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Î±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. Frontiers in Immunology, 2021, 12, 719077.	2.2	9
912	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. Biochemical Pharmacology, 2021, 189, 114424.	2.0	27
914	Efficacy of COVID-19 vaccines: From clinical trials to real life. Therapie, 2021, 76, 277-283.	0.6	30
915	Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality. Nature Medicine, 2021, 27, 1321-1323.	15.2	35
917	From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine, 2021, 81, 101003.	2.7	13
918	Nanoformulations of Drugs Based on Biodegradable Lactide Copolymers with Various Molecular Structures and Architectures. Nanobiotechnology Reports, 2021, 16, 421-438.	0.2	13
919	COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines. Infectious Disease Reports, 2021, 13, 685-699.	1.5	72

#	Article	IF	Citations
920	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Reports, 2021, 36, 109353.	2.9	95
921	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	6.3	316
922	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine, 2021, 13, .	5.8	56
923	Peroxisomes exhibit compromised structure and matrix protein content in SARS-CoV-2-infected cells. Molecular Biology of the Cell, 2021, 32, 1273-1282.	0.9	26
924	Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant. Vaccines, 2021, 9, 737.	2.1	5
925	Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liverâ€Enriched Transcription Factors and Functional Proteins in Endâ€Stage Cirrhotic Human Hepatocytes. Hepatology Communications, 2021, 5, 1911-1926.	2.0	7
926	Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection. Journal of Advanced Research, 2022, 36, 211-222.	4.4	13
927	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infectious Diseases, 2021, 7, 2546-2564.	1.8	34
928	Modeling vaccination strategies in an Excel spreadsheet: Increasing the rate of vaccination is more effective than increasing the vaccination coverage for containing COVID-19. PLoS ONE, 2021, 16, e0254430.	1.1	7
929	Pharmacistsâ€™ Perceptions and Drivers of Immunization Practices for COVID-19 Vaccines: Results of a Nationwide Survey Prior to COVID-19 Vaccine Emergency Use Authorization. Pharmacy (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	6
930	Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance. IScience, 2021, 24, 102780.	1.9	4
931	Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?. Pharmaceuticals, 2021, 14, 730.	1.7	8
933	Efficacy of the <scp>COVID</scp>â€19 vaccine in heart transplant recipients: what we know and what we ignore. European Journal of Heart Failure, 2021, 23, 1560-1562.	2.9	3
934	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules, 2021, 11, 993.	1.8	136
936	Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air. International Journal of Molecular Sciences, 2021, 22, 7919.	1.8	8
938	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Research, 2021, 31, 1011-1023.	5.7	48
940	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and Therapy, 2021, 10, 1309-1330.	1.5	28
941	Emerging gene therapies for enhancing the hemostatic potential of platelets. Transfusion, 2021, 61, S275-S285.	0.8	1

#	Article	IF	Citations
944	mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ TÂcell response. Molecular Therapy, 2021, 29, 2227-2238.	3.7	42
945	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484.	10.6	434
946	Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 2021, 39, 4423-4428.	1.7	766
947	SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential. Biophysical Journal, 2021, 120, 2880-2889.	0.2	52
948	Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies. Transplantation, 2021, 105, e234-e243.	0.5	39
949	Detection of SARS-CoV-2-Specific IgA in the Human Milk of COVID-19 Vaccinated Lactating Health Care Workers. Breastfeeding Medicine, 2021, 16, 1004-1009.	0.8	34
950	Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials. Vaccines, 2021, 9, 939.	2.1	25
951	Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients. JAAD Case Reports, 2021, 14, 13-16.	0.4	10
952	A Literature Review on the Vaccination of COVID-19 in Pregnant and Breastfeeding Women: Effectiveness and Safety. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 234-237.	0.1	1
953	Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. Journal of Heart and Lung Transplantation, 2022, 41, 148-157.	0.3	83
954	Lessons Learnt From the COVID-19 Pandemic. Frontiers in Public Health, 2021, 9, 694705.	1.3	24
955	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med, 2021, 2, 979-992.e8.	2.2	127
956	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology, 2021, 74, 1049-1064.	3.6	136
957	Cardiovascular Disease Complicating COVID-19 in the Elderly. Medicina (Lithuania), 2021, 57, 833.	0.8	9
958	Opinion: A serious issue with the standardization of the adenovirus-based COVID-19 vaccines?. Archives of Toxicology, 2021, 95, 3137-3139.	1.9	0
959	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
960	Synthesis and characterization of vitamin D₃-functionalized carbon dots for CRISPR/Cas9 delivery. Nanomedicine, 2021, 16, 1673-1690.	1.7	6
961	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50

#	Article	IF	Citations
962	Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics. Pharmaceutics, 2021, 13, 1365.	2.0	61
963	Immunity to SARSâ€CoVâ€2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
964	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	13.5	228
965	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. EClinicalMedicine, 2021, 38, 100989.	3.2	56
966	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infectious Diseases, The, 2021, 21, 1107-1119.	4.6	345
967	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med, 2021, 2, 965-978.e5.	2.2	40
968	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. Annual Review of Medicine, 2022, 73, 1-16.	5.0	91
969	Attenuated activation of pulmonary immune cells in mRNA-1273â€“vaccinated hamsters after SARS-CoV-2 infection. Journal of Clinical Investigation, 2021, 131, .	3.9	23
970	Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo. PLoS ONE, 2021, 16, e0256401.	1.1	57
971	Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. JAMA Network Open, 2021, 4, e2122255.	2.8	64
972	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	6.6	59
973	Nanoparticles in the clinic: An update post <scp>COVID</scp>â€19 vaccines. Bioengineering and Translational Medicine, 2021, 6, e10246.	3.9	173
975	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine, 2021, 38, 101010.	3.2	28
976	Structure-guided TÂcell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell, 2021, 184, 4401-4413.e10.	13.5	65
977	Vaccine delivery systems toward lymph nodes. Advanced Drug Delivery Reviews, 2021, 179, 113914.	6.6	62
979	The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor. Analytical and Bioanalytical Chemistry, 2021, 413, 7205-7214.	1.9	9
980	Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nature Nanotechnology, 2021, 16, 843-850.	15.6	40
981	Analyzing Social Media to Explore the Attitudes and Behaviors Following the Announcement of Successful COVID-19 Vaccine Trials: Infodemiology Study. JMIR Infodemiology, 2021, 1, e28800.	1.0	35

#	Article	IF	Citations
982	Current development of Zika virus vaccines with special emphasis on virus-like particle technology. Expert Review of Vaccines, 2021, 20, 1483-1498.	2.0	8
983	Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection. Nutrients, 2021, 13, 2800.	1.7	67
984	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Advances, 2021, 5, 3053-3061.	2.5	123
986	Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation. Journal of Chemical Information and Modeling, 2021, 61, 4425-4441.	2.5	100
987	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	6.6	165
988	Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Regional Health - Europe, The, 2021, 7, 100150.	3.0	101
989	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 2241-2251.	13.9	267
990	COVID-19 vaccination in solid-organ transplant recipients: generating new data as fast as possible, but taking clinical decisions as slow as necessary. Clinical Microbiology and Infection, 2021, 27, 1070-1071.	2.8	2
991	Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets. Chemical Papers, 2022, 76, 111-121.	1.0	5
992	Specific approaches to patients affected by dementia and covid-19 in nursing homes: the role of the geriatrician. Ageing Research Reviews, 2021, 69, 101373.	5.0	9
993	Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series. Transplantation Direct, 2021, 7, e743.	0.8	3
995	ViralFP: A Web Application of Viral Fusion Proteins. Frontiers in Medical Technology, 2021, 3, 722392.	1.3	2
996	Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. Vaccines, 2021, 9, 913.	2.1	12
997	SARS-CoV-2 vaccines â€" the biggest medical research project of the 21st century. Current Opinion in Virology, 2021, 49, 52-57.	2.6	12
998	The impact of high-resolution structural data on stemming the COVID-19 pandemic. Current Opinion in Virology, 2021, 49, 127-138.	2.6	2
999	Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals. Infectious Diseases and Therapy, 2021, 10, 2765-2776.	1.8	65
1000	An Update on mRNA-Based Viral Vaccines. Vaccines, 2021, 9, 965.	2.1	14
1001	Analysis of COVIDâ€19 vaccines: Types, thoughts, and application. Journal of Clinical Laboratory Analysis, 2021, 35, e23937.	0.9	61

#	Article	IF	Citations
1002	Promising Technologies in the Field of Helminth Vaccines. Frontiers in Immunology, 2021, 12, 711650.	2.2	24
1003	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses, 2021, 13, 1645.	1.5	8
1004	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens, 2021, 10, 1030.	1.2	33
1005	Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. Computers in Biology and Medicine, 2021, 135, 104634.	3.9	20
1008	Expediting in vitro characterization of mRNA-based gene therapies via high-content fluorescent imaging. Analytical Biochemistry, 2021, 627, 114259.	1.1	2
1009	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science, 2021, 373, 991-998.	6.0	144
1010	Peptide-Assisted Nucleic Acid Delivery Systems on the Rise. International Journal of Molecular Sciences, 2021, 22, 9092.	1.8	11
1011	Discovery and Characterization of Spike Nâ€Terminal Domainâ€Binding Aptamers for Rapid SARSâ€CoVâ€2 Detection. Angewandte Chemie, 2021, 133, 21381-21385.	1.6	14
1013	Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment. Life Sciences, 2021, 278, 119561.	2.0	10
1014	The rapid adaptation of SARS-CoV-2â€“rise of the variants: transmission and resistance. Journal of Microbiology, 2021, 59, 807-818.	1.3	18
1016	Vacinas de mRNA contra a Covid-19: aberta uma nova janela no campo da imunologia. Research, Society and Development, 2021, 10, e246101018818.	0.0	0
1017	Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations. Biologia (Poland), 2021, 76, 3465-3476.	0.8	6
1018	Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles. International Journal of Nanomedicine, 2021, Volume 16, 5981-6002.	3.3	37
1019	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. Exploration of Immunology, 2021, , 199-225.	1.7	5
1020	Developing-country vaccine manufacturersâ€™ technical capabilities can make a difference in global immunization. Vaccine, 2021, 39, 5153-5161.	1.7	5
1021	Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification. Vaccine, 2021, 39, 5326-5330.	1.7	10
1022	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, 36, 109493.	2.9	46
1023	COVID-19 Research: Lessons from Non-Human Primate Models. Vaccines, 2021, 9, 886.	2.1	15

#	Article	IF	Citations
1025	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 2021, 20, 817-838.	21.5	577
1026	Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination. Radiology Case Reports, 2021, 16, 2164-2167.	0.2	7
1027	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner. MBio, 2021, 12, e0100221.	1.8	7
1028	Comparison of Antiâ€“SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine. American Journal of Clinical Pathology, 2022, 157, 212-218.	0.4	6
1030	Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. American Journal of Transplantation, 2021, 21, 3971-3979.	2.6	85
1031	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315.	7.0	57
1032	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	251
1034	Connecting primitive phase separation to biotechnology, synthetic biology, and engineering. Journal of Biosciences, 2021, 46, 1.	0.5	11
1036	Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. Vaccines, 2021, 9, 881.	2.1	86
1037	Should Patient with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) be vaccinated with COVID-19 Vaccines?. Indonesian Journal of Rheumatology, 2021, 13, 492-503.	0.1	0
1038	Discovery and Characterization of Spike Nâ€Terminal Domainâ€Binding Aptamers for Rapid SARSâ€CoVâ€2 Detection. Angewandte Chemie - International Edition, 2021, 60, 21211-21215.	7.2	62
1040	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. International Immunopharmacology, 2021, 97, 107679.	1.7	9
1041	Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies. PLoS ONE, 2021, 16, e0255622.	1.1	21
1043	A Comprehensive Review of the Management of Pregnant Women with COVID-19: Useful Information for Obstetricians. Infection and Drug Resistance, 2021, Volume 14, 3363-3378.	1.1	8
1044	Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. Viruses, 2021, 13, 1595.	1.5	23
1045	The impact of the Covid-19 pandemic on quality of life in skin cancer patients. PLoS ONE, 2021, 16, e0255501.	1.1	8
1046	Genetic Risk Factors for the Development of COVID-19 Coronavirus Infection. Russian Journal of Genetics, 2021, 57, 878-892.	0.2	9
1047	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. Wiener Klinische Wochenschrift, 2021, 133, 931-941.	1.0	79

#	Article	IF	Citations
1048	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. PLoS Pathogens, 2021, 17, e1009772.	2.1	74
1049	Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgraduate Medical Journal, 2022, 98, 389-394.	0.9	137
1050	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 2021, 9, 848.	2.1	64
1051	AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories. Clinical Chemistry, 2021, 67, 1188-1200.	1.5	20
1052	Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 2727-2739.	2.6	197
1053	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 3980-3989.	2.6	120
1054	Review Article: vaccination for patients with inflammatory bowel disease during the COVIDâ€19 pandemic. Alimentary Pharmacology and Therapeutics, 2021, 54, 1110-1123.	1.9	26
1055	Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report. International Journal of Infectious Diseases, 2021, 110, 229-231.	1.5	15
1057	mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors. Future Virology, 2021, , .	0.9	2
1058	Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. Journal of Virology, 2021, 95, e0131321.	1.5	89
1059	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	23
1060	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity, 2021, 54, 2159-2166.e6.	6.6	52
1062	A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice. Virologica Sinica, 2021, 36, 1113-1123.	1.2	11
1063	COVID-19 mRNA vaccination, reactogenicity, work-related absences and the impact on operating room staffing: A cross-sectional study. Perioperative Care and Operating Room Management, 2021, 25, 100220.	0.2	3
1064	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Reports Medicine, 2021, 2, 100405.	3.3	110
1065	Adverse events and preventive measures related to COVID-19 vaccines. Clinical and Experimental Emergency Medicine, 2021, 8, 153-159.	0.5	1
1066	Extracellular miRNAs as mediators of obesityâ€associated disease. Journal of Physiology, 2022, 600, 1155-1169.	1.3	28
1067	COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center. Epilepsy and Behavior, 2021, 122, 108160.	0.9	37

#	Article	IF	Citations
1068	Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation. Nature Communications, 2021, 12, 5333.	5.8	64
1069	COVID-19 Vaccines: Current Conditions and Future Prospects. Biology, 2021, 10, 960.	1.3	14
1070	Study protocol for the SeMaCo study: A longitudinal regional cohort study to assess COVID-19 seroprevalence in blood donors. F1000Research, 0, 10, 982.	0.8	1
1072	Virusâ€Mimic mRNA Vaccine for Cancer Treatment. Advanced Therapeutics, 2021, 4, 2100144.	1.6	11
1073	Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience. Allergy and Asthma Proceedings, 2021, 42, 395-399.	1.0	15
1074	The impact of COVID-19 on the injury pattern for maxillofacial fracture in Daegu city, South Korea. Maxillofacial Plastic and Reconstructive Surgery, 2021, 43, 35.	0.7	10
1075	Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring. American Journal of Transplantation, 2022, 22, 786-800.	2.6	41
1077	Durability of mRNA-1273 vaccineâ€“induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	6.0	459
1079	Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 303.e1-303.e17.	0.7	471
1080	An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest. Computers in Biology and Medicine, 2021, 136, 104703.	3.9	14
1081	Revealing Public Opinion Towards COVID-19 Vaccines With Twitter Data in the United States: Spatiotemporal Perspective. Journal of Medical Internet Research, 2021, 23, e30854.	2.1	87
1082	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	4.7	20
1084	Chemotherapy vs. Immunotherapy in combating nCOVID19: An update. Human Immunology, 2021, 82, 649-658.	1.2	19
1087	Single Micelle Vectors based on Lipid/Block Copolymer Compositions as mRNA Formulations for Efficient Cancer Immunogene Therapy. Molecular Pharmaceutics, 2021, 18, 4029-4045.	2.3	13
1088	RNA Therapeutics - Research and Clinical Advancements. Frontiers in Molecular Biosciences, 2021, 8, 710738.	1.6	39
1089	Potential Effects of Coronaviruses on the Liver: An Update. Frontiers in Medicine, 2021, 8, 651658.	1.2	38
1090	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science, 2021, 374, eabj9853.	6.0	236
1091	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 2021, 9, 1017.	2.1	10

#	Article	IF	Citations
1093	Genomics in medicine: A new era in medicine. World Journal of Methodology, 2021, 11, 231-242.	1.1	5
1094	Trends in psychological distress and COVID-19 incidence across 15 U.S. metropolitan statistical areas in 2020. Social Science and Medicine, 2021, 285, 114285.	1.8	7
1095	The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. Vaccines, 2021, 9, 1101.	2.1	11
1096	Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2. International Journal of Infectious Diseases, 2021, 113, 233-235.	1.5	27
1097	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	6.0	244
1098	Role of different types of nanomaterials against diagnosis, prevention and therapy of COVID-19. Sustainable Cities and Society, 2021, 72, 103046.	5.1	25
1099	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
1101	Saliva-Based ELISAs for Effective SARS-CoV-2 Antibody Monitoring in Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 701411.	2.2	5
1102	Optimising SARS-CoV-2 vaccination schedules. Lancet, The, 2021, 398, 819-821.	6.3	3
1103	A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. Science Advances, 2021, 7, eabh1547.	4.7	44
1104	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology, 2021, 6, eabj2901.	5.6	67
1105	Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests. Vaccine, 2021, 39, 5563-5570.	1.7	14
1106	Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Molecular and Cellular Toxicology, 2022, 18, 1-8.	0.8	73
1107	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. Clinical Microbiology and Infection, 2022, 28, 301.e1-301.e8.	2.8	28
1108	RecaÃda de la purpura trombocitopÃ©nica inmune tras la vacunaciÃ³n frente al sars-cov-2. Medicina ClÃnica, 2021, 158, 497-497.	0.3	1
1109	Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. Cells, 2021, 10, 2541.	1.8	61
1110	Learning from the COVID-19 Pandemic: When Public Health and Tornado Threats Converge. Weather, Climate, and Society, 2021, , .	0.5	0
1111	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778

#	Article	IF	Citations
1112	Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. Frontiers in Immunology, 2021, 12, 652252.	2.2	13
1115	Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches. MSystems, 2021, 6, e0038821.	1.7	10
1116	Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. Advanced Drug Delivery Reviews, 2021, 176, 113889.	6.6	48
1117	Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. Journal of Biomaterials Science, Polymer Edition, 2022, 33, 110-136.	1.9	4
1118	Rapid induction of antigen-specific CD4+ TÂcells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity, 2021, 54, 2133-2142.e3.	6.6	367
1119	Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology, 2022, 162, 88-108.e9.	0.6	41
1120	Nanovaccine: an emerging strategy. Expert Review of Vaccines, 2021, 20, 1273-1290.	2.0	50
1121	Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. International Journal of Infectious Diseases, 2021, 113, 1-6.	1.5	11
1122	Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂcells against a lethal viral infection. Molecular Therapy, 2021, 29, 2769-2781.	3.7	20
1123	Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine, 2021, 174, 1330-1332.	2.0	290
1124	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host and Microbe, 2021, 29, 1437-1453.e8.	5.1	53
1125	Secret messengers: Extracellular RNA communication in the immune system*. Immunological Reviews, 2021, 304, 62-76.	2.8	12
1126	COVID-19 Vaccination Strategy in China: A Case Study. Epidemiologia, 2021, 2, 402-425.	1.1	6
1128	The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Frontiers in Immunology, 2021, 12, 724060.	2.2	5
1129	Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19. Current Stem Cell Research and Therapy, 2022, 17, 166-185.	0.6	5
1130	The Metabolic Response of Various Cell Lines to Microtubule-Driven Uptake of Lipid- and Polymer-Coated Layer-by-Layer Microcarriers. Pharmaceutics, 2021, 13, 1441.	2.0	1
1131	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. MBio, 2021, 12, e0190821.	1.8	32
1132	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	3.9	89

#	Article	IF	Citations
1135	Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Vaccines, 2021, 9, 1047.	2.1	23
1136	Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection. Vaccines, 2021, 9, 1028.	2.1	11
1137	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. PLoS Pathogens, 2021, 17, e1009701.	2.1	12
1138	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	1.8	28
1139	COVID-19 Vaccine Uptake Through the Lived Experiences of Health Care Personnel: Policy and Legal Considerations. Health Equity, 2021, 5, 688-696.	0.8	1
1141	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1â€“2, dose-ranging study. Lancet Infectious Diseases, The, 2021, 21, 1257-1270.	4.6	99
1142	Persistence of neutralizing antibodies a year after SARSâ€CoVâ€2 infection in humans. European Journal of Immunology, 2021, 51, 3202-3213.	1.6	76
1143	Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2. Viruses, 2021, 13, 1936.	1.5	9
1145	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	13.5	131
1146	Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARSâ€CoVâ€2 vaccine. Clinical Transplantation, 2021, 35, e14478.	0.8	28
1147	Nucleic acid delivery for therapeutic applications. Advanced Drug Delivery Reviews, 2021, 178, 113834.	6.6	122
1148	The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2021, 37, 1450-1459.	0.8	64
1149	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. Frontiers in Immunology, 2021, 12, 708848.	2.2	7
1150	Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pathology Research and Practice, 2021, 225, 153565.	1.0	8
1151	Lipid Self-Assemblies under the Atomic Force Microscope. International Journal of Molecular Sciences, 2021, 22, 10085.	1.8	5
1152	Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (ComirnatyÂ®). Vaccines, 2021, 9, 1063.	2.1	27
1153	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-9.	0.8	30
1154	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiology Spectrum, 2021, 9, e0034121.	1.2	114

#	Article	IF	Citations
1155	Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers, 2021, 13, 4621.	1.7	29
1157	Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	9
1158	Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nature Medicine, 2021, 27, 2025-2031.	15.2	361
1159	Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics. Advanced Drug Delivery Reviews, 2021, 176, 113901.	6.6	27
1160	Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. PLoS ONE, 2021, 16, e0252849.	1.1	11
1161	Safety and immunogenicity of a QazCovid-inÂ® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine, 2021, 39, 101078.	3.2	37
1163	Thrombosis formation after COVID-19 vaccination Immunological Aspects: Review article. Saudi Journal of Biological Sciences, 2022, 29, 1073-1078.	1.8	8
1165	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. International Journal of Biological Macromolecules, 2021, 188, 740-750.	3.6	83
1166	Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomedicine and Pharmacotherapy, 2021, 142, 111953.	2.5	64
1167	Exosome-mediated mRNA delivery inÂvivo is safe and can be used to induce SARS-CoV-2 immunity. Journal of Biological Chemistry, 2021, 297, 101266.	1.6	64
1168	Polyplex nanomicelle delivery of self-amplifying RNA vaccine. Journal of Controlled Release, 2021, 338, 694-704.	4.8	7
1169	Biomaterials, biological molecules, and polymers in developing vaccines. Trends in Pharmacological Sciences, 2021, 42, 813-828.	4.0	14
1170	Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. American Journal of Kidney Diseases, 2021, 78, 571-581.	2.1	100
1171	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. Journal of Controlled Release, 2021, 338, 201-210.	4.8	53
1172	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. Clinical Immunology, 2021, 231, 108804.	1.4	5
1173	Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. American Journal of Cardiology, 2021, 156, 129-131.	0.7	33
1174	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
1176	COVID-19 in Children. Pediatric Clinics of North America, 2021, 68, 961-976.	0.9	21

#	Article	IF	Citations
1177	Opportunities for innovation: Building on the success of lipid nanoparticle vaccines. Current Opinion in Colloid and Interface Science, 2021, 55, 101468.	3.4	17
1178	Administration of COVID-19 vaccines in immunocompromised patients. International Immunopharmacology, 2021, 99, 108021.	1.7	51
1179	Herpes Zoster Following the COVID-19 Vaccination in Breast Cancer Long Time Survivor Patients. Cureus, 2021, 13, e18418.	0.2	5
1180	MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103225.	0.9	16
1181	Vaccine design and delivery approaches for COVID-19. International Immunopharmacology, 2021, 100, 108086.	1.7	21
1182	Recent advances in therapeutic nucleic acids and their analytical methods. Journal of Pharmaceutical and Biomedical Analysis, 2021, 206, 114368.	1.4	22
1183	COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy. European Journal of Cancer, 2021, 157, 441-449.	1.3	43
1184	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. International Immunopharmacology, 2021, 100, 108162.	1.7	65
1185	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology, 2021, 563, 134-145.	1.1	74
1186	How does biological sex affect the physiological response to nanomaterials?. Nano Today, 2021, 41, 101292.	6.2	6
1187	pDNA and mRNA vaccines. , 2022, , 157-205.		1
1188	A roadmap to operationalize and evaluate impact in a learning health system. Learning Health Systems, 2021, 5, e10258.	1.1	24
1190	Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study. Frontiers in Medicine, 2020, 7, 608804.	1.2	10
1191	COVID-19 vaccines and women's security. Lancet, The, 2021, 397, 357-358.	6.3	8
1192	The COVID-19 vaccine: A race nearing the finish line. Apollo Medicine, 2021, .	0.0	1
1193	COVID-19 pandemic and the answer of science: a year in review. Anais Da Academia Brasileira De Ciencias, 2021, 93, e20210543.	0.3	4
1194	Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1143-1154.	1.4	24
1195	Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Computational and Structural Biotechnology Journal, 2021, 19, 612-623.	1.9	35

#	Article	IF	Citations
1197	Principles and Challenges in anti-COVID-19 Vaccine Development. International Archives of Allergy and Immunology, 2021, 182, 339-349.	0.9	38
1198	High-Throughput Automation of Endosomolytic Polymers for mRNA Delivery. ACS Applied Bio Materials, 2021, 4, 1640-1654.	2.3	15
1199	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	1.2	18
1200	mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration. Cells, 2021, 10, 187.	1.8	16
1201	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
1203	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMedicine, 2021, 63, 103197.	2.7	31
1204	DNA Nanodevices with Selective Immune Cell Interaction and Function. ACS Nano, 2021, 15, 4394-4404.	7.3	19
1205	Current State of the First COVID-19 Vaccines. Vaccines, 2021, 9, 30.	2.1	64
1207	COVID-19 vaccination in immunocompromised patients. Clinical Rheumatology, 2021, 40, 797-798.	1.0	49
1209	In silico prediction of the in vitro behavior of polymeric gene delivery vectors. Nanoscale, 2021, 13, 8333-8342.	2.8	7
1210	Could Vaccine Dose Stretching Reduce COVID-19 Deaths?. SSRN Electronic Journal, 0, , .	0.4	1
1211	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. Biomolecules, 2021, 11, 196.	1.8	4
1212	Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. Vaccines, 2021, 9, 76.	2.1	28
1213	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Network, 2021, 21, e4.	1.6	26
1216	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection. Clinical Infectious Diseases, 2021, 73, e2992-e2994.	2.9	11
1217	Treatment Approach, Pharmacological Agents and Vaccines. , 2021, , 145-162.		0
1219	siRNA Therapeutics against Respiratory Viral Infectionsâ€"What Have We Learned for Potential COVIDâ€19 Therapies?. Advanced Healthcare Materials, 2021, 10, e2001650.	3.9	47
1221	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20

#	Article	IF	Citations
1222	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. Pathogens, 2021, 10, 138.	1.2	60
1223	COVID-19 vaccines: Where do we stand?. The EuroBiotech Journal, 2021, 5, 4-7.	0.5	1
1224	Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors. Viruses, 2021, 13, 173.	1.5	37
1225	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. Pediatric Infection and Vaccine, 2021, 28, 7.	0.1	7
1226	Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines, 2021, 9, 65.	2.1	310
1227	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovascular Pathology, 2021, 50, 107278.	0.7	55
1228	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology, 2021, 2, .	1.2	59
1229	Evaluation of COVID-19 Vaccine Refusal in Parents. Pediatric Infectious Disease Journal, 2021, 40, e134-e136.	1.1	155
1231	Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant Prevalence. SSRN Electronic Journal, 0, , .	0.4	34
1232	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. Science China Life Sciences, 2020, 63, 1833-1849.	2.3	29
1233	A new approach for COVID-19 treatment by micro-RNA. Medical Hypotheses, 2020, 143, 110203.	0.8	36
1234	Peptides to combat viral infectious diseases. Peptides, 2020, 134, 170402.	1.2	42
1235	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. ACS Biomaterials Science and Engineering, 2021, 7, 1742-1764.	2.6	16
1236	Coronavirus vaccines get a biotech boost. Nature, 2020, 583, 647-649.	13.7	6
1237	Coronavirus vaccines leap through safety trials â€" but which will work is anybodyâ€™s guess. Nature, 2020, 583, 669-670.	13.7	7
1238	All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature, 2020, 586, 501-502.	13.7	23
1239	SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing. Journal of Infectious Diseases, 2021, 223, 1120-1131.	1.9	27
1240	SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum Infectious Diseases, 2021, 8, ofaa555.	0.4	66

#	Article	IF	Citations
1241	The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions. Plastic and Reconstructive Surgery - Global Open, 2020, 8, e3206.	0.3	9
1242	Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. Journal of the Chinese Medical Association, 2021, 84, 9-13.	0.6	2
1243	COVID-19 vaccine development: a pediatric perspective. Current Opinion in Pediatrics, 2021, 33, 144-151.	1.0	76
1304	Studies of Physical Activity and COVID-19 During the Pandemic: A Scoping Review. Journal of Physical Activity and Health, 2020, 17, 1275-1284.	1.0	196
1305	Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood, 2020, 136, 2588-2591.	0.6	127
1306	Development of vaccines for SARS-CoV-2. F1000Research, 2020, 9, 991.	0.8	39
1307	Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 2020, 15, e0244126.	1.1	269
1308	A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. PLoS ONE, 2020, 15, e0244418.	1.1	16
1309	Mucin signature as a potential tool to predict susceptibility to COVIDâ€19. Physiological Reports, 2021, 9, e14701.	0.7	24
1310	COVID-19 vaccines - are we there yet?. Australian Prescriber, 2021, 44, 19-25.	0.5	15
1311	Together We Make the Difference: National Strategy for Recruitment and Participation in Alzheimerâ€™s and Related Dementias Clinical Research. Ethnicity and Disease, 2020, 30, 705-708.	1.0	37
1314	The race for a coronavirus vaccine. Revista Bionatura, 2020, 5, 1290-1292.	0.1	3
1315	Vaccines against Coronavirus Disease: Target Proteins, Immune Responses, and Status of Ongoing Clinical Trials. Journal of Pure and Applied Microbiology, 2020, 14, 2253-2263.	0.3	3
1316	Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis. International Journal of Clinical Virology, 2020, 4, 126-135.	0.1	7
1317	Analysis of Promising Approaches to COVID-19 Vaccine Development. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 216-227.	0.2	10
1318	Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 228-244.	0.2	1
1319	Vaccination Against SARS-CoV-2 in Immunosuppressed Patients with Rheumatic Diseases: Position Statement of the Greek Rheumatology Society. Mediterranean Journal of Rheumatology, 2020, 31, 430.	0.3	4
1320	Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - Review. Research, Society and Development, 2020, 9, e20191211123.	0.0	7

#	Article	IF	Citations
1321	An Italian Guidance Model for the Management of Suspected or Confirmed COVID-19 Patients in the Primary Care Setting. Frontiers in Public Health, 2020, 8, 572042.	1.3	10
1322	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. International Journal of Molecular Sciences, 2020, 21, 9775.	1.8	40
1323	SARS-CoV-2 Spike Protein and Lung Vascular Cells. Journal of Respiration, 2021, 1, 40-48.	0.4	6
1324	Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines. Pharmaceutics, 2021, 13, 45.	2.0	45
1325	Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses, 2021, 13, 54.	1.5	61
1326	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. Vaccines, 2020, 8, 783.	2.1	13
1327	Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Vaccines, 2021, 9, 3.	2.1	74
1328	Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 11.	2.1	17
1329	[Comment] COVIDâ€'19 vaccine safety. International Journal of Molecular Medicine, 2020, 46, 1599-1602.	1.8	52
1330	COVID-19: general overview, pharmacological options and ventilatory support strategies. Multidisciplinary Respiratory Medicine, 2020, 15, 708.	0.6	2
1331	Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian Journal of Medical Research, 2021, 153, 93.	0.4	28
1332	COVID-19 research risks ignoring important host genes due to pre-established research patterns. ELife, 2020, 9, .	2.8	14
1333	Neutralizing SARS-CoV-2. ELife, 2020, 9, .	2.8	5
1334	A case of acute encephalopathy and non-ST segment elevation myocardial infarction following mRNA-1273 vaccination: possible adverse effect?. Clinical and Experimental Vaccine Research, 2021, 10, 293.	1.1	5
1335	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. Journal of Infectious Diseases, 2021, 224, 1849-1860.	1.9	16
1336	BIOTECHNOLOGICAL RESEARCH IN THE CREATION AND PRODUCTION OF ANTIRABIC VACCINES. Biotechnologia Acta, 2021, 14, 28-37.	0.3	0
1337	COVID-19 Vaccine and Fitness to Fly. Aerospace Medicine and Human Performance, 2021, 92, 698-701.	0.2	3
1339	Effectiveness of COVIDâ€'19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 2021, 22, 1407.	0.8	23

#	Article	IF	Citations
1340	mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€“Specific T Cells Persist at 6 Months and Recognize the Delta Variant. Clinical Infectious Diseases, 2022, 75, e898-e901.	2.9	25
1341	BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease. Vaccines, 2021, 9, 1164.	2.1	8
1342	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. Nano Research, 2022, 15, 2196-2225.	5.8	8
1344	A quantitative systems pharmacology approach to support mRNA vaccine development and optimization. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1448-1451.	1.3	8
1345	A comprehensive review on efficient approaches for combating coronaviruses. Biomedicine and Pharmacotherapy, 2021, 144, 112353.	2.5	4
1346	Innovations and development of Covid-19 vaccines: A patent review. Journal of Infection and Public Health, 2022, 15, 123-131.	1.9	27
1347	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. Npj Vaccines, 2021, 6, 125.	2.9	17
1348	T cell immunity to SARS-CoV-2. Seminars in Immunology, 2021, 55, 101505.	2.7	55
1351	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. Journal of Immunological Methods, 2021, 499, 113165.	0.6	6
1352	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. Journal of Controlled Release, 2021, 340, 114-124.	4.8	11
1353	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 2021, 600, 523-529.	13.7	194
1354	Expression and characterization of SARS-CoV-2 spike proteins. Nature Protocols, 2021, 16, 5339-5356.	5.5	31
1355	SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. Expert Review of Vaccines, 2022, 21, 69-81.	2.0	22
1356	A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Pharmaceutics, 2021, 13, 1759.	2.0	42
1357	COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Science Translational Medicine, 2021, 13, eabi8631.	5.8	80
1358	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. Expert Review of Vaccines, 2022, 21, 47-67.	2.0	3
1359	Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discovery, 2021, 7, 99.	3.1	58
1360	Adequate immune response after SARSâ€CoVâ€2 infection and single dose vaccination despite rapid heart transplantation. ESC Heart Failure, 2021, 8, 5568.	1.4	2

#	Article	IF	Citations
1361	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. Journal of Clinical Investigation, 2021, 131, .	3.9	17
1362	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. Current Molecular Medicine, 2022, 22, 621-639.	0.6	2
1363	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines, 2021, 9, 1195.	2.1	90
1364	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines ComirnatyÂ® and COVID-19 mRNA Vaccine ModernaÂ®. Trials, 2021, 22, 724.	0.7	9
1365	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€“boosted nonhuman primates. Science, 2021, 374, 1343-1353.	6.0	83
1366	Nanoparticle approaches against SARS-CoV-2 infection. Current Opinion in Solid State and Materials Science, 2021, 25, 100964.	5.6	21
1367	PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2. Heliyon, 2021, 7, e08124.	1.4	13
1368	Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. Journal of Community Health, 2022, 47, 211-225.	1.9	30
1371	Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929.	2.9	64
1372	Tâ€cell immune response after mRNA SARSâ€CoVâ€2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. British Journal of Haematology, 2022, 196, 548-558.	1.2	73
1374	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement. Vaccines, 2021, 9, 1211.	2.1	5
1375	Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115573.	0.8	25
1376	Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics, 2021, 1, 337-356.	2.3	58
1377	SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. Nature Immunology, 2021, 22, 1452-1464.	7.0	37
1379	COVID-19 mRNA vaccine allergy. Current Opinion in Pediatrics, 2021, 33, 610-617.	1.0	15
1380	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	5.8	18
1381	Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Nano Letters, 2022, 22, 533-542.	4.5	57
1382	Recent Update of COVID-19 Vaccines. Advanced Pharmaceutical Bulletin, 2021, , .	0.6	0

#	Article	IF	Citations
1384	Development of synthetic antigen vaccines for COVID-19. Human Vaccines and Immunotherapeutics, 2021, 17, 3855-3870.	1.4	4
1385	Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. Annals of Neurosciences, 2021, 28, 201-218.	0.9	7
1387	Ultrasonic particles: An approach for targeted gene delivery. Advanced Drug Delivery Reviews, 2021, 179, 113998.	6.6	20
1388	mRNA â€“ A game changer in regenerative medicine, cell-based therapy and reprogramming strategies. Advanced Drug Delivery Reviews, 2021, 179, 114002.	6.6	25
1389	Combining an optimized mRNA template with a double purification process allows strong expression of inÂvitro transcribed mRNA. Molecular Therapy - Nucleic Acids, 2021, 26, 945-956.	2.3	21
1390	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. Biomedicine and Pharmacotherapy, 2021, 144, 112282.	2.5	10
1391	75 million syringes but nothing to put in them: what is Canadaâ€™s plan for a COVID-19 vaccine?. McGill Journal of Medicine, 2020, 18, .	0.1	0
1396	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. Life, 2021, 11, 1152.	1.1	5
1397	Vaccine development and technology for SARSâ€CoVâ€2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	2.5	8
1399	Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report. Human Vaccines and Immunotherapeutics, 2021, 17, 4099-4101.	1.4	10
1400	Impact of formulation on the quality and stability of freeze-dried nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 256-267.	2.0	30
1401	Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. PPAR Research, 2021, 2021, 1-28.	1.1	8
1402	Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFÎ±. Gastroenterology, 2022, 162, 454-467.	0.6	68
1405	The estimated age-group specific influenza vaccine coverage rates in Hong Kong and the impact of the school outreach vaccination program. Human Vaccines and Immunotherapeutics, 2021, , 1-5.	1.4	5
1406	COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. Breast, 2021, 60, 214-222.	0.9	19
1407	COVID-19 mRNA Vaccine Degradation Prediction using Regularized LSTM Model. , 2020, , .		2
1408	What About The Coronavirus Vaccine for Pregnant Women?. Neonatology Today, 2020, 15, 125-127.	0.0	0
1409	Biological Significance of Antiâ€“SARS-CoV-2 Antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	2

#	Article	IF	Citations
1411	A REVIEW ON THE FIFTH PANDEMIC: CORONAVIRUS. Asian Journal of Pharmaceutical and Clinical Research, 0, , 25-31.	0.3	1
1413	SARS-CoV-2: desde sus aspectos genÃ³micos y estructurales hasta su tratamiento. AtenciÃ³n Familiar, 0, 27, 3.	0.0	1
1414	SARS-CoV-2 Leading Vaccine Candidates: Progress and Development. Life and Science, 2020, 1, 7.	0.1	0
1416	Research on Drugs and Vaccines for COVID-19 Should Be Conducted and Published With Caution. Journal of Epidemiology, 2020, 30, 574-575.	1.1	0
1417	Personalized Therapy of Infectious Diseases. , 2021, , 325-341.		1
1418	Vaccines and Treatment of Coronavirus Disease 2019. Korean Journal of Medicine, 2020, 95, 364-369.	0.1	1
1419	SARSâ€'CoVâ€'2 mutation hotspots incidence in different geographic regions. Microbial Biosystems Journal, 2020, 5, 1-8.	0.3	3
1422	Risk Mitigation Measures for Coronavirus Disease 2019. IOP Conference Series: Earth and Environmental Science, 0, 615, 012014.	0.2	0
1423	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
1424	COVID-19 mRNA Vaccine-induced Pneumonitis. Internal Medicine, 2022, 61, 81-86.	0.3	13
1425	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). Juvenis Scientia, 2020, 6, 41-80.	0.1	0
1426	A Computational Search for Peptide Vaccines Using Novel Mathematical Descriptors of Sequences of Emerging Pathogens. Topics in Medicinal Chemistry, 2020, , 195-220.	0.4	2
1427	COVID-19: The latest news and views. Libyan Journal of Medical Sciences, 2020, 4, 99.	0.1	0
1428	Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective. SSRN Electronic Journal, 0, , .	0.4	1
1429	Indian Clinical Trials on COVID-19: A Review of Clinical Trials Registry of India (CTRI). SSRN Electronic Journal, 0, , .	0.4	2
1430	Novel coronavirus vaccine: An international holy grail. Journal of Marine Medical Society, 2020, .	0.0	1
1431	New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. Vaccines, 2021, 9, 1252.	2.1	32
1432	De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis. Case Reports in Nephrology, 2021, 2021, 1-5.	0.2	8

#	Article	IF	Citations
1433	Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery. Journal of Controlled Release, 2022, 341, 616-633.	4.8	29
1434	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). Clinics in Laboratory Medicine, 2022, 42, 111-128.	0.7	8
1435	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Reports, 2021, 25, 101417.	0.4	15
1436	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400.	1.7	63
1437	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity, 2021, 54, 2877-2892.e7.	6.6	260
1438	Performance Characteristics of High-Throughput Serologic Assays for Severe Acute Respiratory Syndrome Coronavirus 2 with Food and Drug Administration Emergency Use Authorization. Clinics in Laboratory Medicine, 2022, 42, 15-29.	0.7	8
1439	Microfluidic transfection of mRNA into human primary lymphocytes and hematopoietic stem and progenitor cells using ultra-fast physical deformations. Scientific Reports, 2021, 11, 21407.	1.6	17
1440	Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. Journal of Clinical Virology, 2021, 145, 105024.	1.6	33
1441	Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses. Npj Vaccines, 2021, 6, 135.	2.9	7
1442	Nanomedicine for the Diagnosis and Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology, 2021, 9, 758121.	2.0	2
1443	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. Clinics in Laboratory Medicine, 2022, 42, 31-56.	0.7	8
1444	Antibody Dynamics and Durability in Coronavirus Disease-19. Clinics in Laboratory Medicine, 2022, 42, 85-96.	0.7	16
1445	SARS-CoV-2 Serology Testing â€“ A Laboratory Primer. Clinics in Laboratory Medicine, 2021, 42, 1-13.	0.7	0
1446	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. Vaccines, 2021, 9, 1261.	2.1	10
1447	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. Vaccines, 2021, 9, 1277.	2.1	1
1450	Vaccipack, A Mobile App to Promote Human Papillomavirus Vaccine Uptake Among Adolescents Aged 11 to 14 Years: Development and Usability Study. JMIR Nursing, 2020, 3, e19503.	0.7	11
1456	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, Ribonuclease I and Human RNase A. Frontiers in Microbiology, 2021, 12, 660149.	1.5	1
1457	Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. Journal of Advanced Pharmaceutical Technology and Research, 2021, 12, 215-221.	0.4	2

#	Article	IF	Citations
1458	Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. Journal of Controlled Release, 2022, 341, 206-214.	4.8	27
1459	Innovative recombinant protein-based vaccinesÂagainst SARS-CoV-2. , 2022, , 193-211.		1
1460	RNA-based vaccines against SARS-CoV-2. , 2022, , 129-152.		1
1461	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transplant Immunology, 2022, 70, 101495.	0.6	58
1462	Analyzing Sentiments and Diffusion Characteristics of COVID-19 Vaccine Misinformation Topics in Social Media. International Journal of Business Analytics, 2021, 9, 1-22.	0.2	10
1463	Application of SARS-CoV-2 Serology to Address Public Health Priorities. Frontiers in Public Health, 2021, 9, 744535.	1.3	4
1464	Antibody Response to BNT162b2 Vaccine in Immune Modifiersâ€“Treated Psoriatic Patients. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 24-28.	0.3	1
1465	Difference of antiâ€viral immunity induced by two mRNA vaccines: Implications in MS patients treated with antiâ€CD20â€depleting therapy. Clinical and Experimental Neuroimmunology, 0, , .	0.5	0
1466	COVIDâ€19 vaccinations: The unknowns, challenges, and hopes. Journal of Medical Virology, 2022, 94, 1336-1349.	2.5	75
1467	A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display. Microorganisms, 2021, 9, 2414.	1.6	6
1468	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	2.1	22
1469	Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in Nicotiana benthamiana Plant as a Vaccine Candidate against COVID-19. Vaccines, 2021, 9, 1337.	2.1	28
1470	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. IScience, 2021, , 103379.	1.9	8
1471	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. Journal of Thoracic Oncology, 2022, 17, 239-251.	0.5	51
1472	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications, 2021, 12, 6871.	5.8	147
1473	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers, 2021, 13, 5829.	1.7	8
1474	Undetectable SARS-CoV-2 active adaptive immunityâ€"post-vaccination or post-COVID-19 severe diseaseâ€"after immunosuppressants use. BMJ Case Reports, 2021, 14, e246308.	0.2	6
1475	Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review. Vaccines, 2021, 9, 1404.	2.1	33

#	Article	IF	Citations
1476	mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Science Translational Medicine, 2021, 13, eabj9827.	5.8	71
1477	Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020â€“2026: A modeling study. Infectious Disease Modelling, 2022, 7, 62-81.	1.2	14
1478	A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 2023, 41, 550-559.	2.0	5
1479	The Function of Immunoproteasomesâ€"An Immunologistsâ€™ Perspective. Cells, 2021, 10, 3360.	1.8	9
1480	The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduction and Targeted Therapy, 2021, 6, 396.	7.1	111
1481	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 2021, 9, 1387.	2.1	51
1482	SARS-CoV-2 Targets and COVID-19 Vaccines. Covid, 2021, 1, 608-621.	0.7	4
1483	SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. BioDrugs, 2022, 36, 41-53.	2.2	26
1484	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. Clinical Microbiology Reviews, 2022, 35, e0012321.	5.7	10
1485	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines, 2021, 9, 1338.	2.1	17
1486	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740.	1.4	16
1487	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Journal of Virology, 2022, 96, JVI0155121.	1.5	18
1488	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72
1489	Nucleoside-Modified mRNA Vaccines Protect IFNAR ^{â€"/â€"} Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. Journal of Virology, 2022, 96, JVI0156821.	1.5	24
1490	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. Pathogens, 2021, 10, 1537.	1.2	19
1492	Covidâ€19 vaccines and variants of concern: A review. Reviews in Medical Virology, 2022, 32, e2313.	3.9	201
1493	Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics. Journal of the American Chemical Society, 2021, 143, 20529-20545.	6.6	16
1494	The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials. Cancers, 2021, 13, 5924.	1.7	19

#	Article	IF	Citations
1495	Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies. Diagnostics, 2021, 11, 2193.	1.3	4
1496	Mimicking the Biology of Engineered Protein and mRNA Nanoparticle Delivery Using a Versatile Microfluidic Platform. Pharmaceutics, 2021, 13, 1944.	2.0	4
1498	Advances in mRNA and other vaccines against MERS-CoV. Translational Research, 2022, 242, 20-37.	2.2	11
1499	Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. Advanced Drug Delivery Reviews, 2022, 181, 114041.	6.6	26
1500	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances, 2022, 6, 774-784.	2.5	42
1502	Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm. Acta Pharmaceutica Sinica B, 2022, 12, 2950-2962.	5.7	33
1503	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. Human Vaccines and Immunotherapeutics, 2024, 17, 4714-4740.	1.4	16
1504	COVID-19 vaccine-induced cellulitis and myositis. Cleveland Clinic Journal of Medicine, 2021, 88, 648-650.	0.6	22
1505	The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. IScience, 2021, 24, 103479.	1.9	224
1506	Non-liver mRNA Delivery. Accounts of Chemical Research, 2022, 55, 13-23.	7.6	61
1508	Temporal variations in country-specific mutational profiles of SARS-CoV-2: effect on vaccine efficacy. Future Virology, 2021, 16, 805-819.	0.9	2
1509	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host and Microbe, 2022, 30, 97-109.e5.	5.1	83
1510	Membrane-dependent relief of translation elongationÂarrest on pseudouridine- and N1-methyl-pseudouridine-modified mRNAs. Nucleic Acids Research, 2022, 50, 7202-7215.	6.5	14
1511	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. RSC Drug Discovery Series, 2021, , 45-60.	0.2	0
1512	Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study. SSRN Electronic Journal, 0, , .	0.4	1
1513	mRNA Vaccine: An Advanced and Transformative Technology for Vaccine Development. , 2021, , 273-287.		0
1515	Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110582.	0.6	18
1516	Higher Antibody Concentrations in Health Care Workers Associated With Greater Reactogenicity Post-Vaccination. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
1517	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale, 2022, 14, 1054-1074.	2.8	22
1518	Microemulsion Based Nanostructures for Drug Delivery. Frontiers in Nanotechnology, 2022, 3, .	2.4	4
1519	Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System. SSRN Electronic Journal, 0, , .	0.4	0
1520	Adverse event of Sinovac Coronavirus vaccine: Deafness. Vaccine, 2022, 40, 521-523.	1.7	14
1521	Intracranial delivery of synthetic mRNA to suppress glioblastoma. Molecular Therapy - Oncolytics, 2022, 24, 160-170.	2.0	15
1522	From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene, 2022, 814, 146134.	1.0	97
1523	Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers. Nano Today, 2022, 43, 101375.	6.2	9
1524	Evidencia disponible sobre el abordaje terapÃ©utico de pacientes con COVID-19: una revisiÃ³n narrativa. Ciencia, TecnologÃa Y Salud, 2020, 7, 363-380.	0.0	1
1525	Immunogenicity and Reactogenicity of Heterologous and Homologous mRNA-1273 and BNT162b2 Vaccination: A Multicenter Non-Inferiority Randomized Trial. SSRN Electronic Journal, 0, , .	0.4	0
1528	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. Cell and Bioscience, 2021, 11, 202.	2.1	13
1529	Correlation of vaccineâ€elicited antibody levels and neutralizing activities against SARSâ€CoVâ€2 and its variants. Clinical and Translational Medicine, 2021, 11, e644.	1.7	7
1530	Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. Frontiers in Immunology, 2021, 12, 798117.	2.2	42
1531	Identification of Amino Acids within Nonstructural Proteins 10 and 14 of the Avian Coronavirus Infectious Bronchitis Virus That Result in Attenuation In Vivo and In Ovo. Journal of Virology, 2022, 96, jvi0205921.	1.5	9
1532	SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review. Tropical Medicine and Infectious Disease, 2022, 7, 9.	0.9	14
1533	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med, 2022, 3, 28-41.e8.	2.2	19
1534	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq1 1 0.784314 rgBT /O Lancet Infectious Diseases, The, 2022, 22, 636-648.	4.6	52
1535	The Evolution and Disparities of Online Attitudes Toward COVID-19 Vaccines: Year-long Longitudinal and Cross-sectional Study. Journal of Medical Internet Research, 2022, 24, e32394.	2.1	10
1536	Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. Drugs and Therapy Perspectives, 2022, 38, 1-9.	0.3	5

#	Article	IF	Citations
1537	Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. Public Health, 2022, 205, 1-5.	1.4	2
1538	mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Reports Medicine, 2022, 3, 100529.	3.3	158
1539	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe, The, 2022, 3, e193-e202.	3.4	45
1540	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Medicinal Chemistry, 2022, 13, 647-675.	1.7	3
1542	Wholeâ€blood cytokine secretion assay as a highâ€throughput alternative for assessing the cellâ€mediated immunity profile after two doses of an adjuvanted SARSâ€CoVâ€2 recombinant protein vaccine candidate. Clinical and Translational Immunology, 2022, 11, e1360.	1.7	14
1543	Innovative vaccine approachesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
1544	A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience. Journal of Clinical and Translational Science, 2022, 6, e21.	0.3	0
1545	On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain. Stochastic Environmental Research and Risk Assessment, 2022, 36, 2941-2948.	1.9	5
1546	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. Science Advances, 2022, 8, eabh3827.	4.7	27
1547	Pharmaceuticals/biotechnologyâ€"engineered proteins, vaccines, DNA vaccines. , 2022, , 217-233.		0
1548	Engineering optimal vaccination strategies: effects of physical properties of the delivery system on functions. Biomaterials Science, 2022, 10, 1408-1422.	2.6	6
1549	Dynamics of antibody response to CoronaVac vaccine. Journal of Medical Virology, 2022, 94, 2139-2148.	2.5	33
1551	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity, 2022, 55, 355-365.e4.	6.6	76
1552	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. Vaccine, 2022, 40, 1289-1298.	1.7	9
1553	Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. Protein Engineering, Design and Selection, 2022, 35, .	1.0	6
1554	IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination. Internal Medicine, 2022, 61, 1033-1037.	0.3	16
1555	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
1557	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences, 2022, 18, 459-472.	2.6	65

#	Article	IF	Citations
1558	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-Micro Letters, 2022, 14, 41.	14.4	26
1559	Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options. Medicine (United States), 2022, 101, e28561.	0.4	15
1560	An Outline of Contributing Vaccine Technologies for SARS CoV2 Advancing in Clinical and Preclinical Phase-Trials. Recent Patents on Biotechnology, 2022, 16, 122-143.	0.4	6
1561	COVID-19: Testing Landscape Post-Infection, -Vaccination, and Future Perspectives. Viral Immunology, 2022, 35, 5-14.	0.6	0
1562	A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays. Microbiology Spectrum, 2022, 10, e0156421.	1.2	8
1563	Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa. Nanomaterials, 2022, 12, 226.	1.9	20
1564	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. Vaccines, 2022, 10, 82.	2.1	16
1565	Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor TÂcell immunotherapy recipients. Cancer Cell, 2022, 40, 236-237.	7.7	16
1566	The Hitchhikerâ€™s Guide to Human Therapeutic Nanoparticle Development. Pharmaceutics, 2022, 14, 247.	2.0	14
1567	Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors. International Journal of Molecular Sciences, 2022, 23, 838.	1.8	15
1568	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science, 2022, 375, .	6.0	68
1569	Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection. Cancer Control, 2022, 29, 10732748211070707.	0.7	3
1570	Evaluating Correlates of Protection for Mix-Match Vaccine Against COVID-19 VOCs With Potential of Evading Immunity. SSRN Electronic Journal, 0, , .	0.4	0
1571	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153.	5.8	45
1572	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. Emerging Microbes and Infections, 2022, 11, 250-259.	3.0	3
1573	Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. Journal of Clinical Medicine, 2022, 11, 694.	1.0	10
1574	Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis. Journal of Nephrology, 2022, 35, 143-151.	0.9	12
1575	Synthesis and Potential Applications of Lipid Nanoparticles in Medicine. Materials, 2022, 15, 682.	1.3	52

#	Article	IF	Citations
1576	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. Frontiers in Medicine, 2021, 8, 806641.	1.2	22
1578	B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. Emerging Microbes and Infections, 2022, 11, 452-464.	3.0	8
1579	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. ELife, 2022, 11, .	2.8	19
1580	COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety. Vaccines, 2022, 10, 164.	2.1	7
1581	Assessment of COVID-19 mRNA vaccination titer and side effects in healthy volunteers. Laboratoriums Medizin, 2022, 46, 107-114.	0.1	6
1583	Sheet, Surveillance, Strategy, Salvage and Shield in global biodefense system to protect the public health and tackle the incoming pandemics. Science of the Total Environment, 2022, 822, 153469.	3.9	2
1584	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
1585	Dynamic and reconfigurable materials from reversible network interactions. Nature Reviews Materials, 2022, 7, 541-556.	23.3	105
1586	The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflammatory Bowel Diseases, 2022, , .	0.9	7
1587	A pandemic-enabled comparison of discovery platforms demonstrates a naiˆve antibody library can match the best immune-sourced antibodies. Nature Communications, 2022, 13, 462.	5.8	17
1589	COVID-19: Not just another respiratory virusâ€”2020. , 2022, , 345-367.		0
1590	Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host and Microbe, 2022, 30, 41-52.e5.	5.1	44
1591	A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. Life, 2022, 12, 130.	1.1	1
1592	Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomaterials Science, 2022, 10, 549-559.	2.6	56
1593	mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. Frontiers in Immunology, 2021, 12, 821538.	2.2	11
1594	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses, 2022, 14, 144.	1.5	12
1595	DOCK2 regulates antifungal immunity by regulating RAC GTPase activity. Cellular and Molecular Immunology, 2022, 19, 602-618.	4.8	9
1596	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. Journal of Clinical Microbiology, 2022, 60, jcm0239021.	1.8	5

#	Article	IF	Citations
1597	Narrative Review: Addressing Covid-19 Vaccine Concerns in Special and Vulnerable Populations. Hospital Pharmacy, 0, , 001857872110664.	0.4	0
1598	The Kinetics of COVID-19 Vaccine Response in a Community-Vaccinated Population. Journal of Immunology, 2022, 208, 819-826.	0.4	9
1599	Cytolysin A (ClyA): A Bacterial Virulence Factor with Potential Applications in Nanopore Technology, Vaccine Development, and Tumor Therapy. Toxins, 2022, 14, 78.	1.5	7
1600	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. IScience, 2022, 25, 103602.	1.9	6
1601	Efficacy of lopinavirâ€“ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis. Future Virology, 2022, 17, 169-189.	0.9	13
1603	Optimal Timing of COVID-19 Vaccination in the Peri-Transplant Period: A Single Institution Case Series. Transplantation Proceedings, 2022, 54, 1409-1411.	0.3	1
1604	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell, 2022, 185, 1008-1024.e15.	13.5	101
1605	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. Clinical Infectious Diseases, 2022, 75, e878-e879.	2.9	20
1606	OS DESAFIOS DA SAÃšDE DIGITAL NA PANDEMIA DE COVID-19: UMA REVISÃƒO INTEGRATIVA NO SCIELO. Recisatec, 2022, 2, e2182.	0.0	0
1607	17th Annual Meeting of the Oligonucleotide Therapeutics Society: A Tribute to Bob Letsinger, Progress in Nâ€‰=â€‰1 Treatments, and Successful First In-Humans CRISPR Trials. Nucleic Acid Therapeutics, 2022, 32, 1-7.	2.0	0
1608	Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discovery, 2022, 8, 10.	3.1	100
1609	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease, 2022, 33, 1-22.	1.0	47
1610	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med, 2022, 3, 188-203.e4.	2.2	11
1611	Zinc associated nanomaterials and their intervention in emerging respiratory viruses: Journey to the field of biomedicine and biomaterials. Coordination Chemistry Reviews, 2022, 457, 214402.	9.5	28
1612	Rapid colloidal gold immunochromatographic assay for the detection of SARS-CoV-2 total antibodies after vaccination. Journal of Materials Chemistry B, 2022, 10, 1786-1794.	2.9	21
1613	COVID-19 vaccine therapeutic trials review: published results and registered protocols. Journal of Global Health Reports, 0, 5, .	1.0	0
1614	Efficacious nanomedicine track toward combating COVID-19. Nanotechnology Reviews, 2022, 11, 680-698.	2.6	4
1615	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clinical Infectious Diseases, 2022, 75, e630-e644.	2.9	65

#	Article	IF	Citations
1617	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Annals of Medicine, 2022, 54, 524-540.	1.5	225
1618	A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. Vaccine, 2022, 40, 2044-2052.	1.7	11
1619	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARSâ€CoVâ€2 vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2381-2392.	2.7	14
1620	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe, The, 2022, 3, e173-e183.	3.4	31
1621	Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. PLoS ONE, 2022, 17, e0262922.	1.1	10
1624	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell, 2022, 185, 614-629.e21.	13.5	40
1625	A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	94
1626	Non-Canonical Host Intracellular Niche Links to New Antimicrobial Resistance Mechanism. Pathogens, 2022, 11, 220.	1.2	4
1627	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naÃ¯ve and Experienced Individuals. Viruses, 2022, 14, 370.	1.5	5
1628	COVIDâ€19Â vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€”EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	2.7	12
1630	A review of the safety and efficacy of current COVID-19 vaccines. Frontiers of Medicine, 2022, 16, 39-55.	1.5	19
1631	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-20.	1.4	163
1632	Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVIDâ€19). Clinical Respiratory Journal, 2022, 16, 293-300.	0.6	11
1633	Protein and peptide engineering for chemical exchange saturation transfer imaging in the age of synthetic biology. NMR in Biomedicine, 2023, 36, e4712.	1.6	8
1634	Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. Journal of Hematology and Oncology, 2022, 15, 15.	6.9	21
1635	Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. Molecular Therapy, 2022, 30, 1913-1925.	3.7	21
1636	Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Internal Medicine, 2022, 182, 153.	2.6	182
1637	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2â€“experienced individuals. Science Translational Medicine, 2022, 14, .	5.8	65

#	Article	IF	Citations
1638	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell, 2022, 40, 255-276.	7.7	45
1640	Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis. Journal of Nanobiotechnology, 2022, 20, 75.	4.2	11
1641	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. Clinical Biochemistry, 2022, 101, 19-25.	0.8	5
1643	Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. Journal of Proteome Research, 2022, 21, 274-288.	1.8	16
1644	Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature Communications, 2021, 12, 7101.	5.8	100
1645	The germinal centre B cell response to SARS-CoV-2. Nature Reviews Immunology, 2022, 22, 7-18.	10.6	150
1646	Deep dissection of the antiviral immune profile of patients with COVID-19. Communications Biology, 2021, 4, 1389.	2.0	9
1647	Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e1037-e1045.	2.9	90
1648	Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Journal of Infectious Diseases, 2022, 225, 1701-1709.	1.9	9
1649	Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19â€“Convalescent Individuals. Journal of Infectious Diseases, 2022, 225, 1905-1908.	1.9	14
1654	Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial. Infectious Diseases of Poverty, 2021, 10, 138.	1.5	16
1656	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	2.2	21
1658	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4
1659	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science, 2021, , eabl6251.	6.0	12
1660	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. Science Translational Medicine, 2021, , eabi8961.	5.8	22
1661	Optimal strategy for a dose-escalation vaccination against COVID-19 in refugee camps. AIMS Mathematics, 2022, 7, 9288-9310.	0.7	5
1662	Intubation and mortality prediction in hospitalized COVID-19 patients using a combination of convolutional neural network-based scoring of chest radiographs and clinical data. BJR|Open, 2022, 4, .	0.4	6
1663	Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers. Clinical and Experimental Vaccine Research, 2022, 11, 121.	1.1	7

#	Article	IF	Citations
1665	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
1666	Probabilistic classification of antiâ€SARSâ€CoVâ€2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	1.7	4
1667	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. Journal of Primary Care and Community Health, 2022, 13, 215013192210892.	1.0	21
1668	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110566.	0.7	13
1669	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. Frontiers in Immunology, 2022, 13, 835830.	2.2	19
1670	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nature Reviews Rheumatology, 2022, 18, 191-204.	3.5	105
1671	Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Therapy, 2023, 30, 785-793.	2.2	9
1672	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. Pathogens, 2022, 11, 275.	1.2	9
1673	Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. Vaccines, 2022, 10, 290.	2.1	18
1674	Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nature Medicine, 2022, 28, 934-938.	15.2	27
1675	COVID-19 Vaccine: Between Myth and Truth. Vaccines, 2022, 10, 349.	2.1	12
1676	Innovation Opportunity and Challenge of Standardization in Response to COVID-19 Pandemic and the Socio-Economic Impact: A Case Study in Indonesia. Standards, 2022, 2, 66-82.	0.6	3
1677	Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. International Journal of Environmental Research and Public Health, 2022, 19, 2392.	1.2	11
1678	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Scientific Reports, 2022, 12, 2628.	1.6	34
1679	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cellular and Molecular Life Sciences, 2022, 79, 142.	2.4	24
1680	Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses inÂvivo. Cell Chemical Biology, 2022, 29, 811-823.e7.	2.5	6
1681	Transient Myopericarditis Following Vaccination for COVID-19. Journal of Medical Cases, 2022, 13, 80-84.	0.4	1
1682	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunologic Research, 2022, 70, 289-315.	1.3	34

#	Article	IF	Citations
1683	Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. International Journal of Molecular Sciences, 2022, 23, 2408.	1.8	13
1684	The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. Environmental Science and Pollution Research, 2023, 30, 61430-61454.	2.7	6
1685	Acantholytic Dyskeratosis Post-COVID Vaccination. American Journal of Dermatopathology, 2022, Publish Ahead of Print, .	0.3	5
1686	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. Vaccines, 2022, 10, 312.	2.1	3
1687	Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. Frontiers in Immunology, 2022, 13, 838985.	2.2	16
1688	COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. Leukemia and Lymphoma, 2022, 63, 1723-1727.	0.6	1
1689	SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell, 2022, 185, 603-613.e15.	13.5	176
1690	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nature Computational Science, 2022, 2, 123-131.	3.8	39
1691	Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study. American Journal of Clinical Dermatology, 2022, 23, 385-392.	3.3	3
1692	Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nature Communications, 2022, 13, 1614.	5.8	117
1694	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. Medical Microbiology and Immunology, 2022, 211, 79-103.	2.6	9
1695	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2022, 18, 2040330.	1.4	5
1696	The importance of molecular structure and functionalization of oxo-graphene sheets for gene silencing. Carbon, 2022, , .	5.4	3
1697	Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old. Frontiers in Immunology, 2022, 13, 812126.	2.2	16
1698	Bibliometric Analysis: Nanotechnology and COVID-19. Current Topics in Medicinal Chemistry, 2022, 22, 629-638.	1.0	2
1699	Effectiveness and safety of SARSâ€CoVâ€2 vaccine in Inflammatory Bowel Disease patients: a systematic review, metaâ€analysis and metaâ€regression. Alimentary Pharmacology and Therapeutics, 2022, 55, 1244-1264.	1.9	17
1700	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. International Journal of Peptide Research and Therapeutics, 2022, 28, 77.	0.9	5
1701	Global prevalence of acceptance of COVID-19 vaccines and associated factors in pregnant women: a systematic review and meta-analysis. Expert Review of Vaccines, 2022, 21, 843-851.	2.0	16

#	Article	IF	Citations
1703	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. Frontiers in Immunology, 2022, 13, 845887.	2.2	13
1704	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology, 2022, 23, 532-542.	7.0	178
1705	Current Status and Future Perspectives on MRNA Drug Manufacturing. Molecular Pharmaceutics, 2022, 19, 1047-1058.	2.3	44
1706	The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clinical Chemistry and Laboratory Medicine, 2022, 60, 934-940.	1.4	5
1707	Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. Clinical Immunology, 2022, 236, 108961.	1.4	9
1708	A systematic review on mucocutaneous presentations after COVIDâ€19 vaccination and expert recommendations about vaccination of important immuneâ€mediated dermatologic disorders. Dermatologic Therapy, 2022, 35, e15461.	0.8	31
1710	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. Journal of Clinical Investigation, 2022, 132, .	3.9	27
1711	Coronavirus Disease-2019 in Older People with Cognitive Impairment. Clinics in Geriatric Medicine, 2022, 38, 501-517.	1.0	3
1712	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerging Microbes and Infections, 2022, 11, 1058-1071.	3.0	63
1713	Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. F1000Research, 0, 11, 299.	0.8	0
1714	Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Science Translational Medicine, 2022, 14, eabn9243.	5.8	84
1715	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. ACS Infectious Diseases, 2022, 8, 825-840.	1.8	3
1717	Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy. Molecules, 2022, 27, 1943.	1.7	22
1718	Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcÎ³RIIB and virus-antibody complex with bivalent interaction. Communications Biology, 2022, 5, 262.	2.0	26
1719	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. Journal of Microbiology, 2022, 60, 308-320.	1.3	6
1720	COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System. Annals of Internal Medicine, 2022, 175, 352-361.	2.0	41
1721	SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ TÂcell epitope mutations for impaired cellular immune response. IScience, 2022, 25, 103934.	1.9	7
1723	Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults. JCI Insight, 2022, 7, .	2.3	16

#	Article	IF	Citations
1724	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. Journal of Infectious Diseases, 2022, 226, 1372-1381.	1.9	41
1725	Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine. Frontiers in Immunology, 2022, 13, 786586.	2.2	13
1726	Programmable manipulation of oligonucleotideâ€“albumin interaction for elongated circulation time. Nucleic Acids Research, 2022, 50, 3083-3095.	6.5	14
1727	Dynamic observation of SARSâ€CoVâ€2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVIDâ€19 vaccination. Journal of Clinical Laboratory Analysis, 2022, 36, e24325.	0.9	7
1728	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18.	13.5	179
1729	Current Developments and Challenges of mRNA Vaccines. Annual Review of Biomedical Engineering, 2022, 24, 85-109.	5.7	39
1730	Matrix stiffness regulates lipid nanoparticle-mRNA delivery in cell-laden hydrogels. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 42, 102550.	1.7	5
1731	Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. Frontiers in Public Health, 2022, 10, 834744.	1.3	16
1734	COVID-19 Vaccines in Older Adults. Clinics in Geriatric Medicine, 2022, 38, 605-620.	1.0	10
1735	Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine. Viruses, 2022, 14, 540.	1.5	6
1736	Postvaccination SARS-CoV-2 Infections among Healthcare Professionals: A Real World Evidence Study. Vaccines, 2022, 10, 511.	2.1	1
1737	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Cells, 2022, 11, 1182.	1.8	10
1738	Trends and Innovations of Simulation for Twenty First Century Medical Education. Frontiers in Public Health, 2022, 10, 619769.	1.3	26
1739	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. AAPS PharmSciTech, 2022, 23, 95.	1.5	3
1740	The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients. Microbiology Spectrum, 2022, 10, e0021122.	1.2	8
1741	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine, 2022, 28, 1042-1049.	15.2	61
1742	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biology, 2022, 19, 386-410.	1.5	19
1743	Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine. Cancer Journal (Sudbury, Mass), 2022, 28, 146-150.	1.0	0

#	Article	IF	Citations
1744	Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. ELife, 2022, 11, .	2.8	26
1745	COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): state of the art. Current Cardiology Reviews, 2022, 18, .	0.6	1
1746	RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein. Biomicrofluidics, 2022, 16, 024105.	1.2	2
1747	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. Pathogens, 2022, 11, 368.	1.2	23
1749	Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs. Cell Reports Methods, 2022, 2, 100181.	1.4	9
1750	mRNA cancer vaccines: Advances, trends and challenges. Acta Pharmaceutica Sinica B, 2022, 12, 2969-2989.	5.7	55
1751	Pandemic-response adenoviral vector and RNA vaccine manufacturing. Npj Vaccines, 2022, 7, 29.	2.9	12
1752	Large-scale design and refinement of stable proteins using sequence-only models. PLoS ONE, 2022, 17, e0265020.	1.1	17
1753	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. Journal of the Chinese Medical Association, 2022, 85, 537-542.	0.6	6
1754	Optimizing COVID-19 vaccination programs during vaccine shortages. Infectious Disease Modelling, 2022, 7, 286-298.	1.2	26
1755	Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. Microbiology Spectrum, 2022, 10, e0039622.	1.2	6
1756	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 516.	2.1	2
1758	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. Journal of Personalized Medicine, 2022, 12, 386.	1.1	5
1759	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. Journal of Headache and Pain, 2022, 23, 41.	2.5	43
1760	Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System. Advanced Materials, 2022, 34, e2201095.	11.1	66
1761	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. Biomedicines, 2022, 10, 776.	1.4	8
1762	Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents. Frontiers in Medicine, 2022, 9, 802312.	1.2	9
1763	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. EClinicalMedicine, 2022, 45, 101326.	3.2	29

#	Article	IF	Citations
1764	Coronavirus-A Crippling Affliction to Humans. Recent Patents on Biotechnology, 2022, 16, .	0.4	2
1765	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	4.9	27
1766	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102482.	1.8	9
1767	COVID-19 Vaccination During Pregnancy. , 2022, 2, 1-7.		0
1768	mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People. Viruses, 2022, 14, 748.	1.5	11
1769	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 1788.	5.8	30
1770	Identification of Natural SARS-CoV-2 Infection in Seroprevalence Studies Among Vaccinated Populations. Mayo Clinic Proceedings, 2022, 97, 754-760.	1.4	13
1771	Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 834.	1.4	16
1772	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. Frontiers in Immunology, 2022, 13, 834942.	2.2	10
1773	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. Annals of Allergy, Asthma and Immunology, 2022, 129, 40-51.	0.5	14
1774	Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nature Communications, 2022, 13, 1891.	5.8	45
1775	Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4. Frontiers in Immunology, 2022, 13, 869042.	2.2	1
1776	From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life. Recent Patents on Biotechnology, 2022, 16, 2-5.	0.4	4
1777	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe, The, 2022, 3, e252-e264.	3.4	29
1778	Prediction of putative potential siRNAs for inhibiting SARS-CoV-2 strains, including variants of concern and interest. Future Microbiology, 2022, 17, 449-463.	1.0	4
1779	Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. Journal of Infection and Public Health, 2022, 15, 573-577.	1.9	7
1780	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open, 2022, 12, e056872.	0.8	12
1781	High viral loads: what drives fatal cases of COVID-19 in vaccinees? â€“ an autopsy study. Modern Pathology, 2022, 35, 1013-1021.	2.9	5

#	Article	IF	Citations
1782	Seroprevalence of SARS-CoV-2 antibodies among blood donors in QuÃ©bec: an update from a serial cross-sectional study. Canadian Journal of Public Health, 2022, 113, 385-393.	1.1	3
1783	Acceptance, effects, and tolerability in the vaccination process against SARS-CoV-2 virus among cancer patients in Bosnia and Herzegovina: a single-center cross-sectional study. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	1
1784	Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines. Advanced Drug Delivery Reviews, 2022, 185, 114281.	6.6	9
1785	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€“ a review. Translational Research, 2022, 242, 1-19.	2.2	3
1786	Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. Frontiers in Immunology, 2022, 13, 882856.	2.2	4
1787	Reprint of: Development of vaccines and vaccinal strategies against COVID-19: the information contributing to shared decision-making. La Presse MÃ©dicale Open, 2022, , 100024.	0.1	0
1788	mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release, 2022, 345, 314-333.	4.8	50
1789	Stroke Associated with COVID-19 Vaccines. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106440.	0.7	21
1790	Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan. Journal of Clinical Virology, 2022, 150-151, 105156.	1.6	5
1791	A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. Molecular Therapy - Methods and Clinical Development, 2022, 25, 205-214.	1.8	33
1792	Discordance Between SARS-CoV-2â€“specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients. Transplantation Direct, 2021, 7, e794.	0.8	28
1793	mRNAç––æ³•çš„ç”¨è¿›å±•ä¸ŽæŒ‘æ˜. Scientia Sinica Vitae, 2023, 53, 30-49.	0.1	1
1794	Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infectious Diseases, 2022, 9, ofab575.	0.4	43
1795	Overview on Covid-19 Vaccine - A Short Review. Journal of Evolution of Medical and Dental Sciences, 2021, 10, 4032-4036.	0.1	0
1796	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. BMJ Open, 2021, 11, e054208.	0.8	7
1797	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. Frontiers in Pharmacology, 2021, 12, 778219.	1.6	0
1799	Vaccination Against COVID-19: Emerging Issues and Future Prospects. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 652-660.	0.2	1
1800	Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV. Journal of Infectious Diseases, 2022, 225, 1937-1947.	1.9	9

#	Article	IF	Citations
1801	Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination. Scientific Reports, 2021, 11, 24448.	1.6	30
1803	Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. GeroScience, 2022, 44, 57-61.	2.1	3
1804	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. Npj Vaccines, 2021, 6, 151.	2.9	36
1806	The multifaceted roles of mass spectrometric analysis in nucleic acids drug discovery and development. Mass Spectrometry Reviews, 2023, 42, 1332-1357.	2.8	4
1807	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Frontiers in Immunology, 2021, 12, 759688.	2.2	29
1808	Nano-chemistry and Bio-conjugation with perspectives on the design of Nano-Immune platforms, vaccines and new combinatorial treatments. Journal of Vaccines and Immunology, 0, , 049-056.	0.3	0
1809	mRNA Vaccines. , 2021, , .		0
1810	Humoral and cellular immune responses to the SARSâ€CoVâ€2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls. Transplant Infectious Disease, 2022, 24, e13772.	0.7	21
1812	A case of trigeminal neuralgia developing after a COVID-19 vaccination. Journal of NeuroVirology, 2022, 28, 181-182.	1.0	12
1814	COMPARES mRNA AND ADENOVIRUS-BASED SARS-CoV-2 VACCINES. International Journal of Applied Pharmaceutics, 0, , 77-82.	0.3	0
1815	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. 3 Biotech, 2022, 12, 15.	1.1	20
1816	Estimating the impact of interventions against COVID-19: From lockdown to vaccination. PLoS ONE, 2021, 16, e0261330.	1.1	23
1817	Comparing hospital-resource utilization by an enhanced pneumonia surveillance programme for COVID-19 with pre-pandemic pneumonia admissions â€“ a Singaporean hospitalâ€™s experience. Journal of Medical Microbiology, 2021, 70, .	0.7	1
1819	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Scientific Reports, 2021, 11, 23921.	1.6	44
1821	Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment. International Journal of Nanomedicine, 2021, Volume 16, 8141-8158.	3.3	12
1822	Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles. Pharmaceutics, 2021, 13, 2097.	2.0	11
1824	Advances in the design and development of SARS-CoV-2 vaccines. Military Medical Research, 2021, 8, 67.	1.9	26
1825	T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants. Frontiers in Medicine, 2021, 8, 793102.	1.2	21

#	Article	IF	Citations
1826	Nanoscience versus Viruses: The SARSâ€CoVâ€2 Case. Advanced Functional Materials, 2022, 32, 2107826.	7.8	8
1827	Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase. BMJ, The, 2021, 375, e067570.	3.0	5
1828	Interferon inducible pseudouridine modification in human mRNA by quantitative nanopore profiling. Genome Biology, 2021, 22, 330.	3.8	44
1829	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. Vaccines, 2022, 10, 37.	2.1	15
1830	Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review. Nanoscale Research Letters, 2021, 16, 174.	3.1	75
1832	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. Methods in Molecular Biology, 2022, 2410, 229-263.	0.4	1
1834	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. Cell Transplantation, 2022, 31, 096368972210902.	1.2	3
1835	Recent and advanced nano-technological strategies for COVID-19 vaccine development. Methods in Microbiology, 2022, , .	0.4	0
1836	Combating Viral Diseases in the Era of Systems Medicine. Methods in Molecular Biology, 2022, 2486, 87-104.	0.4	0
1837	A Case of Myocarditis Presenting With a Hyperechoic Nodule After the First Dose of COVID-19 mRNA Vaccine. Journal of Korean Medical Science, 2022, 37, e131.	1.1	1
1838	Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RÎ³cKO.NOD) for COVID-19. Human Vaccines and Immunotherapeutics, 2022, 18, 1-16.	1.4	6
1839	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Science Translational Medicine, 2022, 14, eabm2311.	5.8	100
1840	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Cell Reports, 2022, 39, 110757.	2.9	10
1842	Nano toolbox in immune modulation and nanovaccines. Trends in Biotechnology, 2022, 40, 1195-1212.	4.9	31
1843	A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose. CEN Case Reports, 2022, 11, 477-481.	0.5	8
1844	Development of antibody resistance in emerging mutant strains of SARS CoVâ€2: Impediment for COVIDâ€19 vaccines. Reviews in Medical Virology, 2022, 32, e2346.	3.9	16
1845	COVID-19 Vaccines: Current and Future Perspectives. Vaccines, 2022, 10, 608.	2.1	26
1846	Isotope Labels Combined with Solution NMR Spectroscopy Make Visible the Invisible Conformations of Small-to-Large RNAs. Chemical Reviews, 2022, 122, 9357-9394.	23.0	12

#	Article	IF	Citations
1847	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. PLoS Pathogens, 2022, 18, e1010155.	2.1	6
1848	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2022, 40, 3020-3031.	0.8	26
1849	Global Gene Expression and Docking Profiling of COVID-19 Infection. Frontiers in Genetics, 2022, 13, 870836.	1.1	9
1850	The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling. Journal of Molecular Graphics and Modelling, 2022, 114, 108193.	1.3	8
1851	The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study. Biomedicines, 2022, 10, 911.	1.4	9
1852	Higher Antibody Concentrations in U.S. Health Care Workers Associated with Greater Reactogenicity Post-Vaccination. Vaccines, 2022, 10, 601.	2.1	7
1853	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. Journal of Molecular Cell Biology, 2022, 14, .	1.5	4
1854	RNA therapy: rich history, various applications and unlimited future prospects. Experimental and Molecular Medicine, 2022, 54, 455-465.	3.2	92
1855	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. Process Biochemistry, 2022, 118, 154-170.	1.8	4
1856	Adapting to vaccination. Nature Ecology and Evolution, 2022, 6, 673-674.	3.4	2
1857	Trigeminal neuropathy after tozinameran vaccination against COVID-19 in postmicrovascular decompression for trigeminal neuralgia: illustrative case. Journal of Neurosurgery Case Lessons, 2022, 3, .	0.1	6
1858	Preclinical study of a DNA vaccine targeting SARS-CoV-2. Current Research in Translational Medicine, 2022, 70, 103348.	1.2	9
1864	The Advisory Committee on Immunization Practicesâ€™ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged â‰¥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines â€" United States, February 2022. Morbidity and Mortality Weekly Report, 2022, 71, 416-421.	9.0	27
1865	Oral Immunization of Mice with Cell Extracts from Recombinant Lactococcus lactis Expressing SARS-CoV-2 Spike Protein. Current Microbiology, 2022, 79, 167.	1.0	6
1866	CoronaVac/Sinovac COVID-19 Vaccine-Related Hypersensitivity Reactions and Second-Dose Vaccine Administration: Tertiary Allergy Center Experience. International Archives of Allergy and Immunology, 2022, 183, 778-784.	0.9	12
1867	Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. Cell Journal, 2021, 23, 523-531.	0.2	4
1868	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, E. coli Ribonuclease I and Human RNase A. Frontiers in Microbiology, 2021, 12, 660149.	1.5	1
1869	EtickÃ© a zÃ¡konnÃ© poÅ¾adavky na podstoupenÃ-oÄkovÃ¡nÃ-k prevenci nemoci COVID-19. Ceska A Slovenska Farmacie, 2022, 71, 3-12.	0.3	0

#	Article	IF	Citations
1871	Humoral immunity against SARSâ€CoVâ€2 variants including omicron in solid organ transplant recipients after three doses of a COVIDâ€19 mRNA vaccine. Clinical and Translational Immunology, 2022, 11, e1391.	1.7	21
1872	Ethical Issues involving the development of Covid-19 vaccines: Role of vaccine development, clinical trials and speed of peer review in dissuading public vaccine hesitancy. Ethics in Biology, Engineering & Medicine, 2022, , .	0.1	0
1873	Live very long and prosper? Transhumanist visions and ambitions in 2021 and beyondâ€¦. Journal of Marketing Management, 2022, 38, 399-422.	1.2	2
1874	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
1875	Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines. , 2022, 135, 212726.		12
1876	Enabling community input to improve equity in and access to translational research: The Community Coalition for Equity in Research. Journal of Clinical and Translational Science, 2022, 6, .	0.3	2
1877	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 2022, 10, 695.	2.1	16
1878	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. Npj Vaccines, 2022, 7, 49.	2.9	7
1879	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. Frontiers in Immunology, 2022, 13, 814365.	2.2	10
1880	A Short Series of Case Reports of COVID-19 in Immunocompromised Patients. Viruses, 2022, 14, 934.	1.5	4
1881	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines, 2022, 10, 712.	2.1	4
1882	Cold atmospheric plasma for addressing the COVIDâ€19 pandemic. Plasma Processes and Polymers, 2022, 19, e2200012.	1.6	9
1883	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Molecular Therapy, 2022, 30, 2984-2997.	3.7	17
1884	Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies. International Journal of Infectious Diseases, 2022, 121, 58-65.	1.5	19
1885	Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. Frontiers in Immunology, 2022, 13, 895209.	2.2	13
1886	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. Frontiers in Immunology, 2022, 13, 843928.	2.2	25
1887	Nanoparticles for Coronavirus Control. Nanomaterials, 2022, 12, 1602.	1.9	9
1888	Recent developments in SARSâ€CoVâ€2 vaccines: A systematic review of the current studies. Reviews in Medical Virology, 2023, 33, e2359.	3.9	17

#	Article	IF	Citations
1889	Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 150.	0.8	16
1890	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. Vaccines, 2022, 10, 717.	2.1	15
1891	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. Biochemistry, 2022, 61, 963-980.	1.2	12
1892	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. PLoS Biology, 2022, 20, e3001609.	2.6	14
1893	Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. BMC Pregnancy and Childbirth, 2022, 22, 402.	0.9	4
1894	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. Cureus, 2022, , .	0.2	3
1895	AAV9-mediated functional screening for cardioprotective cytokines in Coxsackievirus-B3-induced myocarditis. Scientific Reports, 2022, 12, 7304.	1.6	2
1896	Exploring vaccine hesitancy in care home employees in North West England: a qualitative study. BMJ Open, 2022, 12, e055239.	0.8	9
1897	The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine. Frontiers in Microbiology, 2022, 13, .	1.5	8
1898	Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults. Open Forum Infectious Diseases, 2022, 9, .	0.4	11
1899	Efficacy of COVID-19 vaccines by race and ethnicity. Public Health, 2022, , .	1.4	6
1900	Worsening of immune thrombocytopenic purpura in SARS-CoV-2 vaccinated patients. Medicina ClÃnica (English Edition), 2022, 158, 497-497.	0.1	1
1901	Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein Expression Platform. Toxicologic Pathology, 2022, 50, 294-307.	0.9	7
1902	Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review. Cureus, 2022, , .	0.2	3
1903	The potential of RNA-based therapy for kidney diseases. Pediatric Nephrology, 2023, 38, 327-344.	0.9	14
1905	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
1906	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	3
1907	The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology, 2022, 40, 840-854.	9.4	248

#	Article	IF	Citations
1908	A Review of Different Vaccines and Strategies to Combat COVID-19. Vaccines, 2022, 10, 737.	2.1	8
1909	Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial. EClinicalMedicine, 2022, 48, 101444.	3.2	9
1910	SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. EBioMedicine, 2022, 80, 104048.	2.7	12
1911	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	3.9	26
1912	Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 730-737.	1.8	1
1913	Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. , 2022, 1, .		6
1914	Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944.	6.6	74
1915	New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan. Clinical and Experimental Nephrology, 2022, 26, 909-916.	0.7	6
1916	Implementation of the drive-through strategy for COVID-19 vaccination: an experience report. Revista Da Escola De Enfermagem Da U S P, 2022, 56, e20210397.	0.3	1
1917	ImplementaÃ§Ã£o da estratÃ©gia drive-through para vacinaÃ§Ã£o COVID-19: um relato de experiÃªncia. Revista Da Escola De Enfermagem Da U S P, 0, 56, .	0.3	2
1918	Spatiotemporal tracking of the transport of RNA nano-drugs: from transmembrane to intracellular delivery. Nanoscale, 2022, 14, 8919-8928.	2.8	1
1919	Immunoinformatic paradigm predicts macrophage and T-cells epitope responses against globally conserved spike fragments of SARS CoV-2 for universal vaccination. International Immunopharmacology, 2022, , 108847.	1.7	0
1920	Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy. Computational and Structural Biotechnology Journal, 2022, 20, 2442-2454.	1.9	13
1921	Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants. Current Opinion in Immunology, 2022, 77, 102189.	2.4	15
1922	Demographic and Clinical Factors Associated With Antiâ€“SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses. JAMA Network Open, 2022, 5, e2212996.	2.8	9
1923	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	0.4	2
1924	Optimizing Immunization Strategies in Adult Patients With Chronic Liver Disease and Liver Transplant Recipients.. Gastroenterology and Hepatology, 2022, 18, 196-206.	0.2	0
1925	An Open-Publishing Response to the COVID-19 Infodemic.. CEUR Workshop Proceedings, 2021, 2976, 29-38.	2.3	2

#	Article	IF	Citations
1927	Understanding â€œHybrid Immunityâ€• Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2023, 76, e439-e449.	2.9	23
1928	Immunological heterogeneity informs estimation of the durability of vaccine protection. Journal of the Royal Society Interface, 2022, 19, .	1.5	2
1929	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
1930	Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach. Molecular Pharmaceutics, 2022, 19, 1892-1905.	2.3	30
1931	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respiratory Medicine,the, 2022, 10, 749-760.	5.2	65
1932	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Frontiers in Immunology, 2022, 13, .	2.2	37
1933	Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. Infectious Diseases and Therapy, 2022, 11, 1391-1414.	1.8	8
1934	Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. Vaccines, 2022, 10, 799.	2.1	13
1935	Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical Trial. SSRN Electronic Journal, 0, , .	0.4	1
1936	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. Innovare Journal of Medical Sciences, 0, , 6-13.	0.2	0
1937	Nanomedicine to deliver biological macromolecules for treating COVID-19. Vaccine, 2022, 40, 3931-3941.	1.7	9
1938	Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study. Vaccines, 2022, 10, 862.	2.1	5
1939	Humoral and cellular immune memory to four COVID-19 vaccines. Cell, 2022, 185, 2434-2451.e17.	13.5	289
1940	Activity-induced propulsion of a vesicle. Journal of Fluid Mechanics, 2022, 942, .	1.4	2
1942	Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments. Scandinavian Journal of Rheumatology, 2022, 51, 500-505.	0.6	2
1943	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	2.0	1
1944	Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2022, 172, 41-50.	1.3	6
1945	Design and assembly of plant-based COVID-19 candidate vaccines: reÑent development and future prospects. Vavilovskii Zhurnal Genetiki I Selektsii, 2022, 26, 327-335.	0.4	0

#	Article	IF	Citations
1946	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970.	7.0	39
1947	mRNA-1273 vaccination protects against SARS-CoV-2â€“elicited lung inflammation in nonhuman primates. JCI Insight, 2022, 7, .	2.3	3
1949	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477.	3.2	13
1950	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. Current Opinion in Immunology, 2022, 77, 102214.	2.4	7
1952	Advances in Circular RNA and Its Applications. International Journal of Medical Sciences, 2022, 19, 975-985.	1.1	46
1953	Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clinical and Experimental Vaccine Research, 2022, 11, 209.	1.1	4
1955	Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel. Vaccines, 2022, 10, 877.	2.1	3
1956	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. Molecular Immunology, 2022, 149, 107-118.	1.0	2
1957	Making COVID-19 mRNA vaccines accessible: challenges resolved. Expert Review of Vaccines, 2022, 21, 1163-1176.	2.0	6
1958	Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. Vaccines, 2022, 10, 956.	2.1	8
1961	Is Measurement of Systemic IgG Antibodies the Wrong Way to Assess COVID-19 Vaccine Effectiveness for Breakthrough Infections?. journal of applied laboratory medicine, The, 0, , .	0.6	0
1962	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	1.2	24
1965	Medical Mistrust, COVID-19 Stress, and Intent to Vaccinate in Racialâ€“Ethnic Minorities. Behavioral Sciences (Basel, Switzerland), 2022, 12, 186.	1.0	6
1966	The Past, Present, and Future of Non-Viral CAR T Cells. Frontiers in Immunology, 0, 13, .	2.2	39
1967	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
1968	Immunizing the imperfect immune system. Annals of Allergy, Asthma and Immunology, 2022, 129, 562-571.e1.	0.5	16
1969	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	15.2	29
1970	Addressing COVID-19 vaccine hesitancy. Drugs in Context, 0, 11, 1-19.	1.0	11

#	Article	IF	Citations
1971	Comparative Profiles of SARS-CoV-2 Spike-Specific Human Milk Antibodies Elicited by mRNA- and Adenovirus-Based COVID-19 Vaccines. Breastfeeding Medicine, 2022, 17, 638-646.	0.8	11
1972	Impact of COVID19 on Maxillofacial Fractures in the Province of Lâ€™Aquila, Abruzzo, Italy. Review of 296 Patients Treated With Statistical Comparison of the Two-Year Pre-COVID19 and COVID19. Journal of Craniofacial Surgery, 2022, 33, 1182-1184.	0.3	8
1973	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Nature Microbiology, 2022, 7, 974-985.	5.9	30
1976	Global prevalence and clinical manifestations of cutaneous adverse reactions following COVIDâ€19 vaccination: A systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1947-1968.	1.3	26
1977	Lessons from SARSâ€‘CoVâ€‘2 and its variants (Review). Molecular Medicine Reports, 2022, 26, .	1.1	5
1978	Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	15
1979	Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. Journal of Nanobiotechnology, 2022, 20, .	4.2	52
1981	Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose. Hormones, 0, , .	0.9	5
1982	Immunological memory to <scp>SARSâ€CoV</scp>â€2 infection and <scp>COVID</scp>â€19 vaccines. Immunological Reviews, 2022, 310, 27-46.	2.8	137
1984	The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. Journal of Pharmacy Practice, 2023, 36, 953-966.	0.5	6
1985	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Vaccine, 2022, 40, 5275-5293.	1.7	3
1986	Use of Nanomaterials for Diagnosis and Treatment: The Advancement of Next-Generation Antiviral Therapy. Microbial Drug Resistance, 2022, 28, 670-697.	0.9	4
1988	Robust anti-SARS-CoV2 single domain antibodies cross neutralize multiple viruses. IScience, 2022, 25, 104549.	1.9	2
1989	Nanomaterial-based delivery of vaccine through nasal route: Opportunities, challenges, advantages, and limitations. Journal of Drug Delivery Science and Technology, 2022, 74, 103533.	1.4	12
1990	Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle. Journal of Inorganic Biochemistry, 2022, 234, 111899.	1.5	7
1991	Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. European Journal of Pharmaceutical Sciences, 2022, 176, 106234.	1.9	14
1992	COVID-19 vaccine hesitancy in six geopolitical zones in Nigeria: a cross sectional survey. Pan African Medical Journal, 0, 42, .	0.3	8
1993	mRNA delivery technologies: Toward clinical translation. International Review of Cell and Molecular Biology, 2022, , 207-293.	1.6	5

#	Article	IF	Citations
1994	Lipid nanoparticles and nanoemulsions exploited in the diagnosis and treatment of infectious diseases. , 2022, , 229-273.		0
1995	Knowledge, attitude, and practice toward the novel COVID-19 outbreak: A cross-sectional study in Palestitine. , 2022, 1, 162.		0
1996	Severe acute respiratory syndrome coronavirus-2: An era of struggle and discovery leading to the emergency use authorization of treatment and prevention measures based on computational analysis. , 2022, , 559-582.		0
1997	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
1998	Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis. , 2022, 1, 103-112.		3
1999	Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination. Biomedicines, 2022, 10, 1538.	1.4	27
2000	Comparison of COVID-19 Vaccines Introduced in Korea. Biomedical Science Letters, 2022, 28, 67-82.	0.0	1
2001	Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects. Pathogens, 2022, 11, 743.	1.2	11
2002	Myths about diversity in clinical trials reduce return on investment for industry. Nature Medicine, 2022, 28, 1520-1522.	15.2	6
2004	Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina (Lithuania), 2022, 58, 874.	0.8	9
2005	mRNA vaccines: Past, present, future. Asian Journal of Pharmaceutical Sciences, 2022, 17, 491-522.	4.3	24
2006	Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARSâ€CoVâ€2 vaccine. Clinical and Translational Medicine, 2022, 12, .	1.7	4
2007	An Overview on Immunity Booster Foods in Coronavirus Disease (COVID-19). Combinatorial Chemistry and High Throughput Screening, 2023, 26, 1251-1284.	0.6	1
2008	Evaluation of Patients with Vaccine Allergies Prior to mRNA-Based COVID-19 Vaccination. Vaccines, 2022, 10, 1025.	2.1	4
2009	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
2010	Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages. Frontiers in Immunology, 0, 13, .	2.2	9
2011	Hyperactivity of the CD155 immune checkpoint suppresses anti-viral immunity in patients with coronary artery disease. , 2022, 1, 634-648.		5
2012	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. Scientific Reports, 2022, 12, .	1.6	23

#	Article	IF	Citations
2013	Prior antihistamine agent successfully impaired cutaneous adverse reactions to <scp>COVID</scp>â€19 vaccine. Journal of Cutaneous Immunology and Allergy, 2022, 5, 170-173.	0.2	1
2014	Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. Communications Medicine, 2022, 2, .	1.9	9
2015	Advances in Infectious Disease Vaccine Adjuvants. Vaccines, 2022, 10, 1120.	2.1	32
2016	Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study. Journal of Personalized Medicine, 2022, 12, 1107.	1.1	5
2017	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines, 2022, 10, 1068.	2.1	9
2018	Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2. Journal of Molecular Cell Biology, 2022, 14, .	1.5	2
2019	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
2020	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nature Communications, 2022, 13, .	5.8	53
2021	Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry. IScience, 2022, 25, 104716.	1.9	6
2022	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	1.7	10
2023	Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	7
2024	Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. Journal of Infectious Diseases, 0, , .	1.9	8
2025	Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 1069.	2.1	2
2026	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Vaccines, 2022, 10, 1071.	2.1	14
2027	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
2028	The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ TÂcell responses. Cell Reports, 2022, 40, 111138.	2.9	13
2029	Guardians of the oral and nasopharyngeal galaxy: <scp>IgA</scp> and protection against <scp>SARSâ€CoV</scp>â€2 infection*. Immunological Reviews, 2022, 309, 75-85.	2.8	32
2030	Multiple Evanescent White Dot Syndrome Developing Three Days following Administration of mRNA-1273 Booster Vaccine: Case Report. Case Reports in Ophthalmology, 2022, 13, 570-577.	0.3	4

#	Article	IF	Citations
2031	Next RNA Therapeutics: The Mine of Non-Coding. International Journal of Molecular Sciences, 2022, 23, 7471.	1.8	34
2032	Incorporating Fuzzy Cognitive Inference for Vaccine Hesitancy Measuring. Sustainability, 2022, 14, 8434.	1.6	0
2033	Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines. Biomedicines, 2022, 10, 1676.	1.4	5
2034	Bâ€cell repopulation dynamics and drug pharmacokinetics impact <scp>SARSâ€CoV</scp>â€2 vaccine efficacy in <scp>antiâ€CD20</scp>â€treated multiple sclerosis patients. European Journal of Neurology, 2022, 29, 3317-3328.	1.7	13
2035	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. International Journal of Infectious Diseases, 2022, 122, 793-801.	1.5	17
2036	Clinical Presentations of Adult and Pediatric SARSâ€CoVâ€2â€Positive Cases in a Community Cohort, Nashville, Tennessee. Journal of Medical Virology, 0, , .	2.5	1
2037	Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. Antibody Therapeutics, 2022, 5, 177-191.	1.2	6
2038	SARS-CoV-2 Vaccination: What Can We Expect Now?. Vaccines, 2022, 10, 1093.	2.1	0
2039	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. Vaccines, 2022, 10, 1103.	2.1	11
2040	Case of reactive sacroiliitis possibly induced by an mRNA coronavirus disease vaccine. BMJ Case Reports, 2022, 15, e249063.	0.2	3
2041	Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine. Journal of Clinical Virology Plus, 2022, 2, 100094.	0.4	2
2042	Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19. IScience, 2022, 25, 104719.	1.9	0
2043	Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Current Opinion in Chemical Biology, 2022, 70, 102172.	2.8	40
2044	Exposure to avian coronavirus vaccines is associated with increased levels of <scp>SARSâ€CoV</scp>â€2â€crossâ€reactive antibodies. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3648-3662.	2.7	2
2045	SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Science Translational Medicine, 2022, 14, .	5.8	32
2046	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. Frontiers in Immunology, 0, 13, .	2.2	31
2047	Tools shaping drug discovery and development. Biophysics Reviews, 2022, 3, .	1.0	3
2049	Alternative Strategies to Increase the Immunogenicity of Covid-19 Vaccines in Kidney Transplant Recipients Not Responding to Two or Three Doses of an mRNA Vaccine. A Randomized Clinical Trial. SSRN Electronic Journal, 0, , .	0.4	4

#	Article	IF	Citations
2050	NMR spectroscopy spotlighting immunogenicity induced by COVID-19 vaccination to mitigate future health concerns. Current Research in Immunology, 2022, 3, 199-214.	1.2	1
2051	The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics. European Journal of Dermatology, 2022, 32, 195-206.	0.3	1
2052	EFFECT OF COVID-19 VACCINATION ON OUTCOME OF PATIENTS WITH COVID-19 INFECTION-A RETROSPECTIVE OBSERVATIONAL STUDY.. , 2022, , 53-55.		0
2053	Recent Updates on mRNA Vaccines. Vaccines, 2022, 10, 1209.	2.1	1
2054	Peimine inhibits variants of <scp>SARSâ€CoV</scp> â€2 cell entry via blocking the interaction between viral spike protein and <scp>ACE2</scp>. Journal of Food Biochemistry, 2022, 46, .	1.2	8
2055	SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Nature Communications, 2022, 13, .	5.8	24
2056	Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy. Nature Communications, 2022, 13, .	5.8	29
2058	Anti-TNFÎ± Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines, 2022, 10, 1186.	2.1	8
2059	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. Npj Vaccines, 2022, 7, .	2.9	13
2060	Transient Global Amnesia Related to the Third Coronavirus Disease-19 (COVID-19) Vaccination. Cureus, 2022, , .	0.2	1
2061	Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients. BMC Infectious Diseases, 2022, 22, .	1.3	3
2062	A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	4
2064	Vaccines against SARS-CoV-2 variants and future pandemics. Expert Review of Vaccines, 2022, 21, 1363-1376.	2.0	6
2065	SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	28
2066	Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Vaccine, 2022, 40, 5701-5708.	1.7	0
2067	Current Vaccine Platforms in Enhancing T-Cell Response. Vaccines, 2022, 10, 1367.	2.1	8
2068	Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. Journal of Antimicrobial Chemotherapy, 2022, 77, 2706-2712.	1.3	4
2069	Nanoparticles in clinical trials of COVID-19: An update. International Journal of Surgery, 2022, 104, 106818.	1.1	22

#	Article	IF	Citations
2070	Vaccines platforms and COVID-19: what you need to know. Tropical Diseases, Travel Medicine and Vaccines, 2022, 8, .	0.9	16
2071	Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Human Immunology, 2022, 83, 755-767.	1.2	10
2072	Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. Inflammopharmacology, 0, , .	1.9	3
2073	Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine, 2022, 40, 5657-5663.	1.7	10
2074	A Temperature-Sensitive Recombinant of Avian Coronavirus Infectious Bronchitis Virus Provides Complete Protection against Homologous Challenge. Journal of Virology, 2022, 96, .	1.5	5
2075	Characteristics and Clinical Ocular Manifestations in Patients with Acute Corneal Graft Rejection after Receiving the COVID-19 Vaccine: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 4500.	1.0	5
2077	Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic. Current Infectious Disease Reports, 2022, 24, 129-145.	1.3	17
2078	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. International Journal of Molecular Sciences, 2022, 23, 8982.	1.8	4
2079	Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface. Frontiers in Immunology, 0, 13, .	2.2	3
2080	Influence of <scp>COVID</scp>â€19 <scp>mRNA</scp> vaccination on the efficacy and safety of Botulinum toxin type A injections. Journal of Cosmetic Dermatology, 2022, 21, 3663-3666.	0.8	6
2082	A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients. Viruses, 2022, 14, 1822.	1.5	25
2083	Immune response induced in rodents by anti-CoVid19 plasmid DNA vaccine via pyro-drive jet injector inoculation. Immunological Medicine, 2022, 45, 251-264.	1.4	5
2084	The current status of COVID-19 vaccines. A scoping review. Drug Discovery Today, 2022, 27, 103336.	3.2	7
2085	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Frontiers in Immunology, 0, 13, .	2.2	19
2086	Emerging trends of research on mRNA vaccines: A co-citation analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
2087	Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Reports, 2022, 40, 111214.	2.9	24
2088	Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, .	2.2	2
2089	A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. F1000Research, 0, 11, 909.	0.8	0

#	Article	IF	Citations
2090	Neutralizing antibodies to SARSâ€CoVâ€2 variants of concern including Delta and Omicron in subjects receiving mRNAâ€1273, BNT162b2, and Ad26.COV2.S vaccines. Journal of Medical Virology, 2022, 94, 5678-5690.	2.5	16
2091	Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins. International Journal of Molecular Sciences, 2022, 23, 8680.	1.8	7
2092	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. Science Translational Medicine, 2022, 14, .	5.8	15
2093	New-onset IgA nephropathy following COVID-19 vaccination. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 26-39.	0.2	20
2094	A platform technology for generating subunit vaccines against diverse viral pathogens. Frontiers in Immunology, 0, 13, .	2.2	7
2095	Dual effects of supplemental oxygen on pulmonary infection, inflammatory lung injury, and neuromodulation in aging and COVID-19. Free Radical Biology and Medicine, 2022, 190, 247-263.	1.3	5
2096	Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. , 2022, 2, 196-206.		6
2097	mRNA produced by VSW-3 RNAP has high-level translation efficiency with low inflammatory stimulation. , 2022, 1, 100056.		9
2098	Therapeutic approaches to Epsteinâ€“Barr virus cancers. Current Opinion in Virology, 2022, 56, 101260.	2.6	7
2099	Morphology-driven protein corona manipulation for preferential delivery of lipid nanodiscs. Nano Today, 2022, 46, 101609.	6.2	11
2100	Prevention and management of adverse events following COVID-19 vaccination using traditional Korean medicine: An online survey of public health doctors. World Journal of Clinical Cases, 0, 10, 10053-10065.	0.3	5
2101	COVID-19: Vaccines and therapeutics. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128987.	1.0	4
2102	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. The Lancet Regional Health - Western Pacific, 2022, 29, 100586.	1.3	6
2103	Hazards of vaccinating the way out of Covid-19 pandemic: Study of adverse events following immunization (Aefi) in India. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, .	0.0	0
2104	Safety surveillance and challenges in accelerated COVID-19 vaccine development. Therapeutic Advances in Drug Safety, 2022, 13, 204209862211164.	1.0	6
2105	N-Gram-Codon and Recurrent Neural Network (RNN) to Update Pfizer-BioNTech mRNA Vaccine. International Journal of Software Science and Computational Intelligence, 2022, 14, 1-24.	1.8	5
2106	Basic biotechnology applications in viral diseases. , 2022, , 105-113.		0
2107	Recent advances in nanotechnology approaches for non-viral gene therapy. Biomaterials Science, 2022, 10, 6862-6892.	2.6	15

#	Article	IF	Citations
2109	Development of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) Vaccines. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2022, 31, 484.	0.0	0
2110	Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. Infection and Chemotherapy, 2022, 54, 504.	1.0	2
2111	Clinical Development of mRNA Vaccines: Challenges and Opportunities. Current Topics in Microbiology and Immunology, 2022, , 167-186.	0.7	2
2112	Cationic polymer synergizing with a disulfide-containing enhancer achieved efficient nucleic acid and protein delivery. Biomaterials Science, 2022, 10, 6230-6243.	2.6	9
2113	Covid-19: Treatment conclusion with kinds of vaccine and drugs. AIP Conference Proceedings, 2022, , .	0.3	0
2114	mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency. Biomaterials Science, 2022, 10, 5566-5582.	2.6	11
2115	Vaccine History: From Smallpox to Covid-19. Engineering Materials, 2022, , 519-543.	0.3	0
2116	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
2117	SARS-COV-2 and Other mRNA Vaccines. RNA Technologies, 2022, , 113-138.	0.2	0
2118	Hospital-Based RNA Therapeutics. RNA Technologies, 2022, , 73-92.	0.2	0
2119	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. Scientific Reports, 2022, 12, .	1.6	3
2120	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Frontiers in Microbiology, 0, 13, .	1.5	14
2121	Lipid-Based Drug Delivery Systems for Diseases Managements. Biomedicines, 2022, 10, 2137.	1.4	14
2122	Antibody response and intraâ€host viral evolution after plasma therapy in <scp>COVID</scp>â€19 patients preâ€exposed or not to Bâ€cellâ€depleting agents. British Journal of Haematology, 2022, 199, 549-559.	1.2	9
2123	Psychological and situational factors associated with COVID-19 vaccine intention among postpartum women in Pakistan: a cross-sectional study. BMJ Open, 2022, 12, e063469.	0.8	2
2124	Low rate of SARS-CoV-2 incident infection identified by weekly screening PCR in a prospective year-long cohort study. PLoS ONE, 2022, 17, e0274078.	1.1	0
2125	Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. Scientific Reports, 2022, 12, .	1.6	5
2126	Protection against SARS-CoV-2 transmission by a parenteral primeâ€"Intranasal boost vaccine strategy. EBioMedicine, 2022, 84, 104248.	2.7	17

#	Article	IF	Citations
2127	Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection. Vaccines, 2022, 10, 1504.	2.1	2
2129	A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination. Viruses, 2022, 14, 2118.	1.5	1
2131	mRNA nanomedicine: Design and recent applications. Exploration, 2022, 2, .	5.4	37
2132	Assessing emerging technologies from an arms control perspective. Frontiers in Research Metrics and Analytics, 0, 7, .	0.9	0
2133	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. Health Research Policy and Systems, 2022, 20, .	1.1	5
2134	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. ACS Infectious Diseases, 2022, 8, 2119-2132.	1.8	1
2135	Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy). Vaccines, 2022, 10, 1616.	2.1	3
2136	Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine. Cell Reports Medicine, 2022, 3, 100752.	3.3	14
2137	Struktur Biomolekul dan Mekanisme Aksi Vaksin Sars-Cov-2 Efektif dalam Melawan Covid-19. , 2022, 2, 1-10.		0
2141	Lipidâ€based nucleic acid therapeutics with in vivo efficacy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	3
2142	Immune responses to SARS-CoV-2 vaccines in celiac disease. Scandinavian Journal of Gastroenterology, 2023, 58, 142-147.	0.6	5
2143	Haemonchosis in Sheep and Goats, Control Strategies and Development of Vaccines against Haemonchus contortus. Animals, 2022, 12, 2339.	1.0	11
2144	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. Nature Communications, 2022, 13, .	5.8	11
2145	Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis. Frontiers in Public Health, 0, 10, .	1.3	6
2147	Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Science Advances, 2022, 8, .	4.7	22
2148	Facilitators and barriers to COVID-19 vaccination among healthcare workers and the general population in Guinea. BMC Infectious Diseases, 2022, 22, .	1.3	7
2149	Current clinical status of new COVID-19 vaccines and immunotherapy. Environmental Science and Pollution Research, 0, , .	2.7	5
2150	Shedding of infectious SARS-CoV-2 despite vaccination. PLoS Pathogens, 2022, 18, e1010876.	2.1	36

#	Article	IF	Citations
2151	In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
2154	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. International Journal of Molecular Sciences, 2022, 23, 10374.	1.8	10
2156	De Novo Diagnosis of Lymphocytic Colitis After SARS-CoV-2 Vaccination. ACG Case Reports Journal, 2022, 9, e00849.	0.2	2
2157	PSYCHOGENIC NONEPILEPTIC SEIZURES FOLLOWING COVID 19 VACCINE: A REPORT OF TWO CASES IN COLOMBIA. Archivos De Neurociencias, 0, , .	0.0	0
2158	SARS-CoV-2 in immunocompromised individuals. Immunity, 2022, 55, 1779-1798.	6.6	50
2159	COVID-19 and cellular senescence. Nature Reviews Immunology, 2023, 23, 251-263.	10.6	54
2160	Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation Direct, 2022, 8, e1389.	0.8	4
2161	Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership. Vaccine, 2022, 40, 6133-6140.	1.7	6
2162	mRNA vaccines: A novel weapon to control infectious diseases. Frontiers in Microbiology, 0, 13, .	1.5	10
2164	Monkeypox virus: An emerging epidemic. Microbial Pathogenesis, 2022, 173, 105794.	1.3	22
2166	Medicine, 2021, 110, 2099-2103.	0.0	0
2167	Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics, 2022, 12, 7509-7531.	4.6	43
2168	Recombinant Vaccines: The Revolution Ahead. , 2022, , 163-200.		0
2169	ÕŠÕ¡Õ¿Õ¾Õ¡Õ½Õ¿Õ¡Õ¶ÕµÕ¸Õ©Õ« Õ¶Õ¥Ö€Õ¡Ö€Õ¯Õ¸Õ¾ Õ¹Õ¡Õ´Õ¡Õ¶Õ¡Õ¾Õ¸Ö€Õ® Õ¸Õ½Õ« Õ¾Õ¶Õ¡Õ½		0
2170	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. Cell Reports, 2022, 41, 111496.	2.9	20
2171	Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. Journal of Clinical Investigation, 2022, 132, .	3.9	12
2172	SARS-CoV-2 vaccine strategies in kidney transplant recipients. Lancet Infectious Diseases, The, 2023, 23, 263-264.	4.6	3
2173	Ocular effects caused by viral infections and corresponding vaccines: An overview of varicella zoster virus, measles virus, influenza viruses, hepatitis B virus, and SARS-CoV-2. Frontiers in Medicine, 0, 9, .	1.2	3

#	Article	IF	Citations
2174	Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open, 2022, 8, e002575.	1.8	3
2176	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. Vaccines, 2022, 10, 1655.	2.1	12
2177	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science, 2022, 29, .	2.6	77
2178	Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine. International Journal of Molecular Sciences, 2022, 23, 12333.	1.8	4
2179	Prime-boost, double-dose influenza vaccine immunity in COPD: a pilot observational study. ERJ Open Research, 2023, 9, 00641-2021.	1.1	1
2180	Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling. Vaccine, 2022, 40, 7032-7041.	1.7	4
2181	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS ONE, 2022, 17, e0263861.	1.1	12
2182	Genetically modified organisms: adapting regulatory frameworks for evolving genome editing technologies. Biological Research, 2022, 55, .	1.5	10
2183	Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes. International Journal of Molecular Sciences, 2022, 23, 12231.	1.8	4
2184	Recent Advances in Drug Delivery System Fabricated by Microfluidics for Disease Therapy. Bioengineering, 2022, 9, 625.	1.6	8
2185	Catching the Wave: Detecting Strain-Specific SARS-CoV-2 Peptides in Clinical Samples Collected during Infection Waves from Diverse Geographical Locations. Viruses, 2022, 14, 2205.	1.5	1
2187	Pandemicâ€™s silver lining. MAbs, 2022, 14, .	2.6	1
2188	Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. Microorganisms, 2022, 10, 1999.	1.6	4
2189	Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants. Vaccines, 2022, 10, 1807.	2.1	9
2190	Nanotechnology-Driven Delivery Systems in Inoculation Therapies. Methods in Molecular Biology, 2023, , 39-57.	0.4	0
2191	Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response. International Journal of Peptide Research and Therapeutics, 2022, 28, .	0.9	1
2192	COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. Cellular Signalling, 2023, 101, 110495.	1.7	11
2193	An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. Journal of Nanobiotechnology, 2022, 20, .	4.2	38

#	Article	IF	Citations
2194	Design Strategies for and Stability of mRNAâ€“Lipid Nanoparticle COVID-19 Vaccines. Polymers, 2022, 14, 4195.	2.0	13
2195	Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity. Vaccines, 2022, 10, 1708.	2.1	3
2196	Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. Lancet Infectious Diseases, The, 2023, 23, 307-319.	4.6	31
2197	Latest Trends in Nucleic Acidsâ€™ Engineering Techniques Applied to Precision Medicine. Methods in Molecular Biology, 2023, , 25-38.	0.4	2
2198	Forensic and Pharmaceutical Risks in the Organization of Pharmacotherapy of Covid, Post-Covid and Long-Covid Disorders. COVID-19 and Vaccination Practice Standards.. SSP Modern Pharmacy and Medicine, 2022, 2, 1-24.	2.4	38
2199	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nature Medicine, 2023, 29, 247-257.	15.2	98
2200	A Singleâ€Administration Microneedle Skin Patch for Multiâ€Burst Release of Vaccine against SARSâ€CoVâ€2. Advanced Materials Technologies, 2023, 8, .	3.0	4
2201	Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death. Cell Chemical Biology, 2022, 29, 1601-1615.e7.	2.5	6
2202	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. Frontiers in Immunology, 0, 13, .	2.2	5
2203	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	3
2204	Post-COVID-19 vaccine SARS-CoV-2 antibody investigation in healthcare professionals. The European Research Journal, 0, , 1-8.	0.1	0
2205	Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers. Vaccines, 2022, 10, 1809.	2.1	1
2206	Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon. PLoS ONE, 2022, 17, e0274829.	1.1	1
2207	Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. IScience, 2022, 25, 105412.	1.9	8
2208	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. Npj Vaccines, 2022, 7, .	2.9	24
2209	Anti-PF4 antibodies associated with disease severity in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	16
2210	Efficacy and safety profile of two-dose SARS-CoV-2 vaccines in cancer patients: An observational study in China. World Journal of Clinical Cases, 0, 10, 11411-11418.	0.3	0
2211	Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity. Vaccine, 2022, 40, 6864-6872.	1.7	1

#	Article	IF	Citations
2212	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. Human Vaccines and Immunotherapeutics, 0, , .	1.4	2
2213	Novel coronavirus mutations: Vaccine development and challenges. Microbial Pathogenesis, 2022, 173, 105828.	1.3	7
2214	Innate sensing of mRNA vaccines. Current Opinion in Immunology, 2022, 79, 102249.	2.4	4
2215	AI and the Clinical Immunology/Immunoinformatics for COVID-19. , 2022, , 239-256.		0
2216	Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC). Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211353.	1.5	6
2218	Racial and Ethnic Differences in Maternal and Child COVID-19 Vaccination Intent Among Pregnant and Postpartum Women in the USA (Aprilâ€“June 2020): an Application of Health Belief Model. Journal of Racial and Ethnic Health Disparities, 0, , .	1.8	3
2219	The role of noncoding RNAs in cancer lipid metabolism. Frontiers in Oncology, 0, 12, .	1.3	2
2220	Bio-Orthogonal Chemistry Conjugation Strategy Facilitates Investigation of N-methyladenosine and Thiouridine Guide RNA Modifications on CRISPR Activity. CRISPR Journal, 2022, 5, 787-798.	1.4	4
2221	Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. Biomedicines, 2022, 10, 2892.	1.4	4
2222	A tetrahedral framework nucleic acid based multifunctional nanocapsule for tumor prophylactic mRNA vaccination. Chinese Chemical Letters, 2023, 34, 107987.	4.8	5
2223	Vaccines and more: The response of Dark Web marketplaces to the ongoing COVID-19 pandemic. PLoS ONE, 2022, 17, e0275288.	1.1	1
2224	Bulk Electroporation for Intracellular Delivery Directly Driven by Mechanical Stimulus. ACS Nano, 2022, 16, 19363-19372.	7.3	12
2225	A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. Immunobiology, 2023, 228, 152302.	0.8	14
2226	Insights into the Structural Complexities of SARS-CoV-2 for Therapeutic and Vaccine Development. Combinatorial Chemistry and High Throughput Screening, 2023, 26, 1945-1959.	0.6	0
2227	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. Expert Review of Vaccines, 2022, 21, 1739-1761.	2.0	2
2228	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. Journal of Proteome Research, 0, , .	1.8	2
2230	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. Infectious Disease Clinics of North America, 2023, 37, 27-45.	1.9	6
2231	A survey of mechanisms underlying current and potential <scp>COVID</scp> â€19 vaccines. Apmis, 0, , .	0.9	0

#	Article	IF	Citations
2232	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. Frontiers in Immunology, 0, 13, .	2.2	1
2233	The engineering challenges and opportunities when designing potent ionizable materials for the delivery of ribonucleic acids. Expert Opinion on Drug Delivery, 2022, 19, 1650-1663.	2.4	2
2234	Determinants of Participation in Immunization Against COVID-19 Before Vaccine Distribution in Iran. Shiraz E Medical Journal, 2022, 23, .	0.1	0
2235	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. Clinics in Laboratory Medicine, 2022, 42, 687-704.	0.7	0
2236	Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. Viruses, 2022, 14, 2541.	1.5	6
2237	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. Frontiers in Microbiology, 0, 13, .	1.5	4
2238	OBAVEZNA VAKCINACIJA PROTIV COVID-19 IZ PERSPEKTIVE LJUDSKIH PRAVA. , 2022, , 37-70.		0
2239	The effect of COVID-19 vaccines on sperm parameters: a systematic review and meta-analysis. Asian Journal of Andrology, 2023, 25, 468-473.	0.8	2
2240	COVID-19 signalome: Potential therapeutic interventions. Cellular Signalling, 2023, 103, 110559.	1.7	5
2241	Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients. Clinical Immunology Communications, 2023, 3, 1-5.	0.5	1
2242	Presentations at the UK National Immunisation Conference. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
2243	IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7
2244	Caveolae-Mediated Extracellular Vesicle (CMEV) Signaling of Polyvalent Polysaccharide Vaccination: A Hostâ€“Pathogen Interface Hypothesis. Pharmaceutics, 2022, 14, 2653.	2.0	2
2246	Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity. Inflammation and Regeneration, 2022, 42, .	1.5	13
2248	Current state of, prospects for, and obstacles to mRNA vaccine development. Drug Discovery Today, 2023, 28, 103458.	3.2	5
2249	Transcriptomic Analysis of the Acute Skeletal Muscle Effects after Intramuscular DNA Electroporation Reveals Inflammatory Signaling. Vaccines, 2022, 10, 2037.	2.1	3
2250	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines, 2022, 10, 2035.	2.1	3
2252	Low acceptance rate of COVIDâ€19 vaccination and reduced quality of life among heart transplant recipients during the COVIDâ€19 pandemic. Journal of Cardiac Surgery, 0, , .	0.3	2

#	Article	IF	Citations
2253	A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. F1000Research, 0, 11, 909.	0.8	1
2254	Controversies around COVID-19 Vaccines and Antidepressants: Scope and Perspective in Malaysia. Current Drug Research Reviews, 2022, 15, .	0.7	0
2255	Neurological Complications Following COVID-19 Vaccination. Current Neurology and Neuroscience Reports, 2023, 23, 1-14.	2.0	12
2256	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	1.7	2
2257	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
2258	Comparing and combining data from immune assays based on leftâ€censored multivariate normal model assuming common assay differences across settings. Statistics in Medicine, 2023, 42, 164-177.	0.8	0
2259	Adverse Events of COVID-19 Vaccination among the Saudi Population: A Systematic Review and Meta-Analysis. Vaccines, 2022, 10, 2089.	2.1	3
2260	Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. Biology, 2022, 11, 1786.	1.3	4
2261	Alkaline Phosphatase-Controllable and Red Light-Activated RNA Modification Approach for Precise Tumor Suppression. Journal of the American Chemical Society, 2022, 144, 23061-23072.	6.6	20
2263	The role of antigen availability during B cell induction and its effect on sustained memory and antibody production after infection and vaccination - Lessons learned from the SARS-CoV-2 pandemic. Clinical and Experimental Immunology, 0, , .	1.1	1
2264	Non-coding RNAs in stroke pathology, diagnostics, and therapeutics. Neurochemistry International, 2023, 162, 105467.	1.9	1
2265	Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses. Antiviral Research, 2023, 210, 105488.	1.9	9
2266	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. Pathogens and Immunity, 2022, 7, 93-119.	1.4	0
2267	Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. Virology Journal, 2022, 19, .	1.4	14
2268	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. Vaccines, 2022, 10, 2110.	2.1	2
2269	Clinical Trial Site Perspectives and Practices on Study Participant Diversity and Inclusion. Clinical Pharmacology and Therapeutics, 2023, 113, 670-679.	2.3	1
2270	Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS Global Public Health, 2022, 2, e0001308.	0.5	2
2271	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. Expert Review of Vaccines, 2023, 22, 35-53.	2.0	8

#	Article	IF	Citations
2272	Nanotechnology in COVID-19 Vaccines. , 2023, , 14-26.		0
2273	Therapeutic challenges in COVID-19. Current Molecular Medicine, 2022, 23, .	0.6	0
2274	Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines, 2022, 10, 2167.	2.1	8
2275	Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency. Genes, 2022, 13, 2287.	1.0	5
2276	COVID-19 Vaccines, Effectiveness, and Immune Responses. International Journal of Molecular Sciences, 2022, 23, 15415.	1.8	9
2277	Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. Molecular Therapy - Nucleic Acids, 2023, 31, 211-223.	2.3	6
2279	mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics. Vaccines, 2022, 10, 2150.	2.1	25
2280	Post COVID-19 irritable bowel syndrome. Gut, 2023, 72, 484-492.	6.1	17
2281	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Scientific Reports, 2022, 12, .	1.6	20
2282	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
2284	Durability of humoral and cellâ€mediated immune response after SARSâ€CoVâ€2 mRNA vaccine administration. Journal of Medical Virology, 2023, 95, .	2.5	5
2285	A new dawn for monoclonal antibodies against antimicrobial resistant bacteria. Frontiers in Microbiology, 0, 13, .	1.5	5
2286	Interaction Kinetics of Individual mRNA-Containing Lipid Nanoparticles with an Endosomal Membrane Mimic: Dependence on pH, Protein Corona Formation, and Lipoprotein Depletion. ACS Nano, 2022, 16, 20163-20173.	7.3	22
2288	5â€Ethynyluridine: A Bioâ€orthogonal Uridine Variant for mRNAâ€Based Therapies and Vaccines. ChemBioChem, 2023, 24, .	1.3	0
2289	Licensed liposomal vaccines and adjuvants in the antigen delivery system. Biotechnologia, 2022, 103, 409-423.	0.3	1
2290	Atomistic Insights into Organization of RNA-Loaded Lipid Nanoparticles. Journal of Physical Chemistry B, 2023, 127, 1158-1166.	1.2	4
2291	mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Frontiers in Immunology, 0, 13, .	2.2	32
2292	The impact of COVID-19 on kidney transplant care. Frontiers in Medicine, 0, 9, .	1.2	1

#	Article	IF	Citations
2293	A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	12
2294	Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination. Mucosal Immunology, 2023, 16, 39-49.	2.7	7
2295	Nonchromatographic Purification of Synthetic RNA. , 2023, , 1-18.		0
2297	Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. International Journal of Molecular Sciences, 2023, 24, 908.	1.8	6
2298	Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review. Cephalalgia, 2023, 43, 033310242211313.	1.8	20
2299	Eosinophilic lymph node abscesses following a COVID-19 vaccination: A case report. Journal of the National Medical Association, 2023, , .	0.6	1
2300	New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 181-195.	0.2	2
2301	Bioinspired Lipid Nanocarriers for RNA Delivery. ACS Bio & Med Chem Au, 2023, 3, 114-136.	1.7	8
2302	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. Biomedical Journal, 2023, 46, 70-80.	1.4	8
2303	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	2.1	14
2304	A comprehensive perspective of traditional Arabic or Islamic medicinal plants as an adjuvant therapy against COVID-19. Saudi Journal of Biological Sciences, 2023, 30, 103561.	1.8	1
2306	A vaccine delivery system promotes strong immune responses against SARSâ€CoVâ€2 variants. Journal of Medical Virology, 2023, 95, .	2.5	6
2307	Systematic modulation of the lipid composition enables the tuning of liposome cellular uptake. Acta Biomaterialia, 2023, 158, 463-474.	4.1	5
2308	Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study. Vaccines, 2023, 11, 120.	2.1	4
2309	COVID-19 vaccines adverse events: potential molecular mechanisms. Immunologic Research, 2023, 71, 356-372.	1.3	18
2310	Incorporation of glycyrrhizic acid and polyene phosphatidylcholine in lipid nanoparticles ameliorates acute liver injury via delivering p65 siRNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2023, 48, 102649.	1.7	4
2311	Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE). BMJ Open, 2022, 12, e069065.	0.8	5
2312	Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies. Pharmaceutics, 2023, 15, 87.	2.0	0

#	Article	IF	Citations
2314	Evolution Of SARS-CoV-2 In The Presence Of Vaccines. , 2022, , .		0
2315	Skin manifestations following antiâ€COVIDâ€19 vaccination: AÂmulticentricstudy from Turkey. Journal of Cosmetic Dermatology, 2023, 22, 354-363.	0.8	3
2316	In silico design and evaluation of a novel mRNA vaccine against BK virus: a reverse vaccinology approach. Immunologic Research, 2023, 71, 422-441.	1.3	4
2317	Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. Vaccines, 2023, 11, 58.	2.1	5
2318	Cancer vaccineâ€™s multiverse and the future ahead. , 2022, , 335-360.		0
2319	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology, 2023, 12, 177.	1.3	11
2321	Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis. Cornea, 2023, 42, 731-738.	0.9	4
2322	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. Molecular Diagnosis and Therapy, 2023, 27, 193-226.	1.6	6
2325	Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza. Journal of Virology, 2023, 97, .	1.5	3
2326	Microfluidic synthesis of multilayered lipidâ€“polymer hybrid nanoparticles for the formulation of low solubility drugs. Soft Matter, 2023, 19, 1596-1605.	1.2	1
2327	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. Viral Immunology, 0, , .	0.6	1
2328	Changes in Personal Protective Equipment Practices of Craniofacial Surgeons during COVID-19: A Cross-sectional Study. Plastic and Reconstructive Surgery - Global Open, 2023, 11, e4793.	0.3	0
2329	Towards a Future of Personalized Vaccinology: Study on Individual Variables Influencing the Antibody Response to the COVID-19 Vaccine. Vaccines, 2023, 11, 217.	2.1	3
2331	Omics approaches in COVID-19: An overview. , 2023, , 3-21.		0
2332	Nanomaterials for <scp>mRNA</scp>â€based therapeutics: Challenges and opportunities. Bioengineering and Translational Medicine, 2023, 8, .	3.9	14
2333	Challenges faced by frontline nurses caring for Covid-19 patients at the GA East Hospital. , 2023, 10, .		0
2334	SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. Frontiers in Immunology, 0, 14, .	2.2	2
2335	Ionizable lipid nanoparticles deliver mRNA to pancreatic Î² cells via macrophage-mediated gene transfer. Science Advances, 2023, 9, .	4.7	35

#	Article	IF	Citations
2336	Novel Ionizable Lipid Nanoparticles for SARSâ€CoVâ€2 Omicron mRNA Delivery. Advanced Healthcare Materials, 2023, 12, .	3.9	11
2337	Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?. Vaccines, 2023, 11, 208.	2.1	5
2338	Nanoscale metal-organic frameworks for the delivery of nucleic acids to cancer cells. International Journal of Pharmaceutics: X, 2023, 5, 100161.	1.2	0
2339	A Short Introduction to Vaccines. , 2023, , 1-32.		0
2340	Polymerâ€Based mRNA Delivery Strategies for Advanced Therapies. Advanced Healthcare Materials, 2023, 12, .	3.9	32
2341	Rapid-response manufacturing of adenovirus-vectored vaccines. Nature Biotechnology, 2023, 41, 314-316.	9.4	3
2342	Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity. IScience, 2023, 26, 106335.	1.9	5
2343	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. Vaccines, 2023, 11, 806.	2.1	1
2344	No(cebo) Vax: COVID-19 Vaccine Beliefs Are Important Determinants of Both Occurrence and Perceived Severity of Common Vaccinesâ€™ Adverse Effects. Psychological Science, 0, , 095679762311638.	1.8	0
2345	Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): AÂscoping review. , 2023, 2, 100079.		2
2346	Susceptibility to reinfection with SARS-CoV-2 virus relative to existing antibody concentrations and T cell response. International Journal of Infectious Diseases, 2023, 131, 100-110.	1.5	3
2347	Evaluation and comparison of four quantitative SARS-CoV-2 serological assays in COVID-19 patients and immunized healthy individuals, cancer patients, and patients with immunosuppressive therapy. Clinical Biochemistry, 2023, 116, 1-6.	0.8	3
2348	Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnology Advances, 2023, 65, 108130.	6.0	10
2349	Translating Scientific Discovery Into Health Policy Impact: Innovative Bibliometrics Bridge Translational Research Publications to Policy Literature. Academic Medicine, 2023, 98, 896-903.	0.8	1
2350	Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerging Infectious Diseases, 2023, 29, 381-388.	2.0	42
2351	Vaccine Design Strategies: Pathogens to Genomes. , 2021, , 440-488.		0
2352	Single-molecule imaging reveals translation-dependent destabilization of mRNAs. Molecular Cell, 2023, 83, 589-606.e6.	4.5	18
2353	Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine. Frontiers in Medicine, 0, 10, .	1.2	4

#	Article	IF	Citations
2354	Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency. Annals of Allergy, Asthma and Immunology, 2023, , .	0.5	0
2355	SARS-CoV-2 Spike-specific IFN-Î³ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation Direct, 2022, 8, e1387.	0.8	8
2356	Highâ€Precision Synthesis of RNAâ€Loaded Lipid Nanoparticles for Biomedical Applications. Advanced Healthcare Materials, 2023, 12, .	3.9	11
2357	Biological Controls and Standards for the Study and Control of Infectious Diseases. , 2023, , 21-34.		0
2358	T Cell Responses to SARS-CoV-2. Annual Review of Immunology, 2023, 41, 343-373.	9.5	48
2359	Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naÃ¯ve and exposed individuals in a phase 2/3, double-blind, randomized study. Vaccine, 2023, 41, 1875-1884.	1.7	7
2360	mRNA vaccines: The future of prevention of viral infections?. Journal of Medical Virology, 2023, 95, .	2.5	24
2361	Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. Biomedicines, 2023, 11, 517.	1.4	4
2362	Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine. Seminars in Arthritis and Rheumatism, 2023, 59, 152177.	1.6	3
2363	Impact of COVID-19 on Cardiovascular Disease. Viruses, 2023, 15, 508.	1.5	15
2364	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. Frontiers in Immunology, 0, 14, .	2.2	2
2365	Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. PLoS ONE, 2023, 18, e0281689.	1.1	8
2366	Employing T-Cell Memory to Effectively Target SARS-CoV-2. Pathogens, 2023, 12, 301.	1.2	0
2367	A recombinant Mycobacterium smegmatis -based surface display system for developing the T cell-based COVID-19 vaccine. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	4
2368	COVID-19 Vaccine-Induced Lichenoid Eruptionsâ€"Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature. Vaccines, 2023, 11, 438.	2.1	1
2369	Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy. Journal of the American Chemical Society, 2023, 145, 4691-4706.	6.6	36
2370	Human brain organoids to explore SARSâ€CoVâ€2â€induced effects on the central nervous system. Reviews in Medical Virology, 2023, 33, .	3.9	7
2371	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity, 2023, 56, 669-686.e7.	6.6	43

#	Article	IF	Citations
2372	IL-10 modified mRNA monotherapy prolongs survival after composite facial allografting through the induction of mixed chimerism. Molecular Therapy - Nucleic Acids, 2023, 31, 610-627.	2.3	0
2373	Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions DMD TNR. Clinical and Experimental Vaccine Research, 2023, 12, 60.	1.1	0
2374	Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery. Nanoscale Advances, 2023, 5, 1853-1869.	2.2	8
2375	Evaluation of Neuroprotective and Adjuvant Activities of Diketopiperazineâ€Based Peptidomimetics. ChemistrySelect, 2023, 8, .	0.7	1
2376	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon, 2023, 9, e13952.	1.4	28
2377	The quest for an HIV-1 vaccine: will mRNA deliver us from evil?. Expert Review of Vaccines, 2023, 22, 267-269.	2.0	2
2378	Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers. Viruses, 2023, 15, 619.	1.5	1
2379	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. Vaccines, 2023, 11, 548.	2.1	1
2380	The Coming of Age of Nucleic Acid Vaccines during COVID-19. MSystems, 2023, 8, .	1.7	5
2381	The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5. Vaccines, 2023, 11, 570.	2.1	0
2382	Application of Traditional Vaccine Development Strategies to SARS-CoV-2. MSystems, 2023, 8, .	1.7	7
2383	Bullous vasculitis following COVID-19 vaccination. Dermatologica Sinica, 2023, 41, 58.	0.2	1
2384	A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. Frontiers in Immunology, 0, 14, .	2.2	10
2385	Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. Frontiers in Immunology, 0, 14, .	2.2	8
2386	Chemistry, structureÂand function of approved oligonucleotide therapeutics. Nucleic Acids Research, 2023, 51, 2529-2573.	6.5	110
2387	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. International Journal of Environmental Research and Public Health, 2023, 20, 4796.	1.2	2
2388	A novel mAb broadly neutralizes SARSâ€CoVâ€2 VOCs in vitro and in vivo, including the Omicron variants. Journal of Medical Virology, 2023, 95, .	2.5	1
2389	Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines, 2023, 11, 636.	2.1	9

#	Article	IF	Citations
2390	Advanced Therapies for Patients with COVID-19. , 2023, , 77-92.		0
2392	Longer intervals between SARSâ€CoVâ€2 infection and mRNAâ€1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
2393	Backgrounderâ€”Part 1. , 2023, , 3-26.		0
2394	Using dashboards to verify coronavirus (COVID-19) vaccinations can reduce fatality rates in countries/regions: Development and usability study. Medicine (United States), 2023, 102, e33274.	0.4	1
2395	Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs. Molecular Pharmaceutics, 2023, 20, 2119-2127.	2.3	7
2397	Open Questions over the COVID-19 Pandemic. , 2023, 1, 210-220.		0
2398	Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe, The, 2023, 4, e309-e318.	3.4	26
2399	COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence. Infectious Disease Clinics of North America, 2023, , .	1.9	1
2400	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. International Journal of Molecular Sciences, 2023, 24, 5944.	1.8	12
2401	Developing Universal Cure and Other Tools based on Coronavirus Disease 2019 (COVID-19): A Literature Review. , 0, 30, 61-69.		0
2402	Reviews of drug candidates for COVID-19. , 0, 36, 219-226.		0
2403	Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2. Journal of Immunology, 2023, 210, 1236-1246.	0.4	4
2404	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nature Communications, 2023, 14, .	5.8	31
2405	Selfâ€Organization of Iron Sulfide Nanoparticles into Complex Multiâ€Compartment Supraparticles. Advanced Materials, 0, , .	11.1	1
2406	Assessment Of Antibody Levels In A Population Vaccinated With Sputnik V. Russian Open Medical Journal, 2023, 12, .	0.1	0
2407	SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature, 2023, 617, 592-598.	13.7	49
2408	Evolution and immunopathology of chikungunya virus informs therapeutic development. DMM Disease Models and Mechanisms, 2023, 16, .	1.2	2
2409	Next-generation materials for RNAâ€“lipid nanoparticles: lyophilization and targeted transfection. Journal of Materials Chemistry B, 2023, 11, 5083-5093.	2.9	1

#	Article	IF	Citations
2411	Genetically-encoded degraders as versatile modulators of intracellular therapeutic targets. Current Opinion in Biomedical Engineering, 2023, , 100458.	1.8	0
2414	Implications of potential clinically relevant interactions between COVIDâ€19 vaccines and concomitant medications. Reviews in Medical Virology, 0, , .	3.9	0
2415	Vaccine Basics and the Development and Rollout of COVID-19 Vaccines. , 2024, , 326-348.		0
2416	Metaâ€analysis: Postâ€COVIDâ€19 functional dyspepsia and irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2023, 58, 6-15.	1.9	8
2417	A fluorinated ionizable lipid improves the mRNA delivery efficiency of lipid nanoparticles. Journal of Materials Chemistry B, 2023, 11, 4171-4180.	2.9	6
2418	Delivering the next generation of cancer immunotherapies with RNA. Cell, 2023, 186, 1535-1540.	13.5	10
2419	Primary Prophylaxis of COVID-19: A Comprehensive Review of approved vaccines. Research Journal of Pharmacy and Technology, 2023, , 917-923.	0.2	0
2420	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines, 2023, 11, 849.	2.1	12
2421	A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications, 2023, 14, .	5.8	21
2422	Understanding Troponin as a Biomarker of Myocardial Injury: Where the Path Crosses with Cardiac Imaging. Cardiology, 2023, 148, 228-229.	0.6	0
2423	Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	2
2424	Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. Nature Communications, 2023, 14, .	5.8	7
2425	Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimerâ€™s disease. Chemical Engineering Journal, 2023, 466, 143152.	6.6	4
2437	New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery. , 2023, , 911-961.		0
2441	Nanotechnology in vaccines and personalized medicine. , 2024, , 304-321.		0
2447	A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. , 2023, 2, .		1
2468	Therapeutic Potential of Rhodium Complexes. Springer Briefs in Molecular Science, 2023, , 13-53.	0.1	0
2491	Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. Advances in Experimental Medicine and Biology, 2023, , 27-49.	0.8	0

#	Article	IF	Citations
2501	Knifeâ€™s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. Experimental and Molecular Medicine, 2023, 55, 1305-1313.	3.2	11
2504	The role of vaccines in the COVID-19 pandemic: what have we learned?. Seminars in Immunopathology, 0, , .	2.8	13
2510	Vaccine adjuvants: mechanisms and platforms. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	41
2514	Vaccine Immunology. , 2023, , 17-36.e7.		0
2515	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
2516	Vaccine Safety. , 2023, , 1679-1695.e10.		0
2517	Zika Virus Vaccines. , 2023, , 1322-1333.e7.		0
2518	Vaccine Manufacturing. , 2023, , 64-76.		0
2522	Nonchromatographic Purification of Synthetic RNA. , 2023, , 2493-2510.		0
2527	Editorial: Delivering nucleic acids to immune and non-immune cells. Frontiers in Immunology, 0, 14, .	2.2	0
2550	mRNA vaccines in disease prevention and treatment. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	9
2574	Team science and building a team. , 2023, , 551-555.		0
2577	COVID-19: An Overview of Virology, Mutations, Pathology, Epidemiology, Diagnosis, Preventions, and Treatments. , 2023, , 1-22.		0
2587	The Impact of the COVID-19 Pandemic on Pancreas Transplantation. , 2023, , 1267-1273.		0
2594	Vaccines and Drugs. Springer Series in Biophysics, 2023, , 887-896.	0.4	0
2598	BioNanotechnology and BioMEMS (BNM): State-of-the-Art Applications, Opportunities, and Challenges. Lab on A Chip, 0, , .	3.1	1
2599	New-Onset Acute Interstitial Nephritis Post-SARS-CoV-2 Infection and COVID-19 Vaccination: A Panoramic Review. Journal of Epidemiology and Global Health, 0, , .	1.1	0
2603	SARS-CoV-2 and innate immunity: the good, the bad, and the â€œgoldilocksâ€• , 2024, 21, 171-183.		4

#	Article	IF	Citations
2613	RNA-based nanomedicines and their clinical applications. Nano Research, 0, , .	5.8	0
2628	Detection of Covid-19 Vaccination Effect Through Proteomic Approaches in Cancer Patients. , 2023, , .		0
2632	Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics. Analyst, The, 0, , .	1.7	0
2643	Nanoscale Vaccines for the Prevention of COVID-19. AAPS Advances in the Pharmaceutical Sciences Series, 2023, , 367-402.	0.2	0
2659	Nichtvirale Vektoren. , 2023, , 87-102.		0
2677	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0
2678	Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis. Journal of Molecular Medicine, 2024, 102, 313-335.	1.7	0
2679	RNA therapeutics for regenerative medicine. Progress in Molecular Biology and Translational Science, 2024, , 163-176.	0.9	0
2684	Recent applications of RNA therapeutic in clinics. Progress in Molecular Biology and Translational Science, 2024, , 115-150.	0.9	0
2690	Simultaneous nanopore profiling of mRNA m6A and pseudouridine reveals translation coordination. Nature Biotechnology, 0, , .	9.4	0
2703	Immunological Interventions for the Management of Coronavirus Disease 2019 (COVID-19). , 2024, , 453-482.		0